Anti-PD-1 / CD40 bispecific antibody and its use
Bispecific antibodies targeting PD-1 and CD40 activate the CD40 pathway in a PD-1-dependent manner, addressing toxicity issues and enhancing immune response in tumors, offering a safer cancer treatment.
Patent Information
- Application Number
- JP2023523084
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2021-04-02
- Filing Date
- 2021-10-13
- Publication Date
- 2026-11-11
- Estimated Expiration
- 2041-10-13
AI Technical Summary
Existing bispecific antibodies face challenges in effectively activating the CD40 pathway without inducing hepatic toxicity, particularly in tissues expressing high levels of FCγRIIB, limiting their therapeutic efficacy in cancer treatment.
Development of antigen-binding protein constructs, such as bispecific antibodies, that specifically bind to PD-1 and CD40, activating the CD40 pathway in a PD-1-dependent manner while avoiding FCγRIIB-mediated aggregation, thereby reducing toxicity and enhancing immune response in tumor microenvironments.
The bispecific antibodies effectively activate the CD40 pathway in tumor sites, amplifying immune responses and reducing side effects like hepatic toxicity, providing a more targeted and safer cancer treatment approach.
Smart Images

Figure 0007948918000037 
Figure 0007948918000038 
Figure 0007948918000039
Abstract
Description
[Technical Field]
[0001] [Claiming priority] This application claims the interests of PCT application number PCT / CN2020 / 120918, filed on 14 October 2020, and PCT application number PCT / CN2021 / 085335, filed on 2 April 2021. These two patents are incorporated herein by reference in their entirety.
[0002] This disclosure relates to antigen-binding protein constructs (e.g., bispecific antibodies or their antigen-binding fragments). [Background technology]
[0003] Bispecific antibodies are artificial proteins that can simultaneously bind to two different types of antigens or two different epitopes. Such bispecificity opens up a wide range of applications, including the redirection of T cells to tumor cells, dual targeting of different disease media, and delivery of payloads to target sites. The approval of catumaxomab (anti-EpCAM and anti-CD3) and blinatumomab (anti-CD19 and anti-CD3) represents a significant milestone in bispecific antibody research and development.
[0004] Bispecific antibodies have a variety of applications. Therefore, it is necessary to continue developing various therapeutic agents based on bispecific antibodies. [Overview of the Initiative]
[0005] This disclosure relates to antigen-binding protein constructs that specifically bind to two or more different antigens (e.g., PD-1 and CD40). In some embodiments, the antigen-binding protein construct is a bispecific antibody targeting PD-1 and CD40. In some embodiments, the bispecific antibodies described herein effectively treat cancer through various mechanisms. For example, a bispecific antibody can block the PD-1 / PD-L1 pathway, thereby activating the immune response. Furthermore, a bispecific antibody can crosslink T cells and APC cells to promote antigen presentation and activate the CD40 pathway in APC cells. Moreover, a bispecific antibody can activate the CD40 pathway in a PD-1-dependent manner, thereby amplifying immune response signals within the tumor microenvironment or tumor-discharging lymph nodes. This mechanism can also reduce overall immune activation and decrease side effects such as hepatic toxicity. In some embodiments, the bispecific antibodies described herein are unable to activate the CD40 pathway by Fc receptor-mediated (e.g., FCγRIIB-mediated) CD40 aggregation (clustering), thereby further reducing toxicity, such as toxicity in tissues expressing high levels of FCγRIIB (e.g., liver).
[0006] In one embodiment, the disclosure provides an antigen-binding protein construct comprising a first antigen-binding site that specifically binds to PD-1 and a second antigen-binding site that specifically binds to CD40.
[0007] In some embodiments, the antigen-binding protein construct induces activation of the CD40 pathway upon binding to cells expressing PD-1. In some embodiments, the antigen-binding protein construct induces activation of the CD40 pathway in the presence of one or more cells expressing PD-1. In some embodiments, the antigen-binding protein construct induces activation of the CD40 pathway in the tumor microenvironment or tumor drainage lymph nodes. In some embodiments, the antigen-binding protein construct does not induce activation of the CD40 pathway in the absence of one or more cells expressing PD-1. In some embodiments, the antigen-binding protein construct can activate the CD40 pathway, where the activation of the CD40 pathway depends on the binding of the antigen-binding protein construct to cells expressing PD-1.
[0008] In some embodiments, the first antigen-binding site binds to cells expressing PD-1. In some embodiments, the cells expressing PD-1 are T cells, NK cells, or myeloid cells (e.g., T cells). In some embodiments, the cells expressing PD-1 are T cells. In some embodiments, the cells are myeloid cells (e.g., macrophages, myeloid-derived immunosuppressive cells (MDSCs), or T cells).
[0009] In some embodiments, the second antigen-binding site binds to cells expressing CD40. In some embodiments, the cells expressing CD40 are antigen-presenting cells.
[0010] In some embodiments, the antigen-binding protein construct comprises an Fc region. In some embodiments, the second antigen-binding site is linked to the Fc region. In some embodiments, the second antigen-binding site is linked to the C-terminus of the Fc region. In some embodiments, the antigen-binding protein construct is incapable of activating CD40 via an Fc receptor (e.g., FCγRIIB)-mediated mechanism or Fc receptor (e.g., FCγRIIB)-mediated aggregation. In some embodiments, the antigen-binding protein construct is incapable of inducing Fc receptor (e.g., FCγRIIB)-mediated aggregation.
[0011] In some embodiments, the antigen-binding protein construct is a bispecific antibody.
[0012] In some embodiments, the first antigen-binding site that specifically binds to PD-1 comprises an ScFv or a VHH domain. In some embodiments, the antigen-binding site that specifically binds to PD-1 comprises a PD-1 ligand (e.g., PD-L1) or a soluble portion thereof. In some embodiments, the second antigen-binding site that specifically binds to CD40 comprises an ScFv or a VHH domain. In some embodiments, the second antigen-binding site that specifically binds to CD40 comprises a CD40 ligand (e.g., CD40L) or a soluble portion thereof.
[0013] In some embodiments, the first antigen-binding site comprises a heavy chain variable region and a light chain variable region as described herein. In some embodiments, the second antigen-binding site comprises a heavy chain variable region and a light chain variable region as described herein.
[0014] In some embodiments, the PD-1 ligand comprises a sequence having at least 80%, 85%, 90%, 95% or 100% identity with amino acids 19 to 238 of SEQ ID NO: 159. In some embodiments, the CD40 ligand comprises a sequence having at least 80%, 85%, 90%, 95% or 100% identity with amino acids 47 to 261 of SEQ ID NO: 160.
[0015] In one embodiment, the present disclosure relates to an antigen-binding protein construct comprising a first heavy chain variable region and a first light chain variable region, and a second heavy chain variable region and a second light chain variable region, wherein in some embodiments, the first heavy chain variable region and the first light chain variable region bind to each other to form a first antigen-binding site that specifically binds to PD-1, and in some embodiments, the second heavy chain variable region and the second light chain variable region bind to each other to form a second antigen-binding site that specifically binds to CD40.
[0016] In some embodiments, the antigen-binding protein construct comprises a first polypeptide comprising a first heavy chain variable region, a first heavy chain constant region 2 (CH2), and a first heavy chain constant region 3 (CH3), and a second polypeptide comprising a second heavy chain variable region, a second heavy chain constant region 2 (CH2), and a second heavy chain constant region 3 (CH3).
[0017] In some embodiments, the antigen-binding protein construct comprises a third polypeptide containing a first light chain variable region and a fourth polypeptide containing a second light chain variable region.
[0018] In some embodiments, the second polypeptide further comprises a second light chain variable region.
[0019] In some embodiments, the antigen-binding protein construct comprises a third polypeptide containing a first light chain variable region.
[0020] In some embodiments, the first polypeptide further comprises a first light chain variable region.
[0021] In some embodiments, the antigen-binding protein construct comprises a first polypeptide including a first heavy chain variable region, a second heavy chain variable region, and a second light chain variable region, and a second polypeptide including the first light chain variable region.
[0022] In some embodiments, the first polypeptide further comprises a heavy chain constant region 1 (CH1), a heavy chain constant region 2 (CH2), and a heavy chain constant region 3 (CH3).
[0023] In some embodiments, the first heavy chain variable region (VH1) includes complementarity-determining regions (CDRs) 1, 2, and 3. In some embodiments, the VH1 CDR1 region includes an amino acid sequence having at least 80% identity with a selected VH1 CDR1 amino acid sequence, the VH1 CDR2 region includes an amino acid sequence having at least 80% identity with a selected VH1 CDR2 amino acid sequence, the VH1 CDR3 region includes an amino acid sequence having at least 80% identity with a selected VH1 CDR3 amino acid sequence, and the first light chain variable region (VL1) includes CDRs 1, 2, and 3. In some embodiments, the VL1 CDR1 region includes an amino acid sequence having at least 80% identity with the selected VL1 CDR1 amino acid sequence, the VL1 CDR2 region includes an amino acid sequence having at least 80% identity with the selected VL1 CDR2 amino acid sequence, and the VL1 CDR3 region includes an amino acid sequence having at least 80% identity with the selected VL1 CDR3 amino acid sequence. In some embodiments, the selected VH1 CDR1, 2, and 3 amino acid sequences and the selected VL1 CDR1, 2, and 3 amino acid sequences are any of the following: (1) According to the Kabat numbering rules, the selected VH1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs: 1, 2, and 3, respectively, and the selected VL1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs: 4, 5, and 6, respectively. (2) According to the Chothia numbering rules, the selected VH1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs. 19, 20, and 21, respectively, and the selected VL1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs. 22, 23, and 24, respectively.
[0024] (3) According to the Kabat numbering rules, the selected VH1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs. 7, 8, and 9, respectively, and the selected VL1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs. 10, 11, and 12, respectively.
[0025] (4) According to the Chothia numbering rules, the selected VH1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs. 25, 26, and 27, respectively, and the selected VL1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs. 28, 29, and 30, respectively.
[0026] (5) In accordance with the Kabat numbering rules, the selected VH1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs. 13, 14, and 15, respectively, and the selected VL1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs. 16, 17, and 18, respectively, and
[0027] (6) In accordance with the Chothia numbering rules, the selected VH1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs. 31, 32, and 33, respectively, and the selected VL1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs. 34, 35, and 36, respectively.
[0028] In some embodiments, the second heavy chain variable region (VH2) includes CDR1, 2, and 3. In some embodiments, the VH2 CDR1 region includes an amino acid sequence having at least 80% identity with a selected VH2 CDR1 amino acid sequence, the VH2 CDR2 region includes an amino acid sequence having at least 80% identity with a selected VH2 CDR2 amino acid sequence, the VH2 CDR3 region includes an amino acid sequence having at least 80% identity with a selected VH2 CDR3 amino acid sequence, and the second light chain variable region (VL2) includes CDR1, 2, and 3. In some embodiments, the VL2 CDR1 region includes an amino acid sequence having at least 80% identity with a selected VL2 CDR1 amino acid sequence, the VL2 CDR2 region includes an amino acid sequence having at least 80% identity with a selected VL2 CDR2 amino acid sequence, and the VL2 CDR3 region includes an amino acid sequence having at least 80% identity with a selected VL2 CDR3 amino acid sequence. In some embodiments, the selected VH2 CDR1, 2, and 3 amino acid sequences and the selected VL2 CDR1, 2, and 3 amino acid sequences are any of the following:
[0029] (1) According to the Kabat numbering rules, the selected VH2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs. 59, 60, and 61, respectively, and the selected VL2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs. 62, 63, and 64, respectively.
[0030] (2) According to the Chothia numbering rules, the selected VH2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs. 77, 78, and 79, respectively, and the selected VL2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs. 80, 81, and 82, respectively.
[0031] (3) According to the Kabat numbering rules, the selected VH2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs. 65, 66, and 67, respectively, and the selected VL2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs. 68, 69, and 70, respectively.
[0032] (4) According to the Chothia numbering rules, the selected VH2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs. 83, 84, and 85, respectively, and the selected VL2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs. 86, 87, and 88, respectively.
[0033] (5) In accordance with the Kabat numbering rules, the selected VH2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs. 71, 72, and 73, respectively, and the selected VL2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs. 74, 75, and 76, respectively, and (6) In accordance with the Chothia numbering rules, the selected VH2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs. 89, 90, and 91, respectively, and the selected VL2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs. 92, 93, and 94, respectively. In some embodiments, this disclosure relates to antigen-binding protein constructs, and hereby, (1) According to the Kabat numbering rules, the selected VH1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs: 1, 2, and 3, respectively; the selected VL1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs: 4, 5, and 6, respectively; the selected VH2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs: 65, 66, and 67, respectively; the selected VL2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs: 68, 69, and 70, respectively; or (2) In accordance with the Chothia numbering rules, the selected VH1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs. 19, 20, and 21, respectively; the selected VL1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs. 22, 23, and 24, respectively; the selected VH2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs. 83, 84, and 85, respectively; and the selected VL2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs. 86, 87, and 88, respectively.
[0034] In some embodiments, the first heavy chain variable region includes a sequence having at least 80%, 85%, 90%, or 95% identity with sequence number 40, 41, 42, or 53, and the first light chain variable region includes a sequence having at least 80%, 85%, 90%, or 95% identity with sequence number 43, 44, 45, or 54.
[0035] In some embodiments, the first heavy chain variable region includes a sequence having at least 80%, 85%, 90%, or 95% identity with sequence numbers 46, 47, 48, 49, or 55, and the first light chain variable region includes a sequence having at least 80%, 85%, 90%, or 95% identity with sequence numbers 50, 51, 52, or 56. In some embodiments, the first heavy chain variable region includes a sequence having at least 80%, 85%, 90%, or 95% identity with SEQ ID NO: 57, and the first light chain variable region includes a sequence having at least 80%, 85%, 90%, or 95% identity with SEQ ID NO: 58.
[0036] In some embodiments, the second heavy chain variable region includes a sequence having at least 80%, 85%, 90%, or 95% identity with sequence numbers 98, 99, 100, or 120, and the second light chain variable region includes a sequence having at least 80%, 85%, 90%, or 95% identity with sequence numbers 101, 102, 103, 104, or 121.
[0037] In some embodiments, the second heavy chain variable region includes a sequence having at least 80%, 85%, 90%, or 95% identity with sequence numbers 105, 106, 107, 108, 122, 126, or 128, and the second light chain variable region includes a sequence having at least 80%, 85%, 90%, or 95% identity with sequence numbers 109, 110, 111, 123, 127, or 129.
[0038] In some embodiments, the second heavy chain variable region includes a sequence having at least 80%, 85%, 90%, or 95% identity with sequence numbers 112, 113, 114, 115, or 124, and the second light chain variable region includes a sequence having at least 80%, 85%, 90%, or 95% identity with sequence numbers 116, 117, 118, 119, or 125.
[0039] In some embodiments, the first heavy chain variable region includes a sequence having at least 80%, 85%, 90%, or 95% identity with sequence number 41, the first light chain variable region includes a sequence having at least 80%, 85%, 90%, or 95% identity with sequence number 45, the second heavy chain variable region includes a sequence having at least 80%, 85%, 90%, or 95% identity with sequence number 108 or 126, and the second light chain variable region includes a sequence having at least 80%, 85%, 90%, or 95% identity with sequence number 110 or 127.
[0040] In some embodiments, the first polypeptide comprises a sequence having at least 80%, 85%, 90%, or 95% identity with SEQ ID NO: 130, and the third polypeptide comprises a sequence having at least 80%, 85%, 90%, or 95% identity with SEQ ID NO: 131.
[0041] In some embodiments, the second polypeptide comprises a sequence having at least 80%, 85%, 90%, or 95% identity with sequence number 132 or 133.
[0042] In some embodiments, the first polypeptide comprises a sequence having at least 80%, 85%, 90%, or 95% identity with SEQ ID NO: 130, the second polypeptide comprises a sequence having at least 80%, 85%, 90%, or 95% identity with SEQ ID NO: 132 or 133, and the third polypeptide comprises a sequence having at least 80%, 85%, 90%, or 95% identity with SEQ ID NO: 131.
[0043] In some embodiments, the first polypeptide comprises a sequence having at least 80%, 85%, 90%, or 95% identity with SEQ ID NO: 134 or 135, and the second polypeptide comprises a sequence having at least 80%, 85%, 90%, or 95% identity with SEQ ID NO: 136.
[0044] In some embodiments, the first polypeptide comprises a sequence having at least 80%, 85%, 90%, or 95% identity with SEQ ID NO: 137 or 138, and the second polypeptide comprises a sequence having at least 80%, 85%, 90%, or 95% identity with SEQ ID NO: 139.
[0045] In some embodiments, the antigen-binding protein construct is a bispecific antibody.
[0046] In some embodiments, the antigen-binding protein construct is Fab-scFv-Fc.
[0047] In some embodiments, the antigen-binding protein constructs are TrioMab, a bispecific antibody with a covalent light chain, CrossMab, 2:1 CrossMab, 2:2 CrossMab, Duobody, a bivariable domain antibody (DVD-Ig), scFv-IgG, an IgG-IgG morphological antibody, a Fab-scFv-Fc morphological antibody, TF, ADAPTIR, a bispecific T cell-inducing antibody (BiTE), BiTE-Fc, a biaffinity retargeting antibody (DART), DART-Fc (DART with Fc), tetravalent DART, a tandem biantibody (TandAb), scFv-scFv-scFv, ImmTAC, a triplicate nanobody, or a triplicate killer cell engager (TriKE).
[0048] In some embodiments, the antigen-binding protein construct comprises one or more heavy chain constant domains derived from IgG1 or IgG4.
[0049] In some embodiments, the one or more heavy chain constant domains include LALA mutations and / or knob-into-hole (KIH) mutations.
[0050] In one embodiment, the present disclosure relates to a bispecific antibody or antigen-binding fragment thereof comprising a first heavy chain polypeptide including a first heavy chain variable region, a first light chain polypeptide including a first light chain variable region, a second heavy chain polypeptide including a second heavy chain variable region, and a second light chain polypeptide including a second light chain variable region.
[0051] In some embodiments, the first heavy chain variable region and the first light chain variable region bind to each other to form a first antigen-binding site that specifically binds to PD-1, and the second heavy chain variable region and the second light chain variable region bind to each other to form a second antigen-binding site that specifically binds to CD40.
[0052] In some embodiments, the Disclosure relates to a bispecific antibody or antigen-binding fragment thereof comprising a first heavy chain variable region (VH1) comprising complementarity-determining regions (CDRs) 1, 2, and 3, a first light chain variable region (VL1) comprising CDRs 1, 2, and 3, a second heavy chain variable region (VH2) comprising complementarity-determining regions (CDRs) 1, 2, and 3, and a second light chain variable region (VL2) comprising CDRs 1, 2, and 3, wherein in some embodiments, the VH1 CDR1 region comprises an amino acid sequence having at least 80% identity with a selected VH1 CDR1 amino acid sequence, the VH1 CDR2 region comprises an amino acid sequence having at least 80% identity with a selected VH1 CDR2 amino acid sequence, the VH1 CDR3 region comprises an amino acid sequence having at least 80% identity with a selected VH1 CDR3 amino acid sequence, and in some embodiments, the VL1 CDR1 region comprises a selected VL1 The VL1 CDR2 region includes an amino acid sequence having at least 80% identity with the CDR1 amino acid sequence, the VL1 CDR3 region includes an amino acid sequence having at least 80% identity with the selected VL1 CDR3 amino acid sequence, and in some embodiments, the VH2 CDR1 region includes an amino acid sequence having at least 80% identity with the selected VH2 CDR1 amino acid sequence, the VH2 CDR2 region includes an amino acid sequence having at least 80% identity with the selected VH2 CDR2 amino acid sequence, the VH2 CDR3 region includes an amino acid sequence having at least 80% identity with the selected VH2 CDR3 amino acid sequence, and in some embodiments, the VL2 CDR1 region includes an amino acid sequence having at least 80% identity with the selected VL2 CDR1 amino acid sequence, and the VL2 CDR2 region includes an amino acid sequence having at least 80% identity with the selected VL2 The VL2 CDR3 region includes an amino acid sequence having at least 80% identity with the CDR2 amino acid sequence, and the VL2 CDR3 region includes an amino acid sequence having at least 80% identity with the selected VL2 CDR3 amino acid sequence.
[0053] In some embodiments, the selected VH1 CDR1, 2, and 3 amino acid sequences, the selected VL1 CDR1, 2, and 3 amino acid sequences, the selected VH2 CDR1, 2, and 3 amino acid sequences, and the selected VL2 CDR1, 2, and 3 amino acid sequences are any of the following: (1) According to the Kabat numbering rules, the selected VH1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs: 1, 2, and 3, respectively; the selected VL1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs: 4, 5, and 6, respectively; the selected VH2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs: 65, 66, and 67, respectively; the selected VL2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs: 68, 69, and 70, respectively; and (2) In accordance with the Chothia numbering rules, the selected VH1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs. 19, 20, and 21, respectively; the selected VL1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs. 22, 23, and 24, respectively; the selected VH2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs. 83, 84, and 85, respectively; and the selected VL2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs. 86, 87, and 88, respectively.
[0054] In some embodiments, the first heavy chain variable region includes a sequence having at least 80%, 85%, 90%, or 95% identity with sequence number 41, the first light chain variable region includes a sequence having at least 80%, 85%, 90%, or 95% identity with sequence number 45, the second heavy chain variable region includes a sequence having at least 80%, 85%, 90%, or 95% identity with sequence number 108 or 126, and the second light chain variable region includes a sequence having at least 80%, 85%, 90%, or 95% identity with sequence number 110 or 127.
[0055] In some embodiments, the first heavy chain polypeptide comprises a sequence having at least 80%, 85%, 90%, or 95% identity with SEQ ID NO: 130, and the first light chain polypeptide comprises a sequence having at least 80%, 85%, 90%, or 95% identity with SEQ ID NO: 131.
[0056] In one embodiment, the present disclosure relates to a bispecific antibody or antigen-binding fragment thereof comprising a heavy chain polypeptide including a first heavy chain variable region, a light chain polypeptide including a first light chain variable region, and a single-chain variable fragment polypeptide including a second heavy chain variable region and a second light chain variable region. In some embodiments, the first heavy chain variable region and the first light chain variable region bind to each other to form a first antigen-binding site that specifically binds to PD-1, and the second heavy chain variable region and the second light chain variable region bind to each other to form a second antigen-binding site that specifically binds to CD40.
[0057] In some embodiments, the single-chain variable fragment polypeptide comprises, from the N-terminus to the C-terminus, a second heavy chain variable region, a linker peptide sequence, a second light chain variable region, a heavy chain constant region 2 (CH2), and a heavy chain constant region 3 (CH3).
[0058] In some embodiments, the linker peptide sequence includes a sequence having at least 80% identity with ASTGGGGSGGGGSGGGGSGGGGS (SEQ ID NO: 152).
[0059] In some embodiments, the Disclosure relates to a bispecific antibody or antigen-binding fragment thereof described herein, comprising a first heavy chain variable region (VH1) comprising complementarity-determining regions (CDRs) 1, 2, and 3, a first light chain variable region (VL1) comprising CDRs 1, 2, and 3, a second heavy chain variable region (VH2) comprising complementarity-determining regions (CDRs) 1, 2, and 3, and a second light chain variable region (VL2) comprising CDRs 1, 2, and 3, wherein in some embodiments, the VH1 CDR1 region comprises an amino acid sequence having at least 80% identity with a selected VH1 CDR1 amino acid sequence, the VH1 CDR2 region comprises an amino acid sequence having at least 80% identity with a selected VH1 CDR2 amino acid sequence, the VH1 CDR3 region comprises an amino acid sequence having at least 80% identity with a selected VH1 CDR3 amino acid sequence, and in some embodiments, the VL1 CDR1 region comprises a selected VL1 The VL1 CDR2 region includes an amino acid sequence having at least 80% identity with the CDR1 amino acid sequence, the VL1 CDR3 region includes an amino acid sequence having at least 80% identity with the selected VL1 CDR3 amino acid sequence, and in some embodiments, the VH2 CDR1 region includes an amino acid sequence having at least 80% identity with the selected VH2 CDR1 amino acid sequence, the VH2 CDR2 region includes an amino acid sequence having at least 80% identity with the selected VH2 CDR2 amino acid sequence, the VH2 CDR3 region includes an amino acid sequence having at least 80% identity with the selected VH2 CDR3 amino acid sequence, and in some embodiments, the VL2 CDR1 region includes an amino acid sequence having at least 80% identity with the selected VL2 CDR1 amino acid sequence, and the VL2 CDR2 region includes an amino acid sequence having at least 80% identity with the selected VL2 The VL2 CDR3 region includes an amino acid sequence having at least 80% identity with the CDR2 amino acid sequence, and the VL2 CDR3 region includes an amino acid sequence having at least 80% identity with the selected VL2 CDR3 amino acid sequence.
[0060] In some embodiments, the selected VH1 CDR1, 2, and 3 amino acid sequences, the selected VL1 CDR1, 2, and 3 amino acid sequences, the selected VH2 CDR1, 2, and 3 amino acid sequences, and the selected VL2 CDR1, 2, and 3 amino acid sequences are any of the following:
[0061] (1) According to the Kabat numbering rules, the selected VH1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs: 1, 2, and 3, respectively; the selected VL1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs: 4, 5, and 6, respectively; the selected VH2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs: 65, 66, and 67, respectively; the selected VL2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs: 68, 69, and 70, respectively; and
[0062] (2) In accordance with the Chothia numbering rules, the selected VH1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs. 19, 20, and 21, respectively; the selected VL1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs. 22, 23, and 24, respectively; the selected VH2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs. 83, 84, and 85, respectively; and the selected VL2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs. 86, 87, and 88, respectively.
[0063] In some embodiments, the first heavy chain variable region includes a sequence having at least 80%, 85%, 90%, or 95% identity with sequence number 41, the first light chain variable region includes a sequence having at least 80%, 85%, 90%, or 95% identity with sequence number 45, the second heavy chain variable region includes a sequence having at least 80%, 85%, 90%, or 95% identity with sequence number 108 or 126, and the second light chain variable region includes a sequence having at least 80%, 85%, 90%, or 95% identity with sequence number 110 or 127.
[0064] In some embodiments, this disclosure relates to a bispecific antibody or an antigen-binding fragment thereof, and herein, (1) The heavy chain polypeptide contains a sequence having at least 80%, 85%, 90%, or 95% identity with SEQ ID NO: 130, and the light chain polypeptide contains a sequence having at least 80%, 85%, 90%, or 95% identity with SEQ ID NO: 131, and (2) The single-stranded variable fragment polypeptide contains a sequence having at least 80%, 85%, 90%, or 95% identity with SEQ ID NO: 132 or 133.
[0065] In one embodiment, the disclosure relates to a bispecific antibody or antigen-binding fragment thereof comprising a heavy chain polypeptide comprising a first heavy chain variable region and a light chain polypeptide comprising a first light chain variable region. In some embodiments, the single-chain variable fragment polypeptide is ligated to the C-terminus of the heavy chain polypeptide. In some embodiments, the single-chain variable fragment polypeptide comprises a second heavy chain variable region and a second light chain variable region. In some embodiments, the first heavy chain variable region and the first light chain variable region bind to each other to form a first antigen-binding site that specifically binds to PD-1, and the second heavy chain variable region and the second light chain variable region bind to each other to form a second antigen-binding site that specifically binds to CD40.
[0066] In some embodiments, a single-chain variable fragment polypeptide is linked to a first heavy-chain polypeptide by a first linker peptide sequence.
[0067] In some embodiments, the first linker peptide sequence includes a sequence having at least 80% identity with GGGSGGGGSGGGGS (SEQ ID NO: 153).
[0068] In some embodiments, the single-chain variable fragment polypeptide comprises a second light chain variable region, a second linker peptide sequence, and a second heavy chain variable region, from the N-terminus to the C-terminus.
[0069] In some embodiments, the second linker peptide sequence includes a sequence having at least 80% identity with GGGGSGGGGSGGGGSGGGGS (SEQ ID NO: 154).
[0070] In some embodiments, the Disclosure relates to a bispecific antibody or antigen-binding fragment thereof described herein, comprising a first heavy chain variable region (VH1) comprising complementarity-determining regions (CDRs) 1, 2, and 3, a first light chain variable region (VL1) comprising CDRs 1, 2, and 3, a second heavy chain variable region (VH2) comprising complementarity-determining regions (CDRs) 1, 2, and 3, and a second light chain variable region (VL2) comprising CDRs 1, 2, and 3, wherein in some embodiments, the VH1 CDR1 region comprises an amino acid sequence having at least 80% identity with a selected VH1 CDR1 amino acid sequence, the VH1 CDR2 region comprises an amino acid sequence having at least 80% identity with a selected VH1 CDR2 amino acid sequence, the VH1 CDR3 region comprises an amino acid sequence having at least 80% identity with a selected VH1 CDR3 amino acid sequence, and in some embodiments, the VL1 CDR1 region comprises a selected VL1 The VL1 CDR2 region includes an amino acid sequence having at least 80% identity with the CDR1 amino acid sequence, the VL1 CDR3 region includes an amino acid sequence having at least 80% identity with the selected VL1 CDR3 amino acid sequence, and in some embodiments, the VH2 CDR1 region includes an amino acid sequence having at least 80% identity with the selected VH2 CDR1 amino acid sequence, the VH2 CDR2 region includes an amino acid sequence having at least 80% identity with the selected VH2 CDR2 amino acid sequence, the VH2 CDR3 region includes an amino acid sequence having at least 80% identity with the selected VH2 CDR3 amino acid sequence, and in some embodiments, the VL2 CDR1 region includes an amino acid sequence having at least 80% identity with the selected VL2 CDR1 amino acid sequence, and the VL2 CDR2 region includes an amino acid sequence having at least 80% identity with the selected VL2 The VL2 CDR3 region includes an amino acid sequence having at least 80% identity with the CDR2 amino acid sequence, and the VL2 CDR3 region includes an amino acid sequence having at least 80% identity with the selected VL2 CDR3 amino acid sequence.
[0071] In some embodiments, the selected VH1 CDR1, 2, and 3 amino acid sequences, the selected VL1 CDR1, 2, and 3 amino acid sequences, the selected VH2 CDR1, 2, and 3 amino acid sequences, and the selected VL2 CDR1, 2, and 3 amino acid sequences are any of the following:
[0072] (1) According to the Kabat numbering rules, the selected VH1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs: 1, 2, and 3, respectively; the selected VL1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs: 4, 5, and 6, respectively; the selected VH2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs: 65, 66, and 67, respectively; the selected VL2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs: 68, 69, and 70, respectively; and
[0073] (2) In accordance with the Chothia numbering rules, the selected VH1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs. 19, 20, and 21, respectively, and the selected VL1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs. 22, 23, and 24, respectively, and the selected VH2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs. 83, 84, and 85, respectively, and the selected VL2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs. 86, 87, and 88, respectively.
[0074] In some embodiments, the first heavy chain variable region includes a sequence having at least 80%, 85%, 90%, or 95% identity with sequence number 41, the first light chain variable region includes a sequence having at least 80%, 85%, 90%, or 95% identity with sequence number 45, the second heavy chain variable region includes a sequence having at least 80%, 85%, 90%, or 95% identity with sequence number 108 or 126, and the second light chain variable region includes a sequence having at least 80%, 85%, 90%, or 95% identity with sequence number 110 or 127.
[0075] In some embodiments, this disclosure relates to a bispecific antibody or its antigen-binding fragment described herein, hereby, (1) The heavy chain polypeptide comprises a sequence having at least 80%, 85%, 90%, or 95% identity with SEQ ID NO: 134 or 135, and (2) The light chain polypeptide contains a sequence that is at least 80%, 85%, 90%, or 95% identical to sequence number 136.
[0076] In some embodiments, this disclosure relates to a bispecific antibody or its antigen-binding fragment described herein, hereby,
[0077] (1) The heavy chain polypeptide contains a sequence having at least 80%, 85%, 90%, or 95% identity with SEQ ID NO: 137 or 138, and
[0078] (2) The light chain polypeptide contains a sequence that is at least 80%, 85%, 90%, or 95% identical to sequence number 139.
[0079] In one embodiment, the disclosure provides a bispecific antibody comprising an anti-PD-1 antibody containing an Fc region and an antigen-binding site that specifically binds to CD40. In some embodiments, the antigen-binding site is ligated to the Fc region of the anti-PD-1 antibody.
[0080] In some embodiments, bispecific antibodies induce activation of the CD40 pathway in immune cells in the presence of one or more cells expressing PD-1. In some embodiments, the antigen-binding site that specifically binds to CD40 includes an ScFv or VHH domain. In some embodiments, the antigen-binding site that specifically binds to CD40 includes a CD40 ligand (e.g., CD40L) or its soluble portion. In some embodiments, the antigen-binding site that specifically binds to CD40 is ligated to the C-terminus of an Fc region. In some embodiments, the antigen-binding site that specifically binds to CD40 is inserted into an Fc region (e.g., site 3A).
[0081] In one embodiment, the disclosure provides an antigen-binding protein construct (e.g., a bispecific antibody or its antigen-binding fragment) comprising, or comprising, an antibody containing an Fc region and an antigen-binding site (e.g., one or two antigen-binding sites) that specifically binds to CD40, wherein the antibody specifically binds to a target. In some embodiments, the antigen-binding site is linked to the Fc region of the antibody.
[0082] In some embodiments, the antigen-binding protein construct induces activation of the CD40 pathway in immune cells in the presence of one or more cells expressing the target. In some embodiments, the antigen-binding protein construct can activate the CD40 pathway. In some embodiments, activation of the CD40 pathway depends on the binding of the antigen-binding protein construct to cells expressing the target. In some embodiments, the antigen-binding protein construct induces activation of the CD40 pathway in the tumor microenvironment or tumor discharge lymph nodes. In some embodiments, the antigen-binding protein construct does not induce activation of the CD40 pathway in the absence of one or more cells expressing the target. In some embodiments, the antigen-binding protein construct cannot activate the CD40 pathway by an Fc receptor-mediated mechanism or Fc receptor-mediated aggregation. In some embodiments, the antigen-binding protein construct cannot activate the CD40 pathway in the absence of cells expressing PD-1.
[0083] In some embodiments, the target is an immune checkpoint molecule. In some embodiments, the target is a cancer-specific antigen or cancer-associated antigen. In some embodiments, the target is PD-1. In some embodiments, the antigen-binding site that specifically binds to CD40 includes an ScFv or VHH domain. In some embodiments, the antigen-binding site that specifically binds to CD40 includes a CD40 ligand (e.g., CD40L) or its soluble portion. In some embodiments, the antigen-binding site that specifically binds to CD40 is ligated to the C-terminus of the Fc region. In some embodiments, the antigen-binding site that specifically binds to CD40 is inserted into the Fc region (e.g., the 3A region).
[0084] In one embodiment, the present disclosure relates to an antibody-drug conjugate comprising an antigen-binding protein construct described herein or a bispecific antibody or antigen-binding fragment described herein, which is covalently bound to a therapeutic agent.
[0085] In some embodiments, the therapeutic agent is a cytotoxic agent or a cell inhibitor.
[0086] In one embodiment, the Disclosure relates to a method for treating a subject with cancer, comprising administering a therapeutically effective amount of a composition comprising an antigen-binding protein construct, a bispecific antibody or antigen-binding fragment, or an antibody-drug conjugate as described herein to the subject.
[0087] In some embodiments, the subjects are suffering from solid tumors.
[0088] In some embodiments, the cancer is non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (SCCHN), head and neck cancer, renal cell carcinoma (RCC), melanoma, bladder cancer, gastric cancer, urothelial carcinoma, Merkel cell carcinoma, triple-negative breast cancer (TNBC), or colorectal cancer.
[0089] In some embodiments, the cancer is melanoma, pancreatic cancer, mesothelioma, or malignant hematological malignancy.
[0090] In some embodiments, the method further includes administering an anti-CTLA4 antibody, an anti-Her2 antibody, or an antibody targeting a tumor-associated antigen (TAA).
[0091] In some embodiments, the method includes administering chemotherapy to a subject. In one embodiment, the Disclosure relates to a method for reducing the growth rate of a tumor, comprising administering to a subject requiring an effective amount of a composition comprising an antigen-binding protein construct, a bispecific antibody or antigen-binding fragment, or an antibody-drug conjugate as described herein.
[0092] In one embodiment, the Disclosure relates to a method for killing tumor cells, comprising administering to a subject requiring an effective amount of a composition comprising an antigen-binding protein construct described herein, a bispecific antibody or antigen-binding fragment described herein, or an antibody-drug conjugate described herein.
[0093] In one embodiment, the disclosure relates to a pharmaceutical composition comprising an antigen-binding protein construct or a bispecific antibody or antigen-binding fragment described herein, and a pharmaceutically acceptable vector.
[0094] In one embodiment, this disclosure relates to a pharmaceutical composition comprising an antibody-drug conjugate described herein and a pharmaceutically acceptable vector.
[0095] In one embodiment, the disclosure relates to a bispecific or multispecific antibody or its antigen-binding fragment comprising a single-chain variable fragment polypeptide that specifically binds to CD40. In some embodiments, the single-chain variable fragment polypeptide is ligated to the C-terminus of the heavy chain polypeptide of the bispecific or multispecific antibody or its antigen-binding fragment.
[0096] In some embodiments, a bispecific or multispecific antibody or its antigen-binding fragment specifically binds to a cancer-specific antigen or cancer-associated antigen.
[0097] In some embodiments, a bispecific or multispecific antibody or its antigen-binding fragment specifically binds to an immune checkpoint molecule.
[0098] In one embodiment, the disclosure provides a nucleic acid comprising a polynucleotide encoding any of the polypeptides described herein. In some embodiments, the nucleic acid encodes a bispecific antibody. In some embodiments, the nucleic acid is cDNA.
[0099] In one embodiment, the present disclosure provides a vector comprising one or more nucleic acids described herein.
[0100] In one embodiment, the disclosure provides cells comprising the vectors described herein. In some embodiments, the cells are CHO cells. In one embodiment, the disclosure provides cells comprising one or more of the nucleic acids described herein.
[0101] As used herein, the term “antigen-binding protein construct” means (i) a single polypeptide comprising one or more antigen-binding domains, or (ii) a complex of two or more polypeptides (e.g., identical or different polypeptides) that together form one or more antigen-binding domains. Non-limiting examples and embodiments of antigen-binding protein constructs are described herein.
[0102] As used herein, the terms “antigen-binding domain,” “antigen-binding region,” or “antigen-binding site” refer to one or more protein domains (e.g., formed from amino acids derived from a single polypeptide or from amino acids derived from two or more polypeptides (e.g., the same or different polypeptides)) that can specifically bind to an antigen. In some embodiments, the antigen-binding domain can bind to an antigen or epitope with specificity and affinity similar to that of naturally occurring antibodies. In some embodiments, the antigen-binding domain may be an antibody or a fragment thereof. An example of an antigen-binding domain is an antigen-binding domain formed from a VH-VL dimer. In some embodiments, the antigen-binding domain may include an alternative skeleton. In some embodiments, the antigen-binding domain is a ligand (e.g., PD-L1, CD154, or its soluble portion). For example, the antigen may be a PD-1 receptor, and the antigen-binding domain (e.g., the soluble portion of PD-L1) can specifically bind to the PD-1 receptor. In some embodiments, the antigen-binding domain is a VHH domain. This specification describes non-exclusive examples of antigen-binding domains.
[0103] As used herein, the term “antibody” means any antigen-binding molecule that comprises at least one (e.g., one, two, three, four, five, or six) complementarity-determining regions (CDRs) (e.g., any three CDRs derived from an immunoglobulin light chain or any three CDRs derived from an immunoglobulin heavy chain) and is capable of specifically binding to an antigen or epitope. Non-limiting examples of antibodies include monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), single-chain antibodies, chimeric antibodies, heavy-chain antibodies, single-domain antibodies (nanobodies), human antibodies, and humanized antibodies. In some embodiments, an antibody may include the Fc region of a human antibody. The term antibody further includes derivatives, such as bispecific antibodies, single-chain antibodies, bivalent antibodies, linear antibodies, and multispecific antibodies formed from antibody fragments.
[0104] As used herein, the term “antigen-binding fragment” refers to a portion of a full-length antibody, where the portion of the antibody is capable of specifically binding to an antigen. In some embodiments, the antigen-binding fragment comprises at least one variable domain (e.g., a heavy-chain variable domain or a light-chain variable domain). Non-limiting examples of antibody fragments include, for example, Fab, Fab', F(ab')2, Fv fragments, and VHH. As used herein, “VHH” is a variable domain of a heavy-chain antibody.
[0105] As used herein, the term “human antibody” refers to an antibody encoded by a human-derived nucleic acid (e.g., a rearranged human immunoglobulin heavy or light chain locus). In some embodiments, human antibodies are collected from humans or produced in human cell cultures (e.g., human hybridoma cells). In some embodiments, human antibodies are produced in non-human cells (e.g., mouse or hamster cell lines). In some embodiments, human antibodies are produced in bacterial or yeast cells. In some embodiments, human antibodies are produced in transgenic non-human animals (e.g., cattle) containing unrearranged or rearranged human immunoglobulin loci (e.g., heavy or light chain human immunoglobulin loci).
[0106] As used herein, the term “humanized antibody” refers to a non-human antibody that contains minimal sequences derived from non-human (e.g., mouse) immunoglobulin and sequences derived from human immunoglobulin. In non-limiting examples, a humanized antibody is a human antibody (receptor antibody) in which the hypervariable region (e.g., CDR) residues of the receptor antibody are replaced with hypervariable region (e.g., CDR) residues derived from a non-human antibody (e.g., donor antibody) having desired specificity, affinity, and capability, e.g., a mouse, rat, or rabbit antibody. In some embodiments, the Fv framework residues of human immunoglobulin are replaced with corresponding non-human (e.g., mouse) immunoglobulin residues. In some embodiments, the humanized antibody may contain residues not found in the receptor antibody or donor antibody. These modifications can be made to further improve antibody performance. In some embodiments, a humanized antibody comprises substantially all portions of at least one, usually two, variable domains, where all or substantially all hypervariable loops (CDRs) correspond to the hypervariable loops of a non-human (e.g., mouse) immunoglobulin, and all or substantially all framework regions are the framework regions of a human immunoglobulin. The humanized antibody may further comprise at least a portion of the immunoglobulin constant region (Fc), usually at least a portion of the constant region of a human immunoglobulin. Humanized antibodies can be produced using molecular biological methods known in the art. Non-limiting examples of methods for producing humanized antibodies are described herein.
[0107] As used herein, the term “chimeric antibody” refers to an antibody containing sequences present in at least two different species (e.g., an antibody derived from two different mammalian species, such as a human and a mouse antibody). A non-limiting example of a chimeric antibody is an antibody containing a variable domain sequence of a non-human (e.g., mouse) antibody (e.g., all or part of the light chain and / or heavy chain variable domain sequence) and a constant domain of a human antibody. Other examples of chimeric antibodies are described herein and are known in the art.
[0108] As used herein, the term “multispecific antigen-binding protein construct” is an antigen-binding protein construct comprising two or more different antigen-binding domains that specifically bind to two or more different epitopes. The two or more different epitopes may be epitopes on the same antigen (e.g., a single polypeptide present on a cell surface) or on different antigens (e.g., different proteins present on the same cell surface or on different cell surfaces). In some embodiments, the multispecific antigen-binding protein construct binds to two different epitopes (i.e., a “bispecific antigen-binding protein construct”). In some embodiments, the multispecific antigen-binding protein construct binds to three different epitopes (i.e., a “triplespecific antigen-binding protein construct”). In some embodiments, the multispecific antigen-binding protein construct binds to four different epitopes (i.e., a “quadrispecific antigen-binding protein construct”). In some embodiments, the multispecific antigen-binding protein construct binds to five different epitopes (i.e., a “quintuplespecific antigen-binding protein construct”). Each binding specificity may be present in any appropriate valency. This specification describes non-exclusive examples of multispecific antigen-binding protein constructs.
[0109] As used herein, the term “bispecific antibody” refers to an antibody that binds to two different epitopes. These epitopes may be on the same antigen or on different antigens.
[0110] As used herein, when referring to antibodies, the term “specific binding” means that the interaction depends on the presence of a specific structure (i.e., an antigenic determinant or epitope) on the target molecule, so that the antibody preferentially interacts with its target molecule (e.g., PD-1) compared to other molecules; in other words, the reagent recognizes and binds to molecules containing a specific structure, rather than all molecules as in the usual case. An antibody that specifically binds to a target molecule can be called a target-specific antibody. For example, an antibody that specifically binds to the PD-1 molecule can be called a PD-1 specific antibody or anti-PD-1 antibody.
[0111] Unless otherwise specified, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art. Methods and materials for the present invention are described herein, but other suitable methods and materials known in the art may also be used. Materials, methods and examples are illustrative and not intended to limit the scope. All publications, patent applications, patents, sequences, database entries, and other references referenced herein are incorporated herein by reference in their entirety. In case of any inconsistency, this specification (including definitions) shall prevail.
[0112] Other features and advantages of the present invention will become apparent from the following specific embodiments and accompanying drawings, as well as from the claims. [Brief explanation of the drawing]
[0113] [Figure 1A] This is a schematic structure of the bispecific antibody Fab-ScFV-IgG. [Figure 1B] This is a schematic structure of the bispecific antibody ScFV-HC-IgG. [Figure 2A] The gel electrophoresis results for Fab-ScFV-IgG4 are shown. M is the marker. Fab-ScFV-IgG4 is located in lane 2. [Figure 2B] The gel electrophoresis results for ScFV-HC-IgG4 are shown. M is the marker. ScFV-HC-IgG4 is located in lane 3. [Figure 3] This shows the luminescence levels in Jurkat-Luc-hPD-1 cells after activation with the anti-PD1 antibody 1A7-H2K3-IgG4 (PD-1), Fab-ScFV-IgG4, or ScFV-HC-IgG4. The antibodies block the PD1 / PD-L1 pathway, thereby activating Jurkat-Luc-hPD-1 cells. The luminescence signal is expressed as relative light units (Rlu). [Figure 4A]The luminescence level in Jurkat-Luc-hCD40 cells is shown when CHO-K1-hPD1 and the selected antibody are present. The antibody is selected from the group consisting of a 1:1 combination of anti-PD-1 antibody 1A7-H2K3-IgG4 and anti-CD40 antibody 6A7-H4K2-IgG2 (PD-1+CD40), Fab-ScFV-IgG4, and ScFV-HC-IgG4. The luminescence signal is expressed as relative light units (Rlu). [Figure 4B] The luminescence level in Jurkat-Luc-hCD40 cells is indicated when the selected antibody is present. The antibody is selected from the group consisting of a 1:1 combination of anti-PD-1 antibody 1A7-H2K3-IgG4 and anti-CD40 antibody 6A7-H4K2-IgG2 (PD-1+CD40), Fab-ScFV-IgG4, and ScFV-HC-IgG4. The luminescence signal is expressed as relative light units (Rlu). [Figure 5] The luminescence level in Jurkat-Luc-hCD40 cells is shown when CHO-K1-hFcγRIIB and selected antibodies are present. The antibodies are selected from the group consisting of the anti-CD40 monoclonal antibody 6A7-H4K2-IgG2(CD40), Fab-ScFV-IgG4, and ScFV-HC-IgG4. The luminescence signal is expressed as relative light units (Rlu). [Figure 6A] The luminescence level in Jurkat-Luc-hCD40 cells is shown when the selected antibody is present. The antibody is selected from the group consisting of the anti-CD40 monoclonal antibody 6A7-H4K2-IgG2(CD40), ScFV-HC-IgG4, and ScFV-HC-IgG1-LALA. The luminescence signal is expressed as relative light units (Rlu). [Figure 6B] This shows the luminescence level in Jurkat-Luc-hCD40 cells when Jurkat-PD1 cells and selected antibodies are present. The antibodies are selected from the group consisting of the anti-CD40 monoclonal antibody 6A7-H4K2-IgG2(CD40), ScFV-HC-IgG4, and ScFV-HC-IgG1-LALA. The luminescence signal is expressed as relative light units (Rlu). [Figure 6C]This shows the luminescence level in Jurkat-Luc-hCD40 cells when CHO-K1-hFcγRIIB cells and selected antibodies are present. The antibodies are selected from the group consisting of the anti-CD40 monoclonal antibody 6A7-H4K2-IgG2(CD40), ScFV-HC-IgG4, and ScFV-HC-IgG1-LALA. The luminescence signal is expressed as relative light units (Rlu). [Figure 7] This figure shows the time course of body weight in B-hCD40 mice injected with mouse colon cancer cells MC38 and treated with the bispecific antibody ScFV-HC-IgG4 or ScFV-HC-IgG1-LALA. Physiological saline (PS) solution was injected as a control. [Figure 8] This figure shows the time course of body weight change in B-hCD40 mice injected with mouse colon cancer cells MC38 and treated with the bispecific antibody ScFV-HC-IgG4 or ScFV-HC-IgG1-LALA. Physiological saline (PS) solution was injected as a control. [Figure 9] This figure shows the mean tumor volume of different groups of B-hCD40 mice injected with mouse colon cancer cells MC38 and treated with the bispecific antibody ScFV-HC-IgG4 or ScFV-HC-IgG1-LALA. Physiological saline (PS) solution was injected as a control. [Figure 10] This figure shows the time course of body weight in B-hPD-1 / hCD40 mice injected with B16F10-hPD-L1 cells and treated with monospecific or bispecific antibodies. Physiological saline (PS) solution was injected as a control. [Figure 11] This figure shows the time course of body weight change in B-hPD-1 / hCD40 mice injected with B16F10-hPD-L1 cells and treated with monospecific or bispecific antibodies. Physiological saline (PS) solution was used as a control. [Figure 12] This figure shows the mean tumor volume of different groups of B-hPD-1 / hCD40 mice injected with B16F10-hPD-L1 cells and treated with monospecific or bispecific antibodies. Physiological saline (PS) solution was injected as a control. [Figure 13]This shows the mean tumor volume at day 25 after grouping of B-hPD-1 / hCD40 mice from different groups that were injected with MC38-hPD-L1 cells and treated with monospecific or bispecific antibodies. Physiological saline (PS) solution was injected as a control. [Figure 14] This figure shows the time course of body weight in B-hPD-1 / hCD40 mice injected with MC38-hPD-L1 cells and treated with monospecific or bispecific antibodies. Physiological saline (PS) solution was injected as a control. [Figure 15] This figure shows the time course of body weight change in B-hPD-1 / hCD40 mice injected with MC38-hPD-L1 cells and treated with monospecific or bispecific antibodies. Physiological saline (PS) solution was injected as a control. [Figure 16] This figure shows the mean tumor volume of different groups of B-hPD-1 / hCD40 mice injected with MC38-hPD-L1 cells and treated with monospecific or bispecific antibodies. Physiological saline (PS) solution was injected as a control. [Figure 17A] This shows the ALT levels in the blood of B-hPD-1 / hCD40 mice on day 7 after grouping, from different groups of mice that were injected with MC38-hPD-L1 cells and treated with monospecific or bispecific antibodies. [Figure 17B] This shows the ALT levels in the blood of B-hPD-1 / hCD40 mice at day 13 after grouping, in different groups of mice that were injected with MC38-hPD-L1 cells and treated with monospecific or bispecific antibodies. [Figure 17C] This shows the blood AST levels of B-hPD-1 / hCD40 mice on day 7 after grouping, in different groups of mice that were injected with MC38-hPD-L1 cells and treated with monospecific or bispecific antibodies. [Figure 17D] This shows the blood AST levels of B-hPD-1 / hCD40 mice on day 13 after grouping, in different groups of mice that were injected with MC38-hPD-L1 cells and treated with monospecific or bispecific antibodies. [Figure 17E]Representative histological section images of the liver and kidney of G1 group B-hPD-1 / hCD40 mice injected with MC38-hPD-L1 cells and treated with PBS are shown. [Figure 17F] Representative histological section images of the liver and kidney of G2 group B-hPD-1 / hCD40 mice injected with MC38-hPD-L1 cells and treated with selicrelumab are shown. [Figure 17G] Representative histological section images of the liver and kidney of G3 group B-hPD-1 / hCD40 mice, which were injected with MC38-hPD-L1 cells and treated with the anti-CD40 monoclonal antibody 6A7-H4K2-IgG2, are shown. [Figure 17H] Representative histological section images of the liver and kidney of B-hPD-1 / hCD40 mice from group G4, which were injected with MC38-hPD-L1 cells and treated with the anti-PD1 monoclonal antibody 1A7-H2K3-IgG4, are shown. [Figure 17I] Representative histological section images of the liver and kidney of G5 group B-hPD-1 / hCD40 mice injected with MC38-hPD-L1 cells and treated with ScFV-HC-IgG4 are shown. [Figure 17J] Representative histological section images of the liver and kidney of G1 group B-hPD-1 / hCD40 mice, which were injected with MC38-hPD-L1 cells and treated with a combination of anti-PD1 monoclonal antibody 1A7-H2K3-IgG4 and anti-CD40 monoclonal antibody 6A7-H4K2-IgG2 (combo), are shown. [Figure 18A] This is a schematic structure of the bispecific antibody PD1-C40-6A7-FV3A. [Figure 18B] The gel electrophoresis results for PD1-C40-6A7-FV3A are shown. M is the marker. PD1-C40-6A7-FV3A is located in lane 4. [Figure 18C]This shows the luminescence level in Jurkat-Luc-hCD40 cells when CHO-K1-hFcγRIIB cells and selected antibodies are present. The antibodies are selected from the group consisting of anti-CD40 monoclonal antibodies 6A7-H4K2-IgG2(CD40), Fab-ScFv-IgG4, and PD1-C40-6A7-FV3A. The luminescence signal is expressed as relative light units (Rlu). [Figure 18D] This shows the luminescence level in Jurkat-Luc-hCD40 cells when CHO-K1-hPD-1 cells (CHO PD-1) and selected antibodies are present. The antibodies are selected from the group consisting of a combination of anti-PD-1 monoclonal antibody 1A7-H2K3-IgG4 and anti-CD40 monoclonal antibody 6A7-H4K2-IgG2 (PD-1+CD40), Fab-ScFv-IgG4, and PD1-C40-6A7-FV3A. The luminescence signal is expressed as relative light units (Rlu). [Figure 19] The CDR sequences of anti-PD1 antibodies 25-1A7, 18-3F1, and 3-6G1, as defined by Kabat numbering, are shown. [Figure 20] The CDR sequences of anti-PD1 antibodies 25-1A7, 18-3F1, and 3-6G1, as defined by Chothia numbering, are shown. [Figure 21] The amino acid sequences of human, mouse, and chimeric PD-1 are shown. [Figure 22-1] The amino acid sequences of the heavy chain variable region and light chain variable region of the humanized mouse anti-PD1 antibody are shown. [Figure 22-2] The amino acid sequences of the heavy chain variable region and light chain variable region of the humanized mouse anti-PD1 antibody are shown. [Figure 22-3] The amino acid sequences of the heavy chain variable region and light chain variable region of the humanized mouse anti-PD1 antibody are shown. [Figure 23] The CDR sequences of the anti-CD40 antibodies 03-7F10, 06-6A7, and 07-4H6, as defined by Kabat numbering, are shown. [Figure 24] The CDR sequences of the anti-CD40 antibodies 03-7F10, 06-6A7, and 07-4H6, as defined by Chothia numbering, are shown. [Figure 25] The amino acid sequences of human, mouse, and chimeric CD40 are shown. [Figure 26-1] The amino acid sequences of the heavy chain variable region and light chain variable region of the humanized and mouse anti-CD40 antibodies are shown. [Figure 26-2] The amino acid sequences of the heavy chain variable region and light chain variable region of the humanized and mouse anti-CD40 antibodies are shown. [Figure 26-3] The amino acid sequences of the heavy chain variable region and light chain variable region of the humanized and mouse anti-CD40 antibodies are shown. [Figure 26-4] The amino acid sequences of the heavy chain variable region and light chain variable region of the humanized and mouse anti-CD40 antibodies are shown. [Figure 27] This figure shows the time course of body weight in B-hPD-1 / hCD40 mice injected with B16F10-hPD-L1 cells and treated with monospecific or bispecific antibodies. PBS solution was injected as a control. [Figure 28] This figure shows the time course of tumor volume in B-hPD-1 / hCD40 mice injected with B16F10-hPD-L1 cells and treated with monospecific or bispecific antibodies. PBS solution was injected as a control. [Figure 29A] This figure shows the tumor volume within 70 days after grouping of B-hPD-1 / hCD40 mice (G2-G7) that were injected with B16F10-hPD-L1 cells and treated with the bispecific antibody ScFV-HC-IgG1-LALA at concentrations of 0.1 mg / kg to 30 mg / kg. PBS solution was injected as the control (G1). [Figure 29B] This figure shows the survival rates within 70 days after grouping of B-hPD-1 / hCD40 mice that were injected with B16F10-hPD-L1 cells and treated with the bispecific antibody ScFV-HC-IgG1-LALA (G2-G7) at concentrations of 0.1 mg / kg to 30 mg / kg. PBS solution was injected as the control (G1). [Figure 30A]This is a set of histograms showing the percentage of mouse CD3+ T cells among CD45+ leukocytes (I), the percentage of mouse CD8+ T cells among CD45+ leukocytes (II), and the ratio of CD8+ T cells to Treg cells among T cells (III) in the MC38 tumor model. [Figure 30B] This is a set of histograms showing the percentage of human PD-1 (CD279)-positive cells in CD8+ T cells (I), human PD-1-positive cells in Treg cells (II), human PD-1-positive cells in CD4+ (non-Treg) T cells (III), and human PD-1-positive cells in NK cells (IV) in the MC38 tumor model. [Figure 30C] This is a set of histograms showing the percentage of dendritic cells (DCs) in mouse CD45+ leukocytes (I), the percentage of myeloid-derived immunosuppressive cells (MDSCs) in mouse CD45+ leukocytes (II), the percentage of CD80+ cells in DC cells (III), and the percentage of MHCII+ cells in DC cells (IV) in the MC38 tumor model. [Figure 30D] This is a set of histograms showing the percentage of mouse CD3+ T cells among CD45+ leukocytes (I), the percentage of mouse CD8+ T cells among CD45+ leukocytes (II), and the ratio of CD8+ T cells to Treg cells among T cells (III) in the B16F10 tumor model. [Figure 30E] This is a set of histograms showing the percentage of human PD-1 (CD279)-positive cells in CD8+ T cells (I), human PD-1-positive cells in Treg cells (II), human PD-1-positive cells in CD4+ (non-Treg) T cells (III), and human PD-1-positive cells in NK cells (IV) in the B16F10 tumor model. [Figure 30F]This is a set of histograms showing the percentage of dendritic cells (DCs) in mouse CD45+ leukocytes (I), the percentage of myeloid-derived immunosuppressive cells (MDSCs) in mouse CD45+ leukocytes (II), the percentage of CD80+ cells in DC cells (III), the percentage of CD86+ cells in DC cells (IV), and the percentage of MHCII+ cells in DC cells (V) in the B16F10 tumor model. [Figure 31A] This document outlines strategies for flow cytometry analysis. [Figure 31B] This document outlines strategies for flow cytometry analysis. [Figure 32] This figure shows the time course of body weight in B-hPD-1 / hCD40 mice injected with MC38-hPD-L1 cells and treated with monoclonal antibodies (G2-G4), bispecific antibodies (G5 and G6), or a combination of monospecific antibodies (G7 and G8). PBS solution was injected as a control (G1). [Figure 33] This figure shows the time course of body weight change in B-hPD-1 / hCD40 mice injected with MC38-hPD-L1 cells and treated with monoclonal antibodies (G2-G4), bispecific antibodies (G5 and G6), or a combination of monospecific antibodies (G7 and G8). PBS solution was injected as a control (G1). [Figure 34] This figure shows the time course of tumor volume in B-hPD-1 / hCD40 mice injected with MC38-hPD-L1 cells and treated with monoclonal antibodies (G2-G4), bispecific antibodies (G5 and G6), or a combination of monospecific antibodies (G7 and G8). PBS solution was injected as a control (G1). [Figure 35] This figure shows the time course of body weight in B-hPD-1 / hCD40 mice injected with monoclonal antibodies (G2 and G3), bispecific antibodies with different structures (G4-G7), or the bispecific antibody ScFV-HC-IgG1-LALA (G8). PBS solution was injected as a control (G1). [Figure 36]This figure shows the time course of body weight change in B-hPD-1 / hCD40 mice injected with monoclonal antibodies (G2 and G3), bispecific antibodies with different structures (G4-G7), or the bispecific antibody ScFV-HC-IgG1-LALA (G8). PBS solution was injected as a control (G1). [Figure 37] This is a schematic structure of the DART-Fc molecule of the bispecific antibody 1A7-sericrelumab-DART-IgG4. DART refers to a biaffinity retargeting antibody. [Figure 38A] This shows the ALT levels of B-hPD-1 / hCD40 mice on day 7 after grouping, in different groups injected with PBS (G1), monoclonal antibodies (G2 and G3), bispecific antibodies with different structures (G4-G7), or the bispecific antibody ScFV-HC-IgG1-LALA (G8). [Figure 38B] The images show the AST levels of B-hPD-1 / hCD40 mice on day 7 after grouping, in different groups injected with PBS (G1), monoclonal antibodies (G2 and G3), bispecific antibodies with different structures (G4-G7), or the bispecific antibody ScFV-HC-IgG1-LALA (G8). [Figure 39] This figure shows the time course of body weight in B-hPD-1 / hCD40 mice that were injected with MC38-hPD-L1 cells and treated with monoclonal antibodies (G2 and G3), a combination of monospecific antibodies (G4), or bispecific antibodies (G5-G6), or injected with PBS solution as a control (G1). [Figure 40] This figure shows the time course of body weight change in B-hPD-1 / hCD40 mice that were injected with MC38-hPD-L1 cells and treated with monoclonal antibodies (G2 and G3), a combination of monospecific antibodies (G4), or bispecific antibodies (G5-G6), or injected with PBS solution as a control (G1). [Figure 41]This figure shows the time course of tumor volume in B-hPD-1 / hCD40 mice that were injected with MC38-hPD-L1 cells and treated with monoclonal antibodies (G2 and G3), a combination of monospecific antibodies (G4), or bispecific antibodies (G5-G6), or injected with PBS solution as a control (G1). [Figure 42A] This shows the luminescence level in Jurkat-Luc-hCD40 cells when Jurkat-PD1 cells and selected antibodies are present. The antibodies are selected from the group consisting of BsAb pembrolizumab-seli-HC-IgG4, 1A7-sericrelumab-FV3A-IgG4, 1A7-sericrelumab-FVHC-IgG4, 1A7-sericrelumab-FVKH-IgG4, 1A7-sericrelumab-DART-IgG4, and the anti-CD40 monoclonal antibody sericrelumab-IgG2. The luminescence signal is expressed as relative light units (Rlu). [Figure 42B] This shows the luminescence level in Jurkat-Luc-hCD40 cells when Jurkat-PD1 cells and selected antibodies are present. The antibodies are selected from the group consisting of BsAb pembrolizumab-6A7-HC-IgG1-LALA, SdAb-6A7-FVHC-IgG1-LALA, pembrolizumab-APX005M-FVHC-IgG4, anti-CD40 monoclonal antibody APX005M-IgG1-S267E, and 6A7-H4K2-IgG2. The luminescence signal is expressed as relative light units (Rlu). [Figure 42C] The luminescence level in Jurkat-Luc-hCD40 cells is shown in the absence of Jukat-luc-PD1 cells and the selected antibody. The antibody is selected from the group consisting of BsAb pembrolizumab-seli-HC-IgG4, 1A7-sericrelumab-FV3A-IgG4, 1A7-sericrelumab-FVHC-IgG4, 1A7-sericrelumab-FVKH-IgG4, 1A7-sericrelumab-DART-IgG4, and the anti-CD40 monoclonal antibody sericrelumab-IgG2. The luminescence signal is expressed as relative light units (Rlu). [Figure 42D]The luminescence level in Jurkat-Luc-hCD40 cells is shown in the absence of Jukat-luc-PD1 cells and the selected antibody. The antibody is selected from the group consisting of BsAb pembrolizumab-6A7-HC-IgG1-LALA, SdAb-6A7-FVHC-IgG1-LALA, pembrolizumab-APX005M-FVHC-IgG4, anti-CD40 monoclonal antibody APX005M-IgG1-S267E, and 6A7-H4K2-IgG2. The luminescence signal is expressed as relative light units (Rlu). [Figure 43] This paper presents a hypothetical mechanism of CD40 signaling pathway activation induced by PD1 / CD40 bispecific antibodies. [Figure 44A] This figure shows the time course of body weight in B-hPD-1 / hCD40 mice injected with MC38-hPD-L1 cells and treated with monoclonal antibodies (G2, G3, and G4), bispecific antibodies (G5-G7), or a combination of monospecific antibodies (G8 and G9). PS solution was injected as a control (G1). [Figure 44B] This figure shows the time course of body weight change in B-hPD-1 / hCD40 mice treated with MC38-hPD-L1 cells and monoclonal antibodies (G2, G3, and G4), bispecific antibodies (G5-G7), or a combination of monospecific antibodies (G8 and G9). PS solution was injected as a control (G1). [Figure 44C] This figure shows the time course of tumor volume in B-hPD-1 / hPD-L1 / hCD40 mice injected with MC38-hPD-L1 cells and treated with a combination of monoclonal antibodies (G2, G3, and G4), bispecific antibodies (G5-G7), or monospecific antibodies (G8 and G9). PS solution was injected as a control (G1). [Figure 45] This figure shows the time course of body weight in B-hPD-1 / hPD-L1 / hCD40 mice injected with MC38-hPD-L1 cells and treated with ScFV-HC-IgG1-LALA (G2 and G5), atezolizumab-6A7-FVHC-IgG1-LALA (G3 and G6), or avelumab-6A7-FVHC-IgG1-LALA (G4 and G7). PBS solution was injected as a control (G1). [Figure 46] This figure shows the time course of body weight change in B-hPD-1 / hPD-L1 / hCD40 mice injected with MC38-hPD-L1 cells and treated with ScFV-HC-IgG1-LALA (G2 and G5), atezolizumab-6A7-FVHC-IgG1-LALA (G3 and G6), or avelumab-6A7-FVHC-IgG1-LALA (G4 and G7). PBS solution was injected as a control (G1). [Figure 47] This figure shows the time course of tumor volume in B-hPD-1 / hPD-L1 / hCD40 mice injected with MC38-hPD-L1 cells and treated with ScFV-HC-IgG1-LALA (G2 and G5), atezolizumab-6A7-FVHC-IgG1-LALA (G3 and G6), or avelumab-6A7-FVHC-IgG1-LALA (G4 and G7). PBS solution was injected as a control (G1). [Figure 48-1] The sequence described herein is shown. [Figure 48-2] The sequence described herein is shown. [Figure 48-3] The sequence described herein is shown. [Figure 48-4] The sequence described herein is shown. [Figure 48-5] The sequence described herein is shown. [Modes for carrying out the invention]
[0114] A bispecific antibody or its antigen-binding fragment is an artificial protein that can simultaneously bind to two different epitopes (for example, two different antigens).
[0115] In some embodiments, bispecific antibodies or their antigen-binding fragments can be constructed by modifying immunoglobulins (e.g., IgG). For example, the Fab region of anti-PD-1 IgG may be replaced with a CD40-targeting scFv domain. Alternatively, a CD40-targeting scFv domain can be ligated to the C-terminus of the anti-PD-1 IgG heavy chain.
[0116] In some embodiments, a bispecific antibody or its antigen-binding fragment may have two arms (arms A and B). Each arm has one heavy chain variable region and one light chain variable region, forming an antigen-binding domain (or antigen-binding site).
[0117] The bispecific antibody or its antigen-binding fragment may be IgG-like and non-IgG-like. The IgG-like bispecific antibody may have two Fab arms and one Fc region, and these two Fab arms bind to different antigens. The non-IgG-like bispecific antibody or antigen-binding fragment may be, for example, a chemically linked Fab (e.g., two Fab regions chemically linked) and a single-chain variable fragment (scFv). For example, an scFv may have two heavy-chain variable regions and two light-chain variable regions. In some embodiments, one arm is an scFv polypeptide. In some embodiments, both arms are scFv polypeptides.
[0118] Anti-PD-1 / CD40 antigen-binding protein construct The immune system can distinguish between normal cells in the body and cells considered "foreign," allowing it to attack foreign cells without affecting normal cells. This mechanism sometimes involves proteins called immune checkpoints. Immune checkpoints are molecules that turn on (co-stimulatory molecules) or turn off signals within the immune system.
[0119] Checkpoint inhibitors can prevent autoimmune diseases by preventing the immune system from attacking normal tissue. Many tumor cells also express checkpoint inhibitors. These tumor cells evade immune monitoring by "co-opting" specific immune checkpoint pathways (particularly in tumor antigen-specific T cells) (Creelan, Benjamin C. "Update on immune checkpoint inhibitors in lung cancer," Cancer Control 21.1 (2014): pp. 80-89). Since many immune checkpoints are initiated by ligand-receptor interactions, they are readily blocked by antibodies against their ligands and / or receptors.
[0120] This disclosure provides anti-PD1 / CD40 antigen-binding protein constructs having various forms as described herein. While we do not wish to be bound by theory, it is hypothesized that in the presence of PD-1-expressing cells, PD1 / CD40 bispecific antibodies can effectively activate the CD40 signaling pathway, and that the mechanism may involve the aggregation of CD40 at the contact surface between PD-1-expressing cells and CD40-expressing cells. The bispecific antibodies can promote the enrichment of CD40 and PD1 molecules at the contact surface. This enrichment further increases CD40 aggregation, thereby activating the CD40 pathway.
[0121] PD-1 PD-1 (Programmed Cell Death-1) defends against autoimmunity through a dual mechanism in which immune checkpoints promote apoptosis (programmed cell death) of antigen-specific T cells in lymph nodes while reducing apoptosis of regulatory T cells (anti-inflammatory, suppressive T cells).
[0122] PD-1 is primarily expressed on the surface of T cells and early B cells, while its two ligands (PD-L1 and PD-L2) are widely expressed in antigen-presenting cells (APCs). The interaction between PD-1 and its ligands plays a crucial role in the negative regulation of the immune response. Inhibiting the binding of PD-1 to its ligands can expose tumor cells to the killing effects of the immune system, thereby killing tumor tissue and achieving the effect of treating cancer.
[0123] PD-L1 is expressed on tumor cells of many different cancers. By binding to PD-1 on T cells, it suppresses it, and PD-L1 expression is a major mechanism by which tumor cells evade immune attack. Conceptually, PD-L1 overexpression can be caused by two mechanisms: congenital and adaptive. Endogenous expression of PD-L1 on cancer cells is associated with cellular / genetic abnormalities in these tumor cells. Activation of cellular signaling pathways, including the AKT and STAT pathways, leads to increased PD-L1 expression. In primary mediastinal B-cell lymphoma, MHC class II transactivator (CIITA) genetically fuses with PD-L1 or PD-L2, leading to overexpression of these proteins. Amplification of chromosomes 9p23-24, where PD-L1 and PD-L2 are located, leads to increased expression of these two proteins in classical Hodgkin lymphoma. Adaptive mechanisms are related to the induction of PD-L1 expression in the tumor microenvironment. PD-L1 can be induced on tumor cells in response to interferon-gamma. In microsatellite-instability colorectal cancer, PD-L1 is primarily expressed on myeloid cells within the tumor and further suppresses the function of cytotoxic T cells.
[0124] The use of PD-1 blocking to enhance antitumor immunity stems from findings in chronic infection models where suppressing PD-1 interactions reversed T cell depletion. Similarly, blocking PD-1 suppresses T cell PD-1 / tumor cell PD-L1 or T cell PD-1 / tumor cell PD-L2 interactions, thereby restoring T cell-mediated antitumor immunity.
[0125] For a detailed explanation of PD-1 and the application of anti-PD-1 antibodies to cancer treatment, see: Topalian, Suzanne L. et al., "Safety, activity, and immune correlates of anti-PD-1 antibody in cancer," New England Journal of Medicine 366.26 (2012): pp. 2443-2454; Hirano, Fumiya et al., "Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity," Cancer Research 65.3 (2005): pp. 1089-1096; Raedler, Lisa A., "Keytruda (pembrolizumab): first PD-1 inhibitor approved for previously treated unresectable or metastatic melanoma," American Health & Drug Benefits 8. Spec Feature (2015) 96; Kwok, Gerry et al., "Pembrolizumab (Keytruda), (2016): pp. 2777–2789; US 20170247454; US 9,834,606 B; and US 8,728,474, each of which is incorporated herein by reference in its entirety.
[0126] CD40 CD40 (also known as Tumor Necrosis Factor Receptor Superfamily Member 5 or TNFRSF5) is a member of the Tumor Necrosis Factor Receptor Superfamily expressed on antigen-presenting cells (APCs) such as dendritic cells (DCs), macrophages, B cells, and monocytes, as well as many non-immune cells and a wide range of tumors. Its interaction with its trimer ligand CD154 (also known as CD40 ligand or CD40L) on activated T helper cells leads to APC activation, thereby inducing adaptive immunity.
[0127] Physiologically, CD40-mediated signaling on APCs is considered representative of the major components of T cell helpers and largely mediates the ability of helper T cells to license APCs. For example, ligation of CD40 to DCs induces increased surface expression of costimulatory and MHC molecules, production of pro-inflammatory cytokines, and enhanced T cell induction. Ligation of CD40 on resting B cells increases antigen-presenting function and proliferation.
[0128] In preclinical models, rat anti-mouse CD40 mAbs have shown remarkable therapeutic activity in the treatment of CD40+ B-cell lymphoma (80%–100% of mice were cured and immune re-attacked in a CD8 T cell-dependent manner), and are also effective against various CD40-negative tumors. These mAbs can remove large tumors in mice suffering from near-terminal disease. CD40 mAbs have been studied in clinical trials and are used to treat melanoma, pancreatic cancer, mesothelioma, hematological malignancies, particularly non-Hodgkin lymphoma, lymphoma, chronic lymphocytic leukemia, and progressive solid tumors.
[0129] Therapeutic anti-CD40 antibodies exhibit a wide range of activity, from potent agonists to antagonists. Currently, this heterogeneity remains unsatisfactory. The primary mechanism of agonist CD40 mAbs is to activate host APCs and induce clinically significant antitumor T-cell responses in patients. These responses include T-cell-independent but macrophage-dependent tumor regression induction. CD40-activated macrophages can become tumor-killing cells, potentially promoting tumor stroma depletion and thereby inducing endogenous tumor breakdown, at least in pancreatic cancer. Importantly, these mechanisms do not require tumors to express CD40, which is why many clinical trials include a large number of tumor patients. While the goal of these strategies is to activate DCs, macrophages, or both, the objective of CD40 mAbs is not necessarily to kill the cells they bind to, for example, through complement-mediated cytotoxicity (CDC) or antibody-dependent cytotoxicity (ADCC). Therefore, by design, strong agonist antibodies do not mediate CDC or ADCC. In contrast, other human CD40 mAbs can mediate CDC and ADCC against CD40+ tumors, including almost all B-cell malignancies, some melanomas, and some cancers. Finally, there is some evidence that CD40 binds to tumor cells and promotes apoptosis, and this can be done without any immunoeffector pathways. This has been shown to be applicable to CD40+ B-cell malignancies, as well as certain solid tumors such as CD40+ cancers and melanomas.
[0130] For a detailed description of CD40 and its function, see, for example, Vonderheide et al., "Agonistic CD40 antibodies and cancer therapy," (2013): pp. 1035-1043; Beatty et al., "CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans," Science 331.6024 (2011): pp. 1612-1616; and Vonderheide et al., "Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody," Journal of Clinical Oncology 25.7 (2007): pp. 876-883. Each of these references is incorporated herein by reference in its entirety.
[0131] In some embodiments, the disclosure provides antigen-binding constructs (e.g., bispecific antibodies) that specifically bind to two different antigens (e.g., PD-1 and CD40). In some embodiments, the antigen-binding constructs (e.g., bispecific antibodies) can crosslink PD-1-expressing cells (e.g., T cells) and CD40-expressing cells (e.g., APC cells) to promote antigen presentation, CD40 linkage, and / or T cell activation. In some embodiments, the antigen-binding constructs can block the PD-1 / PD-L1 pathway to activate an immune response. In some embodiments, the antigen-binding constructs (e.g., bispecific antibodies) can activate the CD40 pathway in antigen-presenting cell (APC) cells (e.g., dendritic cells or macrophages) to induce an antitumor response. In some embodiments, the CD40 activation induced by the antigen-binding constructs (e.g., bispecific antibodies) occurs only in the presence of PD-1-expressing cells (e.g., by a crosslinking effect). Therefore, antigen-binding constructs (e.g., bispecific antibodies) can induce an immune response within the local tumor microenvironment without causing systemic immune activation, which can induce side effects such as hepatic toxicity. Furthermore, in some embodiments, antigen-binding constructs (e.g., bispecific antibodies) cannot activate the CD40 pathway by Fc receptor (e.g., FCγRIIB)-mediated CD40 aggregation. In some embodiments, the methods described herein further reduce toxicity in high-FCγRIIB-expressing tissues, such as the liver and / or kidneys.
[0132] Furthermore, lymph nodes adjacent to the tumor downstream (tumor dissipation lymph nodes (TDLNs)) can undergo significant changes due to the presence of the tumor upstream. TDLNs enrich tumor-specific PD-1+ T cells closely associated with conventional PD-L1+ dendritic cells. Blocking the PD-1 pathway targeting TDLNs can induce enhanced anti-tumor T-cell immunity by inoculating the tumor site with progenitor-exhausted T cells, thereby improving tumor control. In TDLNs, the number and inhibitory activity of regulatory T cells (Tregs) also increase. Some of these Treg cells can be novelly generated in response to specific tumor-derived antigens. In some cases, presentation of novel antigens in TDLNs may not only fail to induce a protective immune response but may also actively induce systemic tolerance. Therefore, in one embodiment, antigen-binding constructs (e.g., bispecific antibodies) can also induce an immune response in tumor-discharging lymph nodes, suppress Treg cell activity in tumor-discharging lymph nodes, and inhibit systemic resistance to tumor antigens.
[0133] In some embodiments, the Disclosure provides a method for reducing the toxicity of an anti-CD40 monoclonal antibody (e.g., sericrelumab). The method comprises producing a multispecific (e.g., bispecific) antibody containing an antigen-binding fragment of an anti-CD40 monoclonal antibody. In some embodiments, the multispecific antibody has an antigen-binding fragment for PD-1. In some embodiments, the multispecific (e.g., bispecific) antibody has a structure as described herein. In some embodiments, it is evaluated by blood biochemical tests (e.g., by measuring ALT and / or AST levels) or by histopathological examination of the liver. In some embodiments, compared to the toxicity of an unmodified anti-CD40 monoclonal antibody, the method described herein can reduce the toxicity of the anti-CD40 monoclonal antibody by less than 80%, less than 70%, less than 60%, less than 50%, less than 40%, less than 30%, less than 20%, or less than 10%.
[0134] In some embodiments, the antibody or its antigen-binding fragment contains the CH1, CH2, and / or CH3 domains of IgG4 (e.g., the CH2 and CH3 domains). In some embodiments, the antibody or its antigen-binding fragment contains a knob-into-hole (KIH) mutation. In some embodiments, the antibody or its antigen-binding fragment contains the CH1, CH2, and CH3 domains of IgG4 in a first polypeptide chain and the CH2, and CH3 domains of IgG4 in a second polypeptide chain. In some embodiments, the antibody or its antigen-binding fragment contains an amino acid sequence having at least 80%, 85%, 90%, or 95% identity with SEQ ID NOs: 149, 150, or 151.
[0135] In some embodiments, the antibody or its antigen-binding fragment contains the CH1, CH2, and / or CH3 domains of IgG1 (e.g., CH1, CH2, and CH3 domains). In some embodiments, the antibody or its antigen-binding fragment contains an LALA mutation. In some embodiments, the antibody or its antigen-binding fragment contains the CH1, CH2, and CH3 domains of IgG1 in a first polypeptide chain and the CH1, CH2, and CH3 domains of IgG1 in a second polypeptide chain. In some embodiments, the antibody or its antigen-binding fragment contains an amino acid sequence having at least 80%, 85%, 90%, or 95% identity with SEQ ID NO: 147 or 148.
[0136] In some embodiments, the antibody or its antigen-binding fragment contains an amino acid sequence in which a lysine residue is deleted at the C-terminus of the IgG (e.g., IgG1 or IgG4) heavy chain constant domain 3 (CH3). In some embodiments, compared to the antibody or antigen-binding fragment containing the C-terminal lysine residue of IgG CH3, the deletion of the C-terminal lysine residue of the IgG CH3 domain reduces the degradation level of the antibody or its antigen-binding fragment by, for example, at least or about 10%, 20%, 30%, 40%, or 50%.
[0137] In some embodiments, the antibody or its antigen-binding fragment includes a light chain constant domain (CL). In some embodiments, the CL includes an amino acid sequence having at least 80%, 85%, 90%, or 95% identity with SEQ ID NO: 146.
[0138] In one embodiment, the present disclosure provides a bispecific antibody or an antigen-binding fragment thereof, which includes:
[0139] (a) A heavy chain polypeptide preferably comprising a first heavy chain variable region (VH1), a heavy chain constant region 1 (CH1), a heavy chain constant region 2 (CH2), and a heavy chain constant region 3 (CH3) from the N-terminus to the C-terminus.
[0140] (b) A light chain polypeptide preferably comprising a first light chain variable region (VL1) and a light chain constant region (CL) from the N-terminus to the C-terminus, and
[0141] (c) Preferably a single-stranded variable fragment polypeptide comprising an scFv domain, a heavy chain constant region 2 (CH2), and a heavy chain constant region 3 (CH3) from the N-terminus to the C-terminus.
[0142] In some embodiments, the scFv domain includes a second heavy chain variable region, a linker peptide sequence, and a second light chain variable region from the N-terminus to the C-terminus.
[0143] In some embodiments, the scFv domain includes a second light chain variable region, a linker peptide sequence, and a second heavy chain variable region from the N-terminus to the C-terminus.
[0144] In some embodiments, the first heavy chain variable region and the first light chain variable region bind to each other to form a first antigen-binding site that specifically binds to PD-1. In some embodiments, the second heavy chain variable region and the second light chain variable region bind to each other to form a second antigen-binding site that specifically binds to CD40.
[0145] In some embodiments, the second heavy chain variable region, the linker peptide sequence, and the second light chain variable region together form an scFv domain that specifically binds to CD40. In some embodiments, the linker peptide sequence includes a sequence having at least 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NOs: 152, 153, or 154. In some embodiments, the CH1, CH2, CH3, and / or CL domains are derived from human IgG (e.g., IgG1 or IgG4). In some embodiments, the human IgG (e.g., IgG1 or IgG4) includes KIH and / or LALA mutations.
[0146] In some embodiments, the sequence of the heavy chain polypeptide is shown in SEQ ID NO: 130. In some embodiments, the sequence of the light chain polypeptide is shown in SEQ ID NO: 131. In some embodiments, the sequence of the single-stranded variable fragment polypeptide is shown in SEQ ID NO: 132 or 133 (e.g., SEQ ID NO: 132). In some embodiments, the sequences of the PD-1 heavy chain and light chain of Fab-ScFV-IgG4 are shown in SEQ ID NO: 130 and SEQ ID NO: 131, respectively, and the sequence of the CD40 arm of Fab-ScFV-IgG4 is shown in SEQ ID NO: 132.
[0147] In some embodiments, the bispecific antibodies or antigen-binding fragments described herein have the schematic structure shown in Figure 1A. In some embodiments, the sequence of the heavy chain polypeptide has at least 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 166. In some embodiments, the sequence of the light chain polypeptide has at least 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 167. In some embodiments, the sequence of the single-chain variable fragment peptide has at least 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 206. In some embodiments, the heavy chain and light chain sequences of the PD-1 arm of the bispecific antibodies or antigen-binding fragments described herein are shown in SEQ ID NO: 166 and SEQ ID NO: 167, respectively, and the sequence of the CD40 arm of the bispecific antibodies or antigen-binding fragments described herein is shown in SEQ ID NO: 173.
[0148] In one embodiment, the present disclosure provides a bispecific antibody or an antigen-binding fragment thereof, which includes:
[0149] (a) Preferably a first heavy chain polypeptide comprising a first heavy chain variable region (VH1), a heavy chain constant region 1 (CH1), a heavy chain constant region 2 (CH2), a heavy chain constant region 3 (CH3), a first linker peptide sequence, and an scFv domain from the N-terminus to the C-terminus.
[0150] (b) A first light chain polypeptide preferably comprising a first light chain variable region (VL1) and a first light chain constant region (CL) from the N-terminus to the C-terminus.
[0151] In some embodiments, the scFv domain includes a second light chain variable region (VL2), a second linker peptide sequence, and a second heavy chain variable region (VH2) from the N-terminus to the C-terminus.
[0152] In some embodiments, the scFv domain includes a second heavy chain variable region (VH2), a second linker peptide sequence, and a second light chain variable region (VL2) from the N-terminus to the C-terminus.
[0153] In some embodiments, the first antigen-binding site specifically binds to an immune checkpoint molecule. In some embodiments, the first antigen-binding site specifically binds to programmed cell death protein 1 (PD-1), cytotoxic T lymphocyte-associated protein 4 (CTLA-4), lymphocyte activation gene 3 (LAG-3), B and T lymphocyte-associated proteins (BTLA), programmed cell death ligand 1 (PD-L1), T cell immune receptor having CD27, CD28, CD47, CD137, CD154, Ig and ITIM domains (TIGIT), glucocorticoid-inducible TNFR-associated protein (GITR), T cell immunoglobulin and mucin domain-3 (TIM-3), or TNF receptor superfamily member 4 (TNFRSF4 or OX40). In some embodiments, the first antigen-binding site specifically binds to PD-1.
[0154] In some embodiments, the first antigen-binding site specifically binds to a cancer-specific antigen or cancer-associated antigen. As used herein, the term “cancer-specific antigen” refers to an antigen that is specifically expressed on the surface of cancer cells. These antigens can be used to identify tumor cells. Normal cells express little to no cancer-specific antigens. Some exemplary cancer-specific antigens include, for example, CD20, PSA, PSCA, PD-L1, Her2, Her3, Her1, β-catenin, CD19, CEACAM3, EGFR, c-Met, EPCAM, PSMA, CD40, MUC1, and IGF1R. PSA is mainly expressed on prostate cancer cells, and Her2 is mainly expressed on breast cancer cells. As used herein, the term “cancer-associated antigen” refers to an antigen that is expressed at relatively high levels on cancer cells but may also be expressed at relatively low levels on normal cells. CD55, CD59, CD46, and many adhesion molecules (e.g., N-cadherin, VE-cadherin, NCAM, Mel-CAM, ICAM, NrCAM, VCAM1, ALCAM, MCAM, etc.) are cancer-associated antigens. Both cancer-specific antigens and cancer-associated antigens are expressed on the surface of cancer cells, but the difference between them is that cancer-associated antigens are also expressed on normal cells, but at much lower levels compared to those expressed on cancer cells. In contrast, cancer-specific antigens are hardly expressed on normal cells, or if they are expressed on normal cells, the amount is extremely low.
[0155] In some embodiments, the second heavy chain variable region and the second light chain variable region bind to each other to form a second antigen-binding site that specifically binds to CD40. In some embodiments, the second antigen-binding site includes or consists of ScFv or VHH.
[0156] In some embodiments, the second antigen-binding site is linked to the Fc region of the antibody (e.g., IgG). In some embodiments, the second antigen-binding site is linked to the C-terminus of the Fc region. In some embodiments, the second antigen-binding site is inserted into the Fc region, for example, at site 3A.
[0157] The 3A site refers to a region in Fc into which a non-natural peptide can be inserted without interfering with the function of the immunoglobulin or the biological activity of the fusion polypeptide. The 3A site is located from position 344 to position 382 (EU numbering). In some embodiments, the non-natural polypeptide replaces one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty In some embodiments, the fusion site is located in the region of positions 351-362 (EU numbering). In some embodiments, a non-natural polypeptide replaces one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, or all of the amino acids (e.g., 351-362) at the fusion site, or is inserted between any two amino acids at the fusion site, for example, at positions 351-352, 352-353, 353-354, 354-355, 355-356, 356-357, 357-358, 358-359, 359-360, 360-361, or 361-362. In some embodiments, the two residues are selected from any two positions of the heavy chain CH3 domain, positions 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, and 363 according to EU numbering. In some embodiments, the non-natural polypeptide substitutes amino acids 358-362 at the fusion site.
[0158] In some embodiments, anti-CD40 scFv is fused to each of the heavy chain CH3 domains of an anti-PD-1 monoclonal antibody. In some embodiments, the bispecific antibody or its antigen-binding fragment described herein has the schematic structure shown in Figure 18A. In some embodiments, the fused heavy chain polypeptide has a sequence having at least 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 161. In some embodiments, the light chain polypeptide has a sequence having at least 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 141. In some embodiments, the fused heavy chain polypeptide includes an anti-PD-1 heavy chain variable region described herein. In some embodiments, the light chain polypeptide includes an anti-PD-1 light chain variable region described herein.
[0159] In some embodiments, the fusion heavy chain polypeptide has a sequence that is at least 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 168. In some embodiments, the light chain polypeptide has a sequence that is at least 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 169.
[0160] In some embodiments, the bispecific antibody or its antigen-binding fragment further comprises a second heavy chain polypeptide having at least 90%, 95%, or 100% identity with a first heavy chain polypeptide, and a second light chain polypeptide having at least 90%, 95%, or 100% identity with a first light chain polypeptide.
[0161] In some embodiments, the second light chain variable region, the linker peptide sequence, and the second heavy chain variable region together form an scFv domain that specifically binds to CD40. In some embodiments, the first linker peptide sequence includes a sequence having at least 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 153 or 154. In some embodiments, the second linker peptide sequence includes a sequence having at least 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 153 or 154. In some embodiments, the CH1, CH2, CH3, and / or CL domains are derived from human IgG (e.g., IgG1 or IgG4). In some embodiments, the human IgG (e.g., IgG1 or IgG4) includes KIH and / or LALA mutations.
[0162] In some embodiments, the antibodies or antigen-binding fragments described herein can block the PD-1 / PD-L1 pathway.
[0163] In some embodiments, the bispecific antibodies or antigen-binding fragments described herein have the schematic structure shown in Figure 1B. In some embodiments, the sequence of the first heavy-chain polypeptide is shown in SEQ ID NO: 134 or 135. In some embodiments, the sequence of the first light-chain polypeptide is shown in SEQ ID NO: 136. In some embodiments, the sequence of the first heavy-chain polypeptide is shown in SEQ ID NO: 137 or 138. In some embodiments, the sequence of the first light-chain polypeptide is shown in SEQ ID NO: 139. In some embodiments, the sequence of the modified heavy chain of ScFv-HC-IgG4 is shown in SEQ ID NO: 134, and the sequence of the light chain of ScFv-HC-IgG4 is shown in SEQ ID NO: 136. In some embodiments, the sequence of the modified heavy chain of ScFv-HC-IgG1-LALA is shown in SEQ ID NO: 137, and the sequence of the light chain of ScFv-HC-IgG1-LALA is shown in SEQ ID NO: 139.
[0164] In some embodiments, the sequence of the first heavy-chain polypeptide includes a sequence having at least 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 162, and the sequence of the first light-chain polypeptide includes a sequence having at least 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 163. In some embodiments, the sequence of the first heavy-chain polypeptide includes a sequence having at least 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 164, and the sequence of the first light-chain polypeptide includes a sequence having at least 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 165. In some embodiments, the sequence of the first heavy-chain polypeptide includes a sequence having at least 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 175, and the sequence of the first light-chain polypeptide includes a sequence having at least 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 176. In some embodiments, the sequence of the first heavy-chain polypeptide includes a sequence having at least 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 177, and the sequence of the first light-chain polypeptide includes a sequence having at least 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 178.
[0165] In some embodiments, the sequence of the first heavy-chain polypeptide includes a sequence having at least 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 172, and the sequence of the first light-chain polypeptide includes a sequence having at least 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 174. In some embodiments, the disclosure provides a bispecific antibody or antigen-binding fragment thereof comprising a polypeptide chain preferably comprising a single variable domain (VHH) that binds to PD-1 from the N-terminus to the C-terminus, optionally a CH1, CH2, CH3, linker peptide sequence, and an scFv domain. In some embodiments, the VHH includes a sequence having at least 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 204.
[0166] In some embodiments, the variable regions (e.g., VH and / or VL) of selected anti-PD-1 antibodies are used to substitute the corresponding anti-PD-1 variable regions (e.g., VH and / or VL) of the bispecific antibodies described herein according to their sequences. For example, the VH sequence of the selected anti-PD-1 antibody can be selected from SEQ ID NOs: 179, 181, 183, 185, 187, 189, 207, or 209, and the VL sequence of the selected anti-PD-1 antibody can be selected from SEQ ID NOs: 180, 182, 184, 186, 188, 190, 208, or 210.
[0167] In some embodiments, the VH and VL of the selected anti-PD-1 antibody are both used to substitute the corresponding VH and VL of the bispecific antibodies described herein according to their sequences. For example, the VH of the selected anti-PD-1 antibody is SEQ ID NO: 179, the VL of the selected anti-PD-1 antibody is SEQ ID NO: 180, the VH of the selected anti-PD-1 antibody is SEQ ID NO: 181, the VL of the selected anti-PD-1 antibody is SEQ ID NO: 182, the VH of the selected anti-PD-1 antibody is SEQ ID NO: 183, the VL of the selected anti-PD-1 antibody is SEQ ID NO: 184, the VH of the selected anti-PD-1 antibody is SEQ ID NO: 185, and the VL of the selected anti-PD-1 antibody is SEQ ID NO: 186. The selected anti-PD-1 antibody VH is SEQ ID NO: 187, the selected anti-PD-1 antibody VL is SEQ ID NO: 188, the selected anti-PD-1 antibody VH is SEQ ID NO: 189, the selected anti-PD-1 antibody VL is SEQ ID NO: 190, the selected anti-PD-1 antibody VH is SEQ ID NO: 207, the selected anti-PD-1 antibody VL is SEQ ID NO: 208, the selected anti-PD-1 antibody VH is SEQ ID NO: 209, and the selected anti-PD-1 antibody VL is SEQ ID NO: 210.
[0168] In some embodiments, the variable regions (e.g., VH and / or VL) of selected anti-CD40 antibodies are used to substitute the corresponding anti-CD40 variable regions (e.g., VH and / or VL) of the bispecific antibodies described herein according to their sequences. For example, the VH sequence of the selected anti-PD-1 antibody can be selected from SEQ ID NOs: 191, 193, 195, 197, or 199, and the VL sequence of the selected anti-PD-1 antibody can be selected from SEQ ID NOs: 192, 194, 196, 198, or 200.
[0169] In some embodiments, the VH and VL of the selected anti-CD40 antibody are both used to substitute the corresponding VH and VL of the bispecific antibodies described herein according to their sequences. For example, the VH of the selected anti-CD40 antibody is SEQ ID NO: 191, the VL of the selected anti-CD40 antibody is SEQ ID NO: 192, the VH of the selected anti-CD40 antibody is SEQ ID NO: 193, the VL of the selected anti-CD40 antibody is SEQ ID NO: 194, the VH of the selected anti-CD40 antibody is SEQ ID NO: 195, the VL of the selected anti-CD40 antibody is SEQ ID NO: 196, the VH of the selected anti-CD40 antibody is SEQ ID NO: 197, the VL of the selected anti-CD40 antibody is SEQ ID NO: 198, the VH of the selected anti-CD40 antibody is SEQ ID NO: 199, and the VL of the selected anti-CD40 antibody is SEQ ID NO: 200.
[0170] Anti-CD40 antibody and antigen-binding fragment This disclosure provides several antibodies and antigen-binding fragments that specifically bind to CD40. Anti-PD-1 / CD40 antigen-binding protein constructs (e.g., bispecific antibodies) or various antigen-binding protein constructs may include antigen-binding sites derived from these antibodies.
[0171] The antibodies and antigen-binding fragments described herein can bind to CD40. This disclosure provides, for example, mouse anti-CD40 antibodies 03-7F10 ("7F10"), 06-6A7 ("6A7"), and 07-4H6 ("4H6"), chimeric antibodies, and humanized antibodies thereof.
[0172] The CDR sequences of 7F10 and 7F10-inducible antibodies (e.g., humanized antibodies) include CDRs of the heavy chain variable domain (SEQ ID NOs. 59-61) and the light chain variable domain (SEQ ID NOs. 62-64), as defined by Kabat numbering. CDRs can also be defined by the Chothia system. According to Chothia numbering, the CDR sequences of the heavy chain variable domain are shown in SEQ ID NOs. 77-79, and the CDR sequences of the light chain variable domain are shown in SEQ ID NOs. 80-82.
[0173] Similarly, the CDR sequences of 6A7 and 6A7-inducing antibodies include CDRs of the heavy chain variable domain (SEQ ID NOs. 65-67) and the light chain variable domain (SEQ ID NOs. 68-70) as defined by Kabat numbering. According to Chothia numbering, the CDR sequences of the heavy chain variable domain are shown in SEQ ID NOs. 83-85, and the CDR sequences of the light chain variable domain are shown in SEQ ID NOs. 86-88.
[0174] The CDR sequences of 4H6 and 4H6-inducing antibodies include CDRs of the heavy chain variable domain (SEQ ID NOs. 71-73) and the light chain variable domain (SEQ ID NOs. 74-76), as defined by Kabat numbering. According to Chothia numbering, the CDR sequences of the heavy chain variable domain are shown in SEQ ID NOs. 89-91, and the CDR sequences of the light chain variable domain are shown in SEQ ID NOs. 92-94.
[0175] Further information is provided regarding the amino acid sequences of the heavy chain variable region and light chain variable region of humanized antibodies. Because the methods of humanizing mouse antibodies differ (for example, sequences may be substituted with different amino acids), the heavy and light chains of antibodies may have more than one version of the humanized sequence. The amino acid sequences of the heavy chain variable region of humanized 7F10 antibodies are shown in SEQ ID NOs. 98-100. The amino acid sequences of the light chain variable region of humanized 7F10 antibodies are shown in SEQ ID NOs. 101-104. Any of these heavy chain variable region sequences (SEQ ID NOs. 98-100) can be paired with any of these light chain variable region sequences (SEQ ID NOs. 101-104).
[0176] Similarly, the amino acid sequences of the heavy chain variable region of humanized 6A7 antibodies are shown in SEQ ID NOs: 105-108. The amino acid sequences of the light chain variable region of humanized 6A7 antibodies are shown in SEQ ID NOs: 109-111. The heavy chain and light chain variable regions may also be modified to enhance stability or interaction. 6A7-H4 can be further modified to obtain SEQ ID NO: 126. 6A7-K2 can be further modified to obtain SEQ ID NO: 127. Similarly, the heavy chain variable region of mouse 6A7 antibodies can be further modified to obtain SEQ ID NO: 128. The light chain variable region of mouse 6A7 antibodies can be further modified to obtain SEQ ID NO: 129. Any of these heavy chain variable region sequences (SEQ ID NOs: 105-108, 126, and 128) can be paired with any of these light chain variable region sequences (SEQ ID NOs: 109-111, 127, and 129). The amino acid sequences of the heavy chain variable region of the humanized 4H6 antibody are shown in SEQ ID NOs: 112-115. The amino acid sequences of the light chain variable region of the humanized 4H6 antibody are shown in SEQ ID NOs: 116-119. Any of these heavy chain variable region sequences (SEQ ID NOs: 112-115) can be paired with any of these light chain variable region sequences (SEQ ID NOs: 116-119).
[0177] As shown in Figure 26, the humanization percentage refers to the percentage of identity of the heavy chain or light chain variable region sequence compared to the human antibody sequence in the International Immunogenetic Information System (IMGT) database. Optimal alignment (top hit) means that the heavy chain or light chain variable region sequence is closer to a particular species than to other species. For example, optimal alignment with humans means that the sequence is closer to humans than to other species. Optimal alignment with humans and cynomolgus monkeys means that the sequence has the same identity percentage as human and cynomolgus monkey sequences, and that these identity percentages are the highest compared to sequences of other species. In some embodiments, the humanization percentage exceeds 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, or 95%. Detailed explanations of how to determine the humanization percentage and how to determine the optimal alignment are publicly known in the art, for example, Jones, Tim D. et al., "The INNs and outs of antibody nonproprietary names," MAbs., Vol. 8, No. 1, Taylor & Francis, 2016, which is incorporated herein by reference in its entirety. Higher humanization percentages generally offer many advantages, including being safer and more effective in humans, more likely to be tolerated in human subjects, and / or less likely to have side effects.
[0178] Furthermore, in some embodiments, the antibody or antigen-binding fragment described herein may further comprise one, two, or three heavy chain variable region CDRs selected from the group consisting of SEQ ID NOs. 59-61, SEQ ID NOs. 65-67, SEQ ID NOs. 71-73, SEQ ID NOs. 77-79, SEQ ID NOs. 83-85 and SEQ ID NOs. 89-91, and / or one, two, or three light chain variable region CDRs selected from the group consisting of SEQ ID NOs. 62-64, SEQ ID NOs. 68-70, SEQ ID NOs. 74-76, SEQ ID NOs. 80-82, SEQ ID NOs. 86-88 and SEQ ID NOs. 92-94.
[0179] In some embodiments, the antibody may have a heavy chain variable region (VH) containing complementarity-determining regions (CDRs) 1, 2, and 3, where the CDR1 region contains or consists of amino acid sequences having at least 80%, 85%, 90%, or 95% identity with a selected VH CDR1 amino acid sequence; the CDR2 region contains or consists of amino acid sequences having at least 80%, 85%, 90%, or 95% identity with a selected VH CDR2 amino acid sequence; and the CDR3 region contains or consists of amino acid sequences having at least 80%, 85%, 90%, or 95% identity with a selected VH CDR3 amino acid sequence. The antibody may also have a light chain variable region (VL) containing CDRs 1, 2, and 3, where the CDR1 region contains a selected VL The CDR1 amino acid sequence contains or consists of an amino acid sequence having at least 80%, 85%, 90%, or 95% identity with the selected VL CDR2 amino acid sequence, and the CDR3 region contains or consists of an amino acid sequence having at least 80%, 85%, 90%, or 95% identity with the selected VL CDR3 amino acid sequence. The selected VH CDR1, 2, and 3 amino acid sequences and the selected VL CDR1, 2, and 3 amino acid sequences are shown in Figure 23 (Kabat CDR) and Figure 24 (Chothia CDR).
[0180] In some embodiments, the antibody or antigen-binding fragment described herein may contain a heavy chain variable domain comprising one, two, or three CDRs from among the CDRs of SEQ ID NO: 59 having 0, 1, or 2 amino acid insertions, deletions, or substitutions, the CDR of SEQ ID NO: 60 having 0, 1, or 2 amino acid insertions, deletions, or substitutions, and the CDR of SEQ ID NO: 61 having 0, 1, or 2 amino acid insertions, deletions, or substitutions.
[0181] In some embodiments, the antibody or antigen-binding fragment described herein may contain a heavy chain variable domain comprising one, two, or three CDRs from among the CDRs of SEQ ID NO: 65 having 0, 1, or 2 amino acid insertions, deletions, or substitutions, the CDR of SEQ ID NO: 66 having 0, 1, or 2 amino acid insertions, deletions, or substitutions, and the CDR of SEQ ID NO: 67 having 0, 1, or 2 amino acid insertions, deletions, or substitutions.
[0182] In some embodiments, the antibody or antigen-binding fragment described herein may contain a heavy chain variable domain comprising one, two, or three CDRs from among the CDRs of SEQ ID NO: 71 having 0, 1, or 2 amino acid insertions, deletions, or substitutions, the CDR of SEQ ID NO: 72 having 0, 1, or 2 amino acid insertions, deletions, or substitutions, and the CDR of SEQ ID NO: 73 having 0, 1, or 2 amino acid insertions, deletions, or substitutions.
[0183] In some embodiments, the antibody or antigen-binding fragment described herein may contain a heavy chain variable domain comprising one, two, or three CDRs from among the CDRs of SEQ ID NO: 77 having 0, 1, or 2 amino acid insertions, deletions, or substitutions, the CDR of SEQ ID NO: 78 having 0, 1, or 2 amino acid insertions, deletions, or substitutions, and the CDR of SEQ ID NO: 79 having 0, 1, or 2 amino acid insertions, deletions, or substitutions.
[0184] In some embodiments, the antibody or antigen-binding fragment described herein may contain a heavy chain variable domain comprising one, two, or three CDRs from among the CDRs of SEQ ID NO: 83 having 0, 1, or 2 amino acid insertions, deletions, or substitutions, the CDR of SEQ ID NO: 84 having 0, 1, or 2 amino acid insertions, deletions, or substitutions, and the CDR of SEQ ID NO: 85 having 0, 1, or 2 amino acid insertions, deletions, or substitutions.
[0185] In some embodiments, the antibody or antigen-binding fragment described herein may include a heavy chain variable domain comprising one, two, or three CDRs from among the CDRs of SEQ ID NO: 89 having 0, 1, or 2 amino acid insertions, deletions, or substitutions, the CDR of SEQ ID NO: 90 having 0, 1, or 2 amino acid insertions, deletions, or substitutions, and the CDR of SEQ ID NO: 91 having 0, 1, or 2 amino acid insertions, deletions, or substitutions.
[0186] In some embodiments, the antibody or antigen-binding fragment described herein may contain a light chain variable domain comprising one, two, or three CDRs from among the CDRs of SEQ ID NO: 62 having 0, 1, or 2 amino acid insertions, deletions, or substitutions, the CDR of SEQ ID NO: 63 having 0, 1, or 2 amino acid insertions, deletions, or substitutions, and the CDR of SEQ ID NO: 64 having 0, 1, or 2 amino acid insertions, deletions, or substitutions.
[0187] In some embodiments, the antibody or antigen-binding fragment described herein may contain a light chain variable domain comprising one, two, or three CDRs from among the CDRs of SEQ ID NO: 68 having 0, 1, or 2 amino acid insertions, deletions, or substitutions, the CDR of SEQ ID NO: 69 having 0, 1, or 2 amino acid insertions, deletions, or substitutions, and the CDR of SEQ ID NO: 70 having 0, 1, or 2 amino acid insertions, deletions, or substitutions.
[0188] In some embodiments, the antibody or antigen-binding fragment described herein may contain a light chain variable domain comprising one, two, or three CDRs from among the CDRs of SEQ ID NO: 74 having 0, 1, or 2 amino acid insertions, deletions, or substitutions, the CDR of SEQ ID NO: 75 having 0, 1, or 2 amino acid insertions, deletions, or substitutions, and the CDR of SEQ ID NO: 76 having 0, 1, or 2 amino acid insertions, deletions, or substitutions.
[0189] In some embodiments, the antibody or antigen-binding fragment described herein may contain a light chain variable domain comprising one, two, or three CDRs from among the following: the CDR of SEQ ID NO: 80 having 0, 1, or 2 amino acid insertions, deletions, or substitutions; the CDR of SEQ ID NO: 81 having 0, 1, or 2 amino acid insertions, deletions, or substitutions; and the CDR of SEQ ID NO: 82 having 0, 1, or 2 amino acid insertions, deletions, or substitutions.
[0190] In some embodiments, the antibody or antigen-binding fragment described herein may contain a light chain variable domain comprising one, two, or three CDRs from among the CDRs of SEQ ID NO: 86 having 0, 1, or 2 amino acid insertions, deletions, or substitutions, the CDR of SEQ ID NO: 87 having 0, 1, or 2 amino acid insertions, deletions, or substitutions, and the CDR of SEQ ID NO: 88 having 0, 1, or 2 amino acid insertions, deletions, or substitutions.
[0191] In some embodiments, the antibody or antigen-binding fragment described herein may contain a light chain variable domain comprising one, two, or three CDRs from among the CDRs of SEQ ID NO: 92 having 0, 1, or 2 amino acid insertions, deletions, or substitutions, the CDR of SEQ ID NO: 93 having 0, 1, or 2 amino acid insertions, deletions, or substitutions, and the CDR of SEQ ID NO: 94 having 0, 1, or 2 amino acid insertions, deletions, or substitutions.
[0192] Insertions, deletions, and substitutions may occur within the CDR sequence, or at one or both ends of the CDR sequence.
[0193] This disclosure further provides an antibody or antigen-binding fragment thereof that binds to CD40. The antibody or antigen-binding fragment comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the heavy chain variable region comprises or consists of an amino acid sequence having at least 80%, 85%, 90%, or 95% identity with a selected VH sequence, and the light chain variable region comprises or consists of an amino acid sequence having at least 80%, 85%, 90%, or 95% identity with a selected VL sequence. In some embodiments, the selected VH sequence is SEQ ID NO: 98, 99, 100, or 120, and the selected VL sequence is SEQ ID NO: 101, 102, 103, 104, or 121. In some embodiments, the selected VH sequence is sequence number 105, 106, 107, 108, 122, 126, or 128, and the selected VL sequence is sequence number 109, 110, 111, 123, 127, or 129. In some embodiments, the selected VH sequence is sequence number 112, 113, 114, 115, or 124, and the selected VL sequence is sequence number 116, 117, 118, 119, or 125.
[0194] In some embodiments, the antibody or its antigen-binding fragment may have three VH CDRs identical to any of the CDRs of the VH sequences described herein. In some embodiments, the antibody or its antigen-binding fragment may have three VL CDRs identical to any of the CDRs of the VL sequences described herein.
[0195] This disclosure further provides nucleic acids comprising polynucleotides encoding polypeptides containing an immunoglobulin heavy chain or an immunoglobulin light chain. The immunoglobulin heavy chain or immunoglobulin light chain contains a CDR as shown in Figure 23 or Figure 24, or has a sequence as shown in Figure 26. When a polypeptide is paired with a corresponding polypeptide (e.g., a corresponding heavy chain variable region or a corresponding light chain variable region), the paired polypeptide binds to CD40 (e.g., human CD40).
[0196] Anti-CD40 antibodies and antigen-binding fragments may also be antibodies or antibody fragments and antibody variants (including derivatives and complexes) of multispecific (e.g., bispecific) antibodies or antibody fragments. Other antibodies provided herein include polyclonal antibodies, monoclonal antibodies, multispecific (multimeric, e.g., bispecific) antibodies, human antibodies, chimeric antibodies (e.g., human-mouse chimeric), single-chain antibodies, intracellularly produced antibodies (i.e., intracellular antibodies), and their antigen-binding fragments. Antibodies or their antigen-binding fragments may be of any type (e.g., IgG, IgE, IgM, IgD, IgA, and IgY), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2), or subclass. In some embodiments, the antibody or its antigen-binding fragment is an IgG antibody or its antigen-binding fragment.
[0197] Antibody fragments are suitable for the provided method insofar as they retain the desired affinity and specificity of the full-length antibody. Therefore, an antibody fragment that binds to CD40 retains its ability to bind to CD40. An Fv fragment is an antibody fragment containing a complete antigen recognition and binding site. This region consists of a dimer of one tightly bound heavy chain variable domain and one light chain variable domain, which may be a naturally covalent bond such as in scFv. In such a configuration, the interaction of the three CDRs in each variable domain limits the antigen-binding site on the surface of the VH-VL dimer. All six CDRs, or a subset thereof, confer antigen-binding specificity to the antibody. However, even a single variable domain (or half of an Fv containing three CDRs specific to a given antigen) has the ability to recognize and bind to the antigen, but with lower affinity than the entire binding site.
[0198] In some embodiments, the antibody or its antigen-binding fragment is a bispecific antibody containing one or more (e.g., one, two, three, or four) scFv domains that bind to CD40 (e.g., human CD40).
[0199] In some embodiments, the anti-CD40 scFv is ligated to the N-terminus of the heavy chain constant domain 2 (CH2) of the IgG (e.g., IgG4) Fc region. In some embodiments, the anti-CD40 scFv is ligated to the C-terminus of the IgG (e.g., IgG1 or IgG4) Fc region. In some embodiments, the anti-CD40 scFv is inserted into the Fc region of IgG (e.g., IgG1 or IgG4) at site 3A, for example. In some embodiments, one polypeptide chain of the antibody or its antigen-binding fragment is ligated to the anti-CD40 scFv. In some embodiments, two polypeptide chains of the antibody or its antigen-binding fragment are ligated to the anti-CD40 scFv.
[0200] In some embodiments, anti-CD40 scFv comprises a heavy chain variable region (VH), a linker peptide, and a light chain variable region (VL) from the N-terminus to the C-terminus. In some embodiments, anti-CD40 scFv comprises a light chain variable region (VL), a linker peptide, and a heavy chain variable region (VH) from the N-terminus to the C-terminus. In some embodiments, the VL-linker peptide-VH structure increases the expression of the antibody or its antigen-binding fragment (e.g., by at least or about 10%, 20%, 30%, 40%, or 50%). The immunoglobulin heavy chain (VH) or immunoglobulin light chain (VL) comprises a CDR shown in Figure 23 or Figure 24, or has the sequence shown in Figure 26. In some embodiments, the linker peptide comprises a sequence having at least 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NOs: 152, 153, or 154. In some embodiments, the anti-CD40 scFv includes a sequence having at least 80%, 85%, 90%, or 95% identity with sequence numbers 155, 156, 157, or 158.
[0201] Anti-PD-1 antibody and antigen-binding fragment This disclosure provides antibodies that specifically bind to PD-1 and antigen-binding fragments thereof. Anti-PD-1 / CD40 antigen-binding protein constructs (e.g., bispecific antibodies) may include antigen-binding sites derived from these antibodies.
[0202] The antibodies and antigen-binding fragments described herein can bind to PD-1. This disclosure provides mouse anti-PD-1 antibodies 25-1A7 ("1A7"), 18-3F1 ("3F1"), and 3-6G1 ("6G1") and their humanized counterparts.
[0203] The CDR sequences of 1A7 and 1A7-inducing antibodies (e.g., humanized antibodies) include CDRs of the heavy chain variable domain (SEQ ID NOs: 1-3) and CDRs of the light chain variable domain (SEQ ID NOs: 4-6), as defined by Kabat numbering. CDRs can also be defined by the Chothia system. According to Chothia numbering, the CDR sequences of the heavy chain variable domain are shown in SEQ ID NOs: 19-21, and the CDR sequences of the light chain variable domain are shown in SEQ ID NOs: 22-24.
[0204] Similarly, the CDR sequences of 3F1 and 3F1-inducing antibodies include CDRs of the heavy chain variable domain (SEQ ID NOs. 7-9) and the light chain variable domain (SEQ ID NOs. 10-12), as defined by Kabat numbering. According to Chothia numbering, the CDR sequences of the heavy chain variable domain are shown in SEQ ID NOs. 25-27, and the CDR sequences of the light chain variable domain are shown in SEQ ID NOs. 28-30.
[0205] The CDR sequences of 6G1 and 6G1-inducing antibodies include CDRs of the heavy chain variable domain (SEQ ID NOs. 13-15) and the light chain variable domain (SEQ ID NOs. 16-18), as defined by Kabat numbering. According to Chothia numbering, the CDR sequences of the heavy chain variable domain are shown in SEQ ID NOs. 31-33, and the CDR sequences of the light chain variable domain are shown in SEQ ID NOs. 34-36.
[0206] Further, amino acid sequences of the heavy chain variable region and light chain variable region of humanized antibodies are provided. Because the methods of humanizing mouse antibodies differ (for example, the sequences may be substituted with different amino acids), the heavy and light chains of antibodies may have more than one version of the humanized sequence. Figure 22 provides the humanization percentages of these humanized sequences.
[0207] The amino acid sequences of the heavy chain variable region of the humanized 1A7 antibody are shown in SEQ ID NOs: 40-42. The amino acid sequences of the light chain variable region of the humanized 1A7 antibody are shown in SEQ ID NOs: 43-45. Any of these heavy chain variable region sequences (SEQ ID NOs: 40-42) may be paired with any of these light chain variable region sequences (SEQ ID NOs: 43-45).
[0208] Similarly, the amino acid sequences of the heavy chain variable region of the humanized 3F1 antibody are shown in SEQ ID NOs: 46-49. The amino acid sequences of the light chain variable region of the humanized 3F1 antibody are shown in SEQ ID NOs: 50-52. Any of these heavy chain variable region sequences (SEQ ID NOs: 46-49) may be paired with any of these light chain variable region sequences (SEQ ID NOs: 50-52).
[0209] Furthermore, in some embodiments, the antibody or antigen-binding fragment described herein may further comprise one, two, or three heavy chain variable region CDRs selected from the group consisting of SEQ ID NOs: 1-3, SEQ ID NOs: 7-9, SEQ ID NOs: 13-15, SEQ ID NOs: 19-21, SEQ ID NOs: 25-27 and SEQ ID NOs: 31-33, and / or one, two, or three light chain variable region CDRs selected from the group consisting of SEQ ID NOs: 4-6, SEQ ID NOs: 10-12, SEQ ID NOs: 16-18, SEQ ID NOs: 22-24, SEQ ID NOs: 28-30 and SEQ ID NOs: 34-36.
[0210] In some embodiments, the antibody may have a heavy chain variable region (VH) containing complementarity-determining regions (CDRs) 1, 2, and 3, where the CDR1 region contains or consists of amino acid sequences having at least 80%, 85%, 90%, or 95% identity with a selected VH CDR1 amino acid sequence; the CDR2 region contains or consists of amino acid sequences having at least 80%, 85%, 90%, or 95% identity with a selected VH CDR2 amino acid sequence; and the CDR3 region contains or consists of amino acid sequences having at least 80%, 85%, 90%, or 95% identity with a selected VH CDR3 amino acid sequence. The antibody may also have a light chain variable region (VL) containing CDRs 1, 2, and 3, where the CDR1 region contains a selected VL The CDR1 amino acid sequence contains or consists of an amino acid sequence having at least 80%, 85%, 90%, or 95% identity with the selected VL CDR2 amino acid sequence, and the CDR3 region contains or consists of an amino acid sequence having at least 80%, 85%, 90%, or 95% identity with the selected VL CDR3 amino acid sequence. The selected VH CDR1, 2, and 3 amino acid sequences and the selected VL CDR1, 2, and 3 amino acid sequences are shown in Figure 19 (Kabat CDR) and Figure 20 (Chothia CDR).
[0211] In some embodiments, the antibody or antigen-binding fragment described herein may contain a heavy chain variable domain comprising one, two, or three CDRs from among the CDRs of SEQ ID NO: 1 having 0, 1, or 2 amino acid insertions, deletions, or substitutions, the CDR of SEQ ID NO: 2 having 0, 1, or 2 amino acid insertions, deletions, or substitutions, and the CDR of SEQ ID NO: 3 having 0, 1, or 2 amino acid insertions, deletions, or substitutions.
[0212] In some embodiments, the antibody or antigen-binding fragment described herein can comprise a heavy chain variable domain comprising 1, 2 or 3 CDRs selected from the CDR of SEQ ID NO:7 with 0, 1 or 2 amino acid insertions, deletions or substitutions, the CDR of SEQ ID NO:8 with 0, 1 or 2 amino acid insertions, deletions or substitutions, and the CDR of SEQ ID NO:9 with 0, 1 or 2 amino acid insertions, deletions or substitutions.
[0213] In some embodiments, the antibody or antigen-binding fragment described herein can comprise a heavy chain variable domain comprising 1, 2 or 3 CDRs selected from the CDR of SEQ ID NO:13 with 0, 1 or 2 amino acid insertions, deletions or substitutions, the CDR of SEQ ID NO:14 with 0, 1 or 2 amino acid insertions, deletions or substitutions, and the CDR of SEQ ID NO:15 with 0, 1 or 2 amino acid insertions, deletions or substitutions.
[0214] In some embodiments, the antibody or antigen-binding fragment described herein can comprise a heavy chain variable domain comprising 1, 2 or 3 CDRs selected from the CDR of SEQ ID NO:19 with 0, 1 or 2 amino acid insertions, deletions or substitutions, the CDR of SEQ ID NO:20 with 0, 1 or 2 amino acid insertions, deletions or substitutions, and the CDR of SEQ ID NO:21 with 0, 1 or 2 amino acid insertions, deletions or substitutions.
[0215] In some embodiments, the antibody or antigen-binding fragment described herein can comprise a heavy chain variable domain comprising 1, 2 or 3 CDRs selected from the CDR of SEQ ID NO:25 with 0, 1 or 2 amino acid insertions, deletions or substitutions, the CDR of SEQ ID NO:26 with 0, 1 or 2 amino acid insertions, deletions or substitutions, and the CDR of SEQ ID NO:27 with 0, 1 or 2 amino acid insertions, deletions or substitutions.
[0216] In some embodiments, the antibody or antigen-binding fragment described herein may comprise a heavy chain variable domain comprising 1, 2 or 3 CDRs selected from the CDR of SEQ ID NO:31 with 0, 1 or 2 amino acid insertions, deletions or substitutions, the CDR of SEQ ID NO:32 with 0, 1 or 2 amino acid insertions, deletions or substitutions, and the CDR of SEQ ID NO:33 with 0, 1 or 2 amino acid insertions, deletions or substitutions.
[0217] In some embodiments, the antibody or antigen-binding fragment described herein may comprise a light chain variable domain comprising 1, 2 or 3 CDRs selected from the CDR of SEQ ID NO:4 with 0, 1 or 2 amino acid insertions, deletions or substitutions, the CDR of SEQ ID NO:5 with 0, 1 or 2 amino acid insertions, deletions or substitutions, and the CDR of SEQ ID NO:6 with 0, 1 or 2 amino acid insertions, deletions or substitutions.
[0218] In some embodiments, the antibody or antigen-binding fragment described herein may comprise a light chain variable domain comprising 1, 2 or 3 CDRs selected from the CDR of SEQ ID NO:10 with 0, 1 or 2 amino acid insertions, deletions or substitutions, the CDR of SEQ ID NO:11 with 0, 1 or 2 amino acid insertions, deletions or substitutions, and the CDR of SEQ ID NO:12 with 0, 1 or 2 amino acid insertions, deletions or substitutions.
[0219] In some embodiments, the antibody or antigen-binding fragment described herein may comprise a light chain variable domain comprising 1, 2 or 3 CDRs selected from the CDR of SEQ ID NO:16 with 0, 1 or 2 amino acid insertions, deletions or substitutions, the CDR of SEQ ID NO:17 with 0, 1 or 2 amino acid insertions, deletions or substitutions, and the CDR of SEQ ID NO:18 with 0, 1 or 2 amino acid insertions, deletions or substitutions.
[0220] In some embodiments, the antibody or antigen-binding fragment described herein may contain a light chain variable domain comprising one, two, or three CDRs from among the CDRs of SEQ ID NO: 22 having 0, 1, or 2 amino acid insertions, deletions, or substitutions, the CDR of SEQ ID NO: 23 having 0, 1, or 2 amino acid insertions, deletions, or substitutions, and the CDR of SEQ ID NO: 24 having 0, 1, or 2 amino acid insertions, deletions, or substitutions.
[0221] In some embodiments, the antibody or antigen-binding fragment described herein may contain a light chain variable domain comprising one, two, or three CDRs from among the CDRs of SEQ ID NO: 28 having 0, 1, or 2 amino acid insertions, deletions, or substitutions, the CDR of SEQ ID NO: 29 having 0, 1, or 2 amino acid insertions, deletions, or substitutions, and the CDR of SEQ ID NO: 30 having 0, 1, or 2 amino acid insertions, deletions, or substitutions.
[0222] In some embodiments, the antibody or antigen-binding fragment described herein may contain a light chain variable domain comprising one, two, or three CDRs from among the CDRs of SEQ ID NO: 34 having 0, 1, or 2 amino acid insertions, deletions, or substitutions, the CDR of SEQ ID NO: 35 having 0, 1, or 2 amino acid insertions, deletions, or substitutions, and the CDR of SEQ ID NO: 36 having 0, 1, or 2 amino acid insertions, deletions, or substitutions.
[0223] Insertions, deletions, and substitutions may occur within the CDR sequence, or at one or both ends of the CDR sequence.
[0224] This disclosure further provides antibodies or antigen-binding fragments thereof that bind to PD-1. The antibody or antigen-binding fragment comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the heavy chain variable region includes or consists of amino acid sequences having at least 80%, 85%, 90%, or 95% identity with a selected VH sequence, and the light chain variable region includes or consists of amino acid sequences having at least 80%, 85%, 90%, or 95% identity with a selected VL sequence. In some embodiments, the selected VH sequence is SEQ ID NO: 40, 41, 42, or 53, and the selected VL sequence is SEQ ID NO: 43, 44, 45, or 54. In some embodiments, the selected VH sequence is SEQ ID NO: 46, 47, 48, 49, or 55, and the selected VL sequence is SEQ ID NO: 50, 51, 52, or 56. In some embodiments, the selected VH sequence is sequence number 57, and the selected VL sequence is sequence number 58.
[0225] In some embodiments, the antibody or its antigen-binding fragment may have three VH CDRs identical to any of the CDRs of the VH sequences described herein. In some embodiments, the antibody or its antigen-binding fragment may have three VL CDRs identical to any of the CDRs of the VL sequences described herein.
[0226] This disclosure further provides nucleic acids comprising polynucleotides encoding an immunoglobulin heavy chain or a polypeptide containing an immunoglobulin heavy chain. The immunoglobulin heavy chain or immunoglobulin light chain comprises a CDR as shown in Figure 19 or Figure 20, or has a sequence as shown in Figure 22. When a polypeptide is paired with a corresponding polypeptide (e.g., a corresponding heavy chain variable region or a corresponding light chain variable region), the paired polypeptide binds to PD-1.
[0227] Anti-PD-1 antibodies and antigen-binding fragments may also be antibodies or antibody fragments and antibody variants (including derivatives and complexes) of multispecific (e.g., bispecific) antibodies or antibody fragments. Other antibodies provided herein include polyclonal antibodies, monoclonal antibodies, multispecific (multimeric, e.g., bispecific) antibodies, human antibodies, chimeric antibodies (e.g., human-mouse chimeric), single-chain antibodies, intracellularly produced antibodies (i.e., intracellular antibodies) and their antigen-binding fragments. Antibodies or their antigen-binding fragments may be of any type (e.g., IgG, IgE, IgM, IgD, IgA, and IgY), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2) or subclass. In some embodiments, the antibody or its antigen-binding fragment is an IgG antibody or its antigen-binding fragment.
[0228] Antibody fragments are suitable for the provided method insofar as they retain the desired affinity and specificity of the full-length antibody. Therefore, an antibody fragment that binds to PD-1 retains its ability to bind to PD-1. An Fv fragment is an antibody fragment containing a complete antigen recognition and binding site. This region consists of a dimer of one tightly bound heavy chain variable domain and one light chain variable domain, which may be a naturally covalent bond such as in scFv. In this configuration, the interaction of the three CDRs of each variable domain limits the antigen-binding site on the surface of the VH-VL dimer. The six CDRs, or a subset thereof, together confer antigen-binding specificity to the antibody. However, even a single variable domain (or half of an Fv containing three CDRs specific to a given antigen) has the ability to recognize and bind to the antigen, but with lower affinity than the entire binding site.
[0229] Characteristics of antibodies Anti-PD1, anti-CD40, or anti-PD-1 / CD40 antigen-binding protein constructs (e.g., antibodies, bispecific antibodies, or antibody fragments thereof) may contain antigen-binding sites derived from any anti-PD-1 antibody, anti-CD40 antibody, or any antigen-binding fragment thereof as described herein.
[0230] The antibodies or antigen-binding fragments thereof described in the present specification can bind to PD-1 and block the binding between PD-1 and PD-L1 and / or the binding between PD-1 and PD-L2. By blocking the binding between PD-1 and PD-L1 and / or the binding between PD-1 and PD-L2, the anti-PD-1 / CD40 antibody disrupts the PD-1 inhibitory pathway (e.g., by blocking the interaction between PD-1 and PD-L1) and upregulates the immune response.
[0231] The affinity of an antibody for its antigen can be measured using common techniques including, for example, ELISA, RIA and surface plasmon resonance (SPR). Affinity can be derived from the quotient of the kinetic rate constants (KD = koff / ka). In some embodiments, the antibody, antigen-binding fragment thereof, or antigen-binding protein construct (e.g., bispecific antibody) has a 0.1s -1 less than, 0.01s -1 less than, 0.001s -1 less than, 0.0001s -1 less than, or 0.00001s -1 less than dissociation rate (koff) can bind to PD-1 (e.g., human PD-1, mouse PD-1 and / or chimeric PD-1). In some embodiments, the dissociation rate (koff) is 0.01s -1 or more, 0.001s -1 or more, 0.0001s -1 or more, or 0.00001s -1 or more. In some embodiments, the dissociation rate (koff) is 1.4×10 -3 s -1 , 1.3×10 -3 s -1 or 1.2×10 -3 s -1 less than.
[0232] In some embodiments, the kinetic association rate (kon) is 1×10 2 / Ms or more, 1×10 3 / Ms or more, 1×10 4 / Ms or more, 1×10 5 / Ms or more, or 1×10 6It is greater than or equal to / Ms. In some embodiments, the dynamic coupling velocity (ka) is 1 × 10⁻⁶ 5 / Ms less than 1 × 10 6 / Ms less than or 1 × 10 7 It is less than / Ms. In some embodiments, the dynamic coupling velocity (ka) is 1.0 × 10⁻⁶ 5 / Ms, 1.2 × 10 5 / Ms or 1.4 × 10 5 It is above / Ms.
[0233] In some embodiments, an antibody, its antigen-binding fragment, or antigen-binding protein construct (e.g., a bispecific antibody) is 1 × 10⁻⁶ -6 Less than M, 1 x 10 -7 Less than M, 1 x 10 -8 Less than M, 1 x 10 -9 Less than M or 1 × 10 -10 PD-1 (e.g., human PD-1, mouse PD-1, and / or chimeric PD-1) can be bound with a KD of less than M. In some embodiments, the KD is 30 nM, 20 nM, 15 nM, 10 nM, 9 nM, 8 nM, 7 nM, 6 nM, 5 nM, 4 nM, 3 nM, 2 nM, or less than 1 nM. In some embodiments, the KD is 1 × 10⁻¹⁶ -7 M or more, 1×10 -8 M or more, 1×10 -9 M or larger or 1 x 10 -10 The KD is M or higher. In some embodiments, the antibody binds to human PD-1 at a KD of approximately 10 nM, 9.5 nM, 9 nM, 8.5 nM, or 8 nM or less.
[0234] Anti-PD-1 / CD40 antigen-binding protein constructs (e.g., bispecific antibodies) may also contain antigen-binding sites derived from any anti-CD40 antibody or its antigen-binding fragment described herein. In some embodiments, the anti-PD1 / CD40 antibodies or their antigen-binding fragments described herein can block the binding between CD40 and CD40L. In some embodiments, the antibody can also promote the CD40 signaling pathway and upregulate the immune response by binding to CD40. Thus, in some embodiments, the antibodies or their antigen-binding fragments described herein are CD40 agonists. In some embodiments, the antibodies or their antigen-binding fragments are CD40 antagonists.
[0235] In some embodiments, an antibody, its antigen-binding fragment, or antigen-binding protein construct (e.g., a bispecific antibody) is used for 0.1 seconds. -1 Less than 0.01s -1 Less than 0.001s -1 Less than 0.0001s -1 Less than or 0.00001s -1 It can bind to CD40 (e.g., human CD40, mouse CD40, and / or chimeric CD40) with a dissociation rate (koff) of less than 0.01 s. In some embodiments, the dissociation rate (koff) is 0.01 s. -1 The above is 0.001s -1 More than 0.0001s -1 or greater than or equal to 0.00001s -1 That concludes the explanation. In some embodiments, the dissociation rate (koff) is 5 × 10⁻⁶. -4 s -1 , 4×10 -4 s -1 or 3 × 10 -4 s -1 It is less than.
[0236] In some embodiments, the kinetic association rate (kon) is 1×10² / Ms or more, 1×10³ / Ms or more, 1×10⁴ / Ms or more, 1×10⁵ / Ms or more, or 1×10⁶ / Ms or more. In some embodiments, the kinetic association rate (ka) is less than 1×10⁵ / Ms, less than 1×10⁶ / Ms, or less than 1×10⁷ / Ms. In some embodiments, the kinetic association rate (ka) is 1.0×10⁵ / Ms, 1.5×10⁵ / Ms, 2×10⁵ / Ms, or 2.5×10⁵ / Ms or more.
[0237] Affinity can be derived from the quotient of the kinetic rate constants (KD=koff / ka). In some embodiments, KD is less than 1×10⁻⁶M, less than 1×10⁻⁷M, less than 1×10⁻⁸M, less than 1×10⁻⁹M, or less than 1×10⁻¹⁰M. In some embodiments, KD is less than 30nM, 20nM, 15nM, 10nM, 9nM, 8nM, 7nM, 6nM, 5nM, 4nM, 3nM, 2nM, or 1nM. In some embodiments, KD is 1×10⁻⁷M or more, 1×10⁻⁸M or more, 1×10⁻⁹M or more, 1×10⁻¹⁰M or more, 1×10⁻¹¹M or more, or 1×10⁻¹²M or more. In some embodiments, the antibody binds to human CD40 with a KD of no more than about 3.5nM, 3nM, 2.5nM, 2nM, or 1.5nM.
[0238] In some embodiments, the antibodies, antigen-binding fragments thereof, or antigen-binding protein constructs (e.g., bispecific antibodies) described herein can block the PD-1 / PD-L1 pathway with an EC50 value (e.g., as determined by a reporter cell activation assay) of about 50%, about 80%, about 100%, about 2-fold, about 3-fold, about 4-fold, or about 5-fold compared to the EC50 value of a PD-1 monoclonal antibody (e.g., 1A7-H2K3-IgG4).
[0239] In some embodiments, the antibodies, antigen-binding fragments, or antigen-binding protein constructs described herein (e.g., bispecific antibodies) can block the PD-1 / PD-L1 pathway at EC50 values of approximately 100 μg / mL, 50 μg / mL, 40 μg / mL, 30 μg / mL, 20 μg / mL, 10 μg / mL, 5 μg / mL, 4 μg / mL, 3 μg / mL, 2 μg / mL, or 1 μg / mL or less (determined, for example, by a reporter cell activation assay).
[0240] In some embodiments, antibodies, their antigen-binding fragments, or antigen-binding protein constructs described herein (e.g., bispecific antibodies) can crosslink T cells (e.g., expressing PD-1) and antigen-presenting cells (e.g., expressing CD40) at EC50 values of approximately 1 μg / mL, 0.5 μg / mL, 0.1 μg / mL, 0.05 μg / mL, 0.04 μg / mL, 0.03 μg / mL, or 0.02 μg / mL or less (determined, for example, by a reporter cell activation assay).
[0241] In some embodiments, antibodies, their antigen-binding fragments, or antigen-binding protein constructs described herein (e.g., bispecific antibodies) can activate antigen-presenting cells (e.g., activating the CD40 pathway in APC cells). In some embodiments, the presence of PD-1-expressing cells can increase APC cell activation by at least 1-fold, 2-fold, 5-fold, 10-fold, 20-fold, 50-fold, 100-fold, 200-fold, 500-fold or more compared to APC cell activation (e.g., transactivation) in the absence of PD-1-expressing cells.
[0242] In some embodiments, cells expressing PD-1 or its targets (e.g., T cells, B cells, NK cells, or myeloid cells) and APC cells can stimulate CD40 aggregation on APC cells by crosslinking of antibodies, antigen-binding fragments, or antigen-binding protein constructs described herein (e.g., bispecific antibodies) by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 2x, 3x, 5x, 10x, or 20x.
[0243] In some embodiments, the antibodies, antigen-binding fragments, or antigen-binding protein constructs described herein (e.g., bispecific antibodies) can increase the immune response, the activity of CD40 or CD40-related pathways, the activity or number of APC cells (e.g., dendritic cells or macrophages) and / or the activity or number of T cells (e.g., CD8+ and / or CD4+ cells) by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 2x, 3x, 5x, 10x, or 20x.
[0244] In some embodiments, antibodies, antigen-binding fragments, or antigen-binding protein constructs described herein (e.g., bispecific antibodies) can activate APC cells (e.g., CD40-expressing) by FCγRIIB at EC50 values of approximately 1 μg / mL, 0.5 μg / mL, 0.1 μg / mL, 0.05 μg / mL, 0.04 μg / mL, 0.03 μg / mL, or 0.02 μg / mL or less (determined, e.g., by a reporter cell activation assay).
[0245] In some embodiments, compared to CD40 monoclonal antibodies (e.g., 6A7-H4K2-IgG2), the antibodies, their antigen-binding fragments, or antigen-binding protein constructs (e.g., bispecific antibodies) described herein can reduce FCγRIIB receptor-mediated cell (e.g., APC cell) activation by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 2x, 3x, 5x, 10x, 20x, 50x, 100x, or 500x.
[0246] In some embodiments, the antibodies, antigen-binding fragments, or antigen-binding protein constructs described herein (e.g., bispecific antibodies) are CD40 agonists. In some embodiments, the antibodies, antigen-binding fragments, or antigen-binding protein constructs (e.g., bispecific antibodies) can increase CD40 signaling in target cells expressing CD40.
[0247] The blocking effect or cell activation of an antibody, its antigen-binding fragment, or antigen-binding protein construct (e.g., a bispecific antibody) can be measured by EC50. EC50 refers to the concentration of a drug that induces half of the response between baseline and maximum. In some embodiments, EC50 is approximately 50 μg / mL, 40 μg / mL, 30 μg / mL, 20 μg / mL, 10 μg / mL, 5 μg / mL, 1 μg / mL, 0.5 μg / mL, 0.2 μg / mL, 0.1 μg / mL, 0.05 μg / mL, 0.04 μg / mL, 0.03 μg / mL, 0.02 μg / mL, 0.01 μg / mL, 0.008 μg / mL, 0.006 μg / mL, 0.005 μg / mL, or 0.001 μg / mL or less.
[0248] In some embodiments, antibodies, their antigen-binding fragments, or antigen-binding protein constructs described herein (e.g., bispecific antibodies) can amplify immune response signals in the tumor microenvironment or tumor discharge lymph nodes by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 2x, 3x, 5x, 10x, or 20x. In some embodiments, antibodies, their antigen-binding fragments, or antigen-binding protein constructs described herein (e.g., bispecific antibodies) can reduce overall immune activation by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 2x, 3x, 5x, 10x, or 20x.
[0249] In some embodiments, the antibodies, antigen-binding fragments, or antigen-binding protein constructs described herein (e.g., bispecific antibodies) may have similar tumor-suppressing activity (e.g., expressed as TGI%) at dose levels of about 90%, 80%, 70%, 60%, 50%, or less, or less than the dose levels of monoclonal antibodies targeting the same antigen (e.g., monoclonal antibodies containing the same heavy-chain variable region and / or light-chain variable region).
[0250] In some embodiments, when administered at similar dose levels, the antibodies, their antigen-binding fragments, or antigen-binding protein constructs described herein (e.g., bispecific antibodies) have at least or about 1, 2, 3, 5, 10, 20, or 50 times higher tumor growth inhibitory effects than monoclonal antibodies targeting the same antigen. In some embodiments, the presence of PD-1-expressing cells can increase the tumor growth inhibitory effect by at least or about 1, 2, 5, 10, 20, 50, 100, 200, 500 or more times compared to the tumor growth inhibitory effect in the absence of PD-1-expressing cells.
[0251] In some embodiments, when administered at similar dose levels, the antibodies, their antigen-binding fragments, or antigen-binding protein constructs (e.g., bispecific antibodies) described herein have at least or about 10%, 20%, 30%, 40%, or 50% lower in vivo toxicity (e.g., blood AST and ALT levels) compared to monoclonal antibodies targeting the same antigen.
[0252] In some embodiments, compared to animals administered monoclonal antibodies targeting the same antigen at similar dose levels, animals (e.g., mice) administered with the antibodies, their antigen-binding fragments, or antigen-binding protein constructs (e.g., bispecific antibodies) described herein have at least 10%, 20%, 30%, 40%, or 50% lower inflammatory levels (e.g., the degree of liver and / or kidney lesions).
[0253] In some embodiments, an antibody, its antigen-binding fragment, or antigen-binding protein construct (e.g., anti-CD40 antibody, anti-PD-1 antibody, or bispecific antibody) has a tumor growth inhibition rate (TGI%) of 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 110%, 120%, 130%, 140%, 150%, 160%, 170%, 180%, 190%, or 200% or more. In some embodiments, the antibody has a tumor growth inhibition rate of 60%, 70%, 80%, 90%, 100%, 110%, 120%, 130%, 140%, 150%, 160%, 170%, 180%, 190%, or less than 200%. TGI% can be determined, for example, on days 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 after the start of treatment, or at 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, or 12 months after the start of treatment. As used herein, the tumor growth inhibition rate (TGI% or TGITV%) is calculated using the following formula: TGI(%)=[1-(Ti-T0) / (Vi-V0)]×100%
[0254] Ti is the mean tumor volume in the treatment group on day i. T0 is the mean tumor volume in the treatment group on day 0. Vi is the mean tumor volume in the control group on day i. V0 is the mean tumor volume in the control group on day 0.
[0255] In some embodiments, the antibody, its antigen-binding fragment, or antigen-binding protein construct (e.g., a bispecific antibody) has a functional Fc region. In some embodiments, the effector function of the functional Fc region is antibody-dependent cell-mediated cytotoxicity (ADCC). In some embodiments, the effector function of the functional Fc region is phagocytosis. In some embodiments, the effector functions of the functional Fc region are ADCC and phagocytosis. In some embodiments, the Fc region is human IgG1, human IgG2, human IgG3, or human IgG4. In some embodiments, the antibody, its antigen-binding fragment, or antigen-binding protein construct (e.g., a bispecific antibody) does not have a functional Fc region. For example, the antibody or antigen-binding fragment is Fab, Fab', F(ab')2, and Fv fragments.
[0256] Antibody and antigen-binding fragments This disclosure provides antibodies, their antigen-binding fragments, or antigen-binding protein constructs (e.g., bispecific antibodies). The antigen-binding protein constructs (e.g., bispecific antibodies) may include anti-CD40 antibodies or their antigen-binding fragments, and anti-PD-1 antibodies or their antigen-binding fragments. These antigen-binding protein constructs (e.g., bispecific antibodies), anti-CD40 antibodies, anti-PD-1 antibodies, and their antigen-binding fragments may have various forms.
[0257] Typically, an antibody (also called an immunoglobulin) consists of two polypeptide chains, namely a light chain and a heavy chain. The non-limiting antibodies of this disclosure may also be complete four-chain immunoglobulin antibodies containing two heavy chains and two light chains. The heavy chain of the antibody may be any isotype (including IgM, IgG, IgE, IgA, or IgD) or a subisotype (including IgG1, IgG2, IgG2a, IgG2b, IgG3, IgG4, IgE1, IgE2, etc.). The light chain may be a κ light chain or a λ light chain. An antibody may contain two identical copies of the light chain and / or two identical copies of the heavy chain. Each heavy chain, containing one variable domain (or variable region, VH) and multiple constant domains (or constant regions), is linked to one another by disulfide bonds within its constant regions to form the antibody "stem". Each light chain, containing one variable domain (or variable region VL) and one constant domain (or constant region), is bonded to a heavy chain by a disulfide bond. The variable region of each light chain is aligned with the variable region of the heavy chain to which it is bonded. Both the variable regions of the light and heavy chains contain three hypervariable regions, which are sandwiched between more conservative framework regions (FRs).
[0258] These hypervariable regions (called complementarity-determining regions (CDRs)) form loops containing the antibody's primary antigen-binding surface. The majority of the four framework regions adopt a β-sheet conformation, and the CDRs form links, and in some cases, loops within the β-sheet structure. The CDRs in each chain are tightly held together by the framework regions and, together with CDRs from other chains, promote the formation of antigen-binding sites.
[0259] Methods for identifying the CDR region of an antibody by analyzing its amino acid sequence are well-known, and many definitions of CDR are commonly used. The Kabat definition is based on sequence variability, while the Chothia definition is based on the location of the structural loop region. These methods and definitions can be found, for example, in Martin, "Protein sequence and structure analysis of antibody variable domains," Antibody Engineering, Springer Berlin Heidelberg, 2001, pp. 422-439; Abhinandan et al., "Analysis and improvements to Kabat and structurally correct numbering of antibody variable domains," Molecular Immunology 45.14 (2008): pp. 3832-3839; Wu, TT and Kabat, EA (1970), J. Exp. Med. Vol. 132: pp. 211-250; Martin et al., Methods Enzymol. Vol. 203: pp. 121-53 (1991); Morea et al., Biophys Chem. Vol. 68 (series 1-3): pp. 9-16 (October 1997); Morea et al., J Mol This is described in Biol., Vol. 275 (Sequence 2): pp. 269-294 (January 1998); Chothia et al., Nature, Vol. 342 (Sequence 6252): pp. 877-883 (December 1989); and Ponomarenko and Bourne, BMC Structural Biology, Vol. 7: p. 64 (2007), each of which is incorporated herein by reference in its entirety. Unless otherwise specified in this disclosure, Kabat numbers are used as the default numbers.
[0260] CDRs are important for recognizing the epitopes of antigens. As used herein, an “epitope” is the smallest portion of a target molecule that can be specifically bound by the antigen-binding domain of an antibody. The minimum size of an epitope can be about 3, 4, 5, 6, or 7 amino acids, but these amino acids do not need to be in a continuous linear sequence of the primary structure of the antigen, as epitopes can depend on the three-dimensional configuration of the antigen based on its secondary and tertiary structures.
[0261] In some embodiments, the antibody is a complete immunoglobulin molecule (e.g., IgG1, IgG2a, IgG2b, IgG3, IgM, IgD, IgE, IgA). The IgG subclasses (IgG1, IgG2, IgG3, and IgG4) are highly conserved, with differences in their constant regions, and in particular, their hinges and upper CH2 domains. The sequences and allotypes of IgG subclasses are publicly known in the art, for example, Vidarsson et al., "IgG subclasses and allotypes: from structure to effector functions," Frontiers in immunology 5 (2014); Irani et al., "Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases," Molecular immunology 67.2 (2015): pp. 171-182; and Shakib, Farouk (eds.), "The human IgG subclasses: molecular analysis of structure, function and regulation," Elsevier, 2016. Each of these publications is incorporated herein by reference in its entirety.
[0262] The antibody may further be an immunoglobulin molecule derived from any species (e.g., human, rodent, mouse, rat, camelid). The antibodies disclosed herein further include, but are not limited to, polyclonal antibodies, monoclonal antibodies, monospecific antibodies, multispecific antibodies, and chimeric antibodies containing an immunoglobulin-binding domain fused with another polypeptide. The term “antigen-binding domain” or “antigen-binding fragment” is a part of the antibody that retains the specific binding activity of the complete antibody, i.e., any part of the antibody that can specifically bind to an epitope on the target molecule of the complete antibody. This includes, for example, Fab, Fab', F(ab')2, and variants of these fragments. Accordingly, in some embodiments, the antibody or its antigen-binding fragment may be, for example, scFv, Fv, Fd, dAb, bispecific antibody, bispecific scFv, biantibody, linear antibody, single-chain antibody molecule, multispecific antibody formed from antibody fragments, and any polypeptide containing an antibody-binding domain or a binding domain homologous thereto. Non-limiting examples of antigen-binding domains include, for example, the heavy and / or light chain CDRs of a complete antibody, the heavy and / or light chain variable regions of a complete antibody, the full-length heavy or light chain of a complete antibody, or a single CDR derived from the heavy or light chain of a complete antibody.
[0263] In some embodiments, the scFv has two heavy chain variable domains and two light chain variable domains. In some embodiments, the scFv has two antigen-binding sites (antigen-binding sites: A and B), and the two antigen-binding sites can bind to their respective target antigens with different affinities.
[0264] In some embodiments, an antibody, its antigen-binding fragment, or an antigen-binding protein construct (e.g., a bispecific antibody) can bind to two different antigens or two different epitopes.
[0265] In some embodiments, an antibody, its antigen-binding fragment, or antigen-binding protein construct (e.g., a bispecific antibody) may contain one, two, or three heavy chain variable regions (CDRs) selected from Figures 19, 20, 23, and 24. In some embodiments, an antibody, its antigen-binding fragment, or antigen-binding protein construct (e.g., a bispecific antibody) may contain one, two, or three light chain variable regions (CDRs) selected from Figures 19, 20, 23, and 24.
[0266] In some embodiments, the antibodies, their antigen-binding fragments, or antigen-binding protein constructs described herein (e.g., bispecific antibodies) may be conjugated to a therapeutic agent. The antibody-drug conjugate, comprising the antibody or its antigen-binding fragment, may be covalently or non-covalently conjugated to the therapeutic agent. In some embodiments, the therapeutic agent is a cytotoxic agent or cell proliferation inhibitor (e.g., cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, teniposide, vincristine, vinblastine, colchicine, doxorubicin, daunorubicin, dihydroxyanthrax diketone, meltansine (DM-1 and DM-4, etc.), mitoxantrone, mitramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, puromycin, epirubicin, and cyclophosphamide and its analogues).
[0267] A single-stranded Fv (scFv) or antibody fragment comprises the VH and VL domains (or regions) of an antibody, where these domains are present within a single polypeptide chain. Typically, the Fv polypeptide further includes a polypeptide linker between the VH and VL domains so that the scFv forms a desired structure for antigen binding. A Fab fragment comprises a variable domain and a constant domain of the light chain, and a variable domain and a first constant domain (CH1) of the heavy chain. An F(ab')2 antibody fragment comprises a pair of Fab fragments, which are typically covalently bonded near their carboxyl group ends via a hinge cysteine between them. Other chemical couplings of antibody fragments are also known in the art.
[0268] A biantibody is a small antibody fragment having two antigen-binding sites, and these fragments contain VH (VH and VL) linked to VL on the same polypeptide chain. By using a linker that is too short to pair between two domains on the same chain, the domains are paired with complementary domains on another chain to generate two antigen-binding sites.
[0269] Linear antibodies contain a pair of tandem Fd segments (VH-CH1-VH-CH1) that, together with a complementary light chain polypeptide, form a pair of antigen-binding sites. Linear antibodies may be bispecific or monospecific.
[0270] Antibody multimerization can be achieved by spontaneous aggregation of antibodies or by chemical or recombination techniques known in the art. For example, a certain percentage of purified antibody preparations (e.g., purified IgG1 molecules) spontaneously forms protein aggregates containing antibody homodimers and other higher-order antibody multimers.
[0271] In some embodiments, multispecific antibodies are bispecific antibodies. Bispecific antibodies can be produced by engineering the interface between a pair of antibody molecules to maximize the percentage of heterodimers recovered from recombinant cell cultures. For example, the interface may include at least a portion of the CH3 domain of the antibody constant domain. In this method, one or more small amino acid side chains from the interface of the first antibody molecule are replaced with larger side chains (e.g., tyrosine or tryptophan). By replacing the large amino acid side chains with small amino acid side chains (e.g., alanine or threonine), a compensated "cavity" of the same or similar size as the large side chains is formed at the interface of the second antibody molecule. This provides a mechanism that results in a higher yield of heterodimers than other unwanted end products (such as homodimers). This method is described, for example, in WO 96 / 27011, which is incorporated herein by reference in its entirety.
[0272] Bispecific antibodies include crosslinked or "heterogeneous complex" antibodies. For example, one antibody in a heterogeneous complex can be coupled to an anti-biotin protein, and the other can be coupled to biotin. Heterogeneous complex antibodies can also be produced using any convenient crosslinking method. Suitable crosslinking agents and techniques are well known in the art and are disclosed in U.S. Patent No. 4,676,980, which is incorporated herein by reference in its entirety.
[0273] Methods for producing bispecific antibodies from antibody fragments are also known in the art. For example, bispecific antibodies can be produced using chemical linking. Brennan et al. (Science, Vol. 229: p. 81, 1985) described a method for generating F(ab')2 fragments from a complete antibody by hydrolytic cleavage of the protein. These fragments are reduced in the presence of sodium arsenite, a dithiol complexing agent, to stabilize adjacent dithiols and prevent intermolecular disulfide formation. The resulting Fab' fragments are then converted to thionitrobenzoate (TNB) derivatives. One of the Fab' TNB derivatives is then converted to a Fab' thiol by reduction with mercaptoethylamine, and a bispecific antibody is formed by mixing it with an equimolar amount of another Fab' TNB derivative.
[0274] Any antibody, its antigen-binding fragment, or antigen-binding protein construct described herein (e.g., a bispecific antibody) can be conjugated to a stabilizing molecule (e.g., a molecule that increases the half-life of the antibody or its antigen-binding fragment in a target or solution). Non-limiting examples of stabilizing molecules include polymers (e.g., polyethylene glycol) or proteins (e.g., serum albumin, such as human serum albumin). Conjugation of a stabilizing molecule can increase the half-life of the antibody or antigen-binding fragment or extend its biological activity in vitro (e.g., in tissue cultures or during storage in the form of a pharmaceutical composition) or in vivo (e.g., in the human body).
[0275] Antibodies, their antigen-binding fragments, or antigen-binding protein constructs (e.g., bispecific antibodies) can also take on various forms. Many different forms of antigen-binding constructs are known in the art, for example, Suurs et al., “A review of bispecific antibodies and antibody constructs in oncology and clinical challenges,” Pharmacology & Therapeutics (2019), which is incorporated herein by reference in its entirety.
[0276] In some embodiments, the antigen-binding protein construct is BiTe, (scFv)2, nanobody-HSA, DART, TandAb, scDiabody, scDiabody-CH3, scFv-CH-CL-scFv, HSAbody, scDiabody-HAS, or tandem scFv. In some embodiments, antigen-binding protein constructs include VHH-scAb, VHH-Fab, double scFab, F(ab')2, double antibody, crossMab, DAF(double bond), DAF(quadruple bond), DutaMab, DT-IgG, knob-in-hole structure (knobs-in-holes) common light chain, knob-in-hole structure component, charge pair, Fab arm exchange, SEEDbody, LUZ-Y, Fcab, κλ-body, orthogonal Fab, DVD-IgG, IgG(H)-scFv, scFv-(H)IgG, IgG(L)-scFv, scFv-(L)IgG, IgG(L,H)-Fv, IgG(H)-V, V(H)-IgG, IgG(L)-V, V(L)-IgG, KIH These include IgG-scFab, 2scFv-IgG, IgG-2scFv, scFv4-Ig, Zybody, DVI-IgG, biantibody-CH3, triple antibody (triple body), miniantibody, minibody, TriBi minibody, scFv-CH3 KIH, Fab-scFv, F(ab')2-scFv2, scFv-KIH, Fab-scFv-Fc, tetravalent HCAb, sc biantibody-Fc, biantibody-Fc, tandem scFv-Fc, intracellular antibody, dock and lock, lmmTAC, IgG-IgG complex, Cov-X-Body, or scFv1-PEG-scFv2.
[0277] In some embodiments, the antigen-binding protein construct may be a TrioMab. In a TrioMab, the two heavy chains originate from different species, where different sequences restrict the heavy-light chain pairing.
[0278] In some embodiments, the antigen-binding protein construct has two distinct heavy chains and one common light chain. The heterodimerization of the heavy chains can be based on a knob-in-hole structure or some other heavy chain pairing techniques.
[0279] In several embodiments, bispecific antibodies can be produced using CrossMAb technology. To achieve precise light chain binding in bispecific heterodimer IgG antibodies using CrossMAb technology, the technology enables the production of various bispecific antibody forms, including bis-(1+1), tris-(2+1), and tetra-(2+2) valent bispecific antibodies, and antibodies based on non-Fc tandem antigen-binding fragments (Fab). These forms can be derived from any existing antibody pair using domain crossover without requiring identification of a common light chain, post-translational processing / in vitro chemical assembly, or introduction of mutant groups to achieve correct light chain binding. The method is described in Klein et al., "The use of CrossMAb technology for the generation of bi- and multispecific antibodies," MAbs., Vol. 8, No. 6, Taylor & Francis, 2016, which is incorporated in its entirety by reference. In several embodiments, the CH1 domain in the heavy chain and the CL domain in the light chain are exchanged.
[0280] In some embodiments, the antigen-binding protein construct may be a 2:1 CrossMab. Another Fab fragment is added to the N-terminus of the VH domain of the CrossMab. The Fab fragment added to the CrossMab increases affinity by achieving bivalent binding.
[0281] In some embodiments, the antigen-binding protein construct may be a 2:2 CrossMab. The tetravalent bispecific antibody is produced by fusing Fab fragments to each C-terminus of the CrossMab. These Fab fragments can be cross-linked such that their CH1s are exchanged with their CLs. The VHs fuse to their CLs, and the VLs fuse to their CH1s. The CrossMab technique in the Fab fragments ensures specific pairing. Affinity can be enhanced by the double bivalent binding.
[0282] The antigen-binding protein construct may also be a duobody. The naturally occurring Fab exchange mechanism in IgG4 antibodies is similar to that of controlled substances in IgG1 antibodies, and this mechanism is called controlled Fab exchange. This form can ensure specific pairing between heavy and light chains.
[0283] In bivariable domain antibodies (DVD-Ig), other VH and variable light chain (VL) domains are added to each N-terminus for bispecific targeting. This morphology is similar to IgG-scFv, but the added binding domains bind individually to each N-terminus, rather than the scFv binding to each heavy chain N-terminus. In scFv-IgG, the two scFv molecules are linked to the C-terminus of the heavy chain (CH3). The scFv-IgG morphology has two distinct divalent binding sites and is therefore also called tetravalent. scFv-IgG does not have the heavy-light chain pairing problem.
[0284] In some embodiments, the antigen-binding protein construct may have an IgG-IgG configuration. Two complete IgG antibodies are conjugated via C-terminuses chemically linked to the heavy chain.
[0285] The antigen-binding protein construct may have a Fab-scFv-Fc configuration. In the Fab-scFv-Fc configuration, a light chain, a heavy chain, and a third chain containing the Fc region and scFv are assembled. This ensures efficient production and purification.
[0286] In some embodiments, the antigen-binding protein construct may be a TF (transformation factor). Three Fab fragments are linked via disulfide crosslinks. The TF form does not have an Fc region.
[0287] ADAPTIR has two scFvs bound to both sides of the Fc region. This discards the complete IgG as the basis of its construct but retains the Fc region to extend its half-life and facilitate purification.
[0288] Bispecific T cell-inducing antibodies ("BiTE") consist of two scFv molecules, VLA VHA and VHB VLB, on a single peptide chain. They possess only a binding domain and lack an Fc region. In BiTE-Fc, the Fc region is fused to the BiTE construct. The addition of the Fc region increases the half-life, thereby extending the effective concentration and avoiding continuous intravenous administration (IV).
[0289] Biaffinity retargeting (DART) antibodies have two peptide chains linking opposite fragments, namely VLA and VHB, and VLB and VHA, with sulfur bonds at their C-terminuses to fuse them. In DART, the sulfur bond can improve stability compared to BiTE.
[0290] In DART-Fc, the Fc region is linked to the DART structure. This is produced by assembling three strands, where two strands are linked by disulfide bonds such as those in DART. One strand contains half of the Fc region, which dimerizes with the third strand, expressing only the Fc region. The addition of the Fc region increases the half-life, thereby extending the effective concentration and avoiding continuous intravenous (IV) administration.
[0291] In tetravalent DART, four peptide chains are assembled. Essentially, two DART molecules are produced, each having half of the Fc region, and they dimerize. This form then divalently binds to both targets and is therefore a tetravalent molecule.
[0292] A tandem biantibody (TandAb) contains two biantibodies. Each biantibody consists of a VHA and a VLB fragment, and the VHA and VLB fragments are covalently linked. These two biantibodies are linked to a peptide chain. Compared to a biantibody consisting of two scFvs, its stability is improved. It has two bivalent binding sites.
[0293] The ScFv-scFv toxin contains two scFvs, one with a toxin and the other with a stable linker. It can be used to specifically deliver the payload.
[0294] In the module scFv-scFv-scFv, one scFv for TAA is tagged with a short, recognizable peptide and assembled into a bsAb consisting of two scFvs, one for CD3 and the other for the recognizable peptide.
[0295] In ImmTAC, a stable and soluble T cell receptor fuses to a CD3-recognizing scFv. By using a TCR, ImmTAC is suitable for targeted proteins, such as intracellular proteins.
[0296] Triple-specific nanobodies consist of two single variable domains (nanobodies) and other modules for extending the half-life. The half-life can be increased by adding additional modules.
[0297] In the triple-specific killer cell engager (TriKE), two scFv cells are linked via a polypeptide linker incorporating human IL-15. Adding a linker that binds to IL-15 increases NK cell survival and proliferation.
[0298] In one embodiment, the present disclosure provides a bispecific antibody or an antigen-binding fragment thereof, which includes: (a) Heavy chain polypeptide: The heavy chain polypeptide preferably comprises, from the N-terminus to the C-terminus, a first light chain variable region (VL1), a first linking peptide sequence, a second heavy chain variable region (VH2), an optional heavy chain constant region 1 (CH1), a heavy chain constant region 2 (CH2), and a heavy chain constant region 3 (CH3), and (b) Light chain polypeptide, which preferably comprises a second light chain variable region (VL2), a second linker peptide sequence, a first heavy chain variable region (VH1), a first light chain variable region (VL1), and an optional light chain constant region (CL) from the N-terminus to the C-terminus.
[0299] In some embodiments, VH1 and VL1 interact with each other to form a first antigen-binding site that specifically binds to PD-1. In some embodiments, VH2 and VL2 interact with each other to form a first antigen-binding site that specifically binds to CD40.
[0300] In some embodiments, VH1 and VL1 interact with each other to form a first antigen-binding site that specifically binds to CD40. In some embodiments, VH2 and VL2 interact with each other to form a first antigen-binding site that specifically binds to PD-1.
[0301] In some embodiments, the first and / or second linker peptides contain a sequence having at least 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 205. In some embodiments, the CH1, CH2, CH3, and / or CL domains are derived from human IgG (e.g., IgG1 or IgG4). In some embodiments, the human IgG (e.g., IgG1 or IgG4) contains KIH and / or LALA mutations.
[0302] In some embodiments, the bispecific antibody or its antigen-binding fragment further comprises a second heavy chain polypeptide having at least 90%, 95%, or 100% identity with a first heavy chain polypeptide, and a second light chain polypeptide having at least 90%, 95%, or 100% identity with a first light chain polypeptide.
[0303] In some embodiments, the bispecific antibodies or antigen-binding fragments described herein have the schematic structure shown in Figure 37. In some embodiments, the heavy chain polypeptide is shown in SEQ ID NO: 170, and the light chain polypeptide is shown in SEQ ID NO: 171.
[0304] Method for producing antigen-binding protein constructs Antibodies can be produced using isolated human protein fragments as immunogens, employing standard techniques for the production of polyclonal and monoclonal antibodies. Polyclonal antibodies can be produced in animals by multiple injections (e.g., subcutaneous or intraperitoneal injection) of the antigen peptide or protein. In some embodiments, the antigen peptide or protein is injected with at least one adjuvant. In some embodiments, the antigen peptide or protein can be compounded with an immunogenic agent in the immunized species. Animals may be injected with the antigen peptide or protein more than once (e.g., two, three, or four times).
[0305] Full-length polypeptides or proteins, or fragments of their antigenic peptides, can be used as immunogens. The antigenic peptide of a protein contains at least eight (e.g., at least 10, 15, 20, or 30) amino acid residues of the amino acid sequence of the protein and includes an epitope of the protein such that an antibody produced against the peptide forms a specific immune complex with the protein.
[0306] Immunogens are typically used to produce antibodies by immunizing a suitable target (e.g., a human or transgenic animal expressing at least one human immunoglobulin locus). Suitable immunogenic preparations may include, for example, recombinant expression or chemically synthesized polypeptides. Such preparations may further include adjuvants (e.g., Freund's complete or incomplete adjuvants) or similar immunostimulants.
[0307] Polyclonal antibodies can be produced as described above by immunizing a suitable target with a polypeptide or its antigenic peptide (e.g., a part of a protein) as an immunogen. Standard techniques allow for monitoring antibody titers over time in immunized targets, for example, using enzyme-linked immunosorbent assay (ELISA), immobilized polypeptides, or peptides. If necessary, antibody molecules are isolated from mammals (e.g., blood) and further purified by known techniques (e.g., protein A or protein G chromatography) to obtain the IgG fraction. At an appropriate time after immunization, for example, when the specific antibody titer is highest, antibody-producing cells can be obtained from the target and used to produce monoclonal antibodies by standard techniques, e.g., the hybridoma technique first described by Kohler et al. (Nature, Vol. 256: pp. 495-497, 1975), the human B-cell hybridoma technique (Kozbor et al., Immunol. Today, Vol. 4: p. 72, 1983), the EBV-hybridoma technique (Cole et al., Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96, 1985), or the trioma technique. Techniques for producing hybridomas are well known (generally Current Protocols in See Immunology, 1994, Coligan et al. (eds.), John Wiley & Sons, Inc., New York, NY. Hybridoma cells that produce monoclonal antibodies are detected by screening for antibodies that bind to the target polypeptide or epitope in the supernatant of the hybridoma culture, for example, using a standard ELISA assay.
[0308] Mutants of the antibodies or antigen-binding fragments described herein can be produced by introducing appropriate nucleotide changes into the DNA encoding the human, humanized, or chimeric antibodies or their antigen-binding fragments described herein, or by peptide synthesis. Such mutants include, for example, deletions, insertions, or substitutions of residues in the amino acid sequence constituting the antigen-binding site of the antibody or antigen-binding domain. In a population of such mutants, some antibodies or antigen-binding fragments have increased affinity for target proteins. Any combination of deletions, insertions, and / or combinations can be used to obtain antibodies or their antigen-binding fragments with increased binding affinity to targets. Amino acid changes introduced into antibodies or antigen-binding fragments can also modify or introduce new post-translational modifications to the antibody or antigen-binding fragment, such as modifying the number of glycosylation sites (e.g., increasing or decreasing them), modifying the type of glycosylation sites (e.g., modifying the amino acid sequence so that different sugars are linked by enzymes present in the cell), or introducing new glycosylation sites.
[0309] The antibodies disclosed herein may originate from any species of animal, including mammals. Non-limiting examples of natural antibodies include antibodies derived from humans, primates (e.g., monkeys and apes), cattle, pigs, horses, sheep, camelids (e.g., camels and llamas), chickens, goats and rodents (e.g., rats, mice, hamsters and rabbits) (including transgenic rodents genetically engineered to produce human antibodies).
[0310] Phage display (panning) can be used to optimize antibody sequences with desired binding affinity. In this technique, a gene encoding single-stranded Fv (including VH or VL) is inserted into the phage's coat protein gene, causing the phage to "display" scFv on its outside while containing the gene for the protein internally, thereby creating a correlation between genotype and phenotype. These display phages can then be screened against a target antigen to detect the interaction between the displayed antigen-binding site and the target antigen. Thus, the amplified protein library, obtained through a process called in vitro selection, can be screened and amplified to obtain antibody sequences with desired binding affinity.
[0311] Human and humanized antibodies include antibodies that have a variable region and a constant region derived from a human germline immunoglobulin sequence (or have the same amino acid sequence as an antibody derived from a human germline immunoglobulin sequence). Human antibodies may contain amino acid residues not encoded by a human germline immunoglobulin sequence (e.g., mutations introduced by random or site-directed mutagenesis in vitro, or by somatic mutation in vivo), such as those found in CDRs.
[0312] Humanized antibodies typically have a human framework (FR) grafted with a non-human CDR. Therefore, humanized antibodies have one or more introduced amino acid sequences of non-human origin. These non-human amino acid residues are usually called “introduced” residues, and they are typically taken from the “introduced” variable domain. Humanization can be performed essentially by substituting the corresponding sequence of a human antibody with, for example, a rodent CDR or CDR sequence. These methods are described, for example, in Jones et al., Nature, Vol. 321: pp. 522-525 (1986); Riechmann et al., Nature, Vol. 332: pp. 323-327 (1988); and Verhoeyen et al., Science, Vol. 239: pp. 1534-1536 (1988), each of which is incorporated herein by reference in its entirety. Thus, a “humanized” antibody is a chimeric antibody in which a portion of the fully human V domain is substituted with a corresponding sequence from a non-human species. In fact, humanized antibodies are typically mouse antibodies, in which several CDR residues and several FR residues are substituted with residues from similar sites in human antibodies.
[0313] More importantly, while humanizing antibodies, it is necessary to retain high specificity and affinity for the antigen, as well as other advantageous biological properties. To achieve this objective, humanized antibodies can be produced by analyzing the parent sequence and various conceptual humanized products using three-dimensional models of the parent sequence and the humanized sequence. Three-dimensional immunoglobulin models are generally available and well known to those skilled in the art. Computer programs can be obtained to describe and display the possible three-dimensional structures of selected candidate immunoglobulin sequences. Examination of these displays allows for the analysis of the possible effects of residues on the function of the candidate immunoglobulin sequence, i.e., the analysis of residues that affect the candidate immunoglobulin's ability to bind to its antigen. By this method, FR residues can be selected and combined from the receptor and transduction sequences to obtain desired antibody characteristics, such as increased affinity for the target antigen.
[0314] Sequence identity or homology is typically the percentage of amino acid residues present in the candidate sequence that are identical to those present in the human, humanized, or chimeric antibody or fragment, after aligning the candidate sequence with the original sequence and introducing gaps where necessary to achieve the maximum percentage sequence identity, without considering any conservative substitutions as part of sequence identity.
[0315] In some embodiments, antibodies, their antigen-binding fragments, or antigen-binding protein constructs (e.g., bispecific antibodies) can be covalently modified. These covalent modifications can be carried out by chemical synthesis or enzymatic synthesis, or by enzymatic or chemical cleavage. Other types of covalent modifications of antibodies or antibody fragments can be introduced into the molecule by reacting target amino acid residues of the antibody or fragment with an organic derivatizing agent that can react with selected side chains or N-terminal or C-terminal residues.
[0316] In some embodiments, antibody variants are provided having carbohydrate structures lacking fucose (directly or indirectly) linked to the Fc region. For example, the amount of fucose in such antibodies may be 1% to 80%, 1% to 65%, 5% to 65%, or 20% to 40%. The amount of fucose is determined by calculating the average amount of intra-sugar fucose in Asn297 relative to the sum of all sugar structures linked to Asn297 (e.g., complexed, heterozygous, and high-mannose structures), and is measured, for example, by MALDI-TOF mass spectrometry (e.g., described in WO 2008 / 077546). Asn297 refers to the aspartinine residue located at approximately position 297 in the Fc region (position 314 in the Eu numbering or Kabat numbering of Fc region residues), however, due to small sequence variations in the antibody, Asn297 may also be located at approximately ±3 amino acid positions upstream or downstream of position 297, i.e., between positions 294 and 300. Such fucosylated variants can have improved ADCC function. In some embodiments, to reduce glycan heterogeneity, the Fc region of the antibody can be further engineered to replace aspartine (N297A) at position 297 with alanine.
[0317] In some embodiments, to improve production efficiency by avoiding Fab-arm exchange, the Fc region of the antibody is further engineered to replace the serine (S228P) at position 228 (EU numbering) of IgG4 with proline. A detailed description of the S228 mutation is provided, for example, in Silva et al., "The S228P mutation prevents in vivo and in vitro IgG4 Fab-arm exchange as demonstrated using a combination of novel quantitative immunoassays and physiological matrix preparation," Journal of Biological Chemistry, 290.9 (2015): pp. 5462-5469, which is incorporated in its entirety by reference.
[0318] In some embodiments, the Leu234Ala / Leu235Ala (EU numbering) (LALA) mutation is introduced to disrupt antibody effector function.
[0319] In some embodiments, the methods described herein are designed to produce bispecific antibodies. Bispecific antibodies can be produced by engineering the interface between a pair of antibody molecules to maximize the percentage of heterodimers recovered from recombinant cell cultures. For example, the interface may include at least a portion of the CH3 domain of the antibody constant domain. In the method, one or more small amino acid side chains from the interface of the first antibody molecule are replaced with larger side chains (e.g., tyrosine or tryptophan). By replacing the large amino acid side chains with small amino acid side chains (e.g., alanine or threonine), a compensated "cavity" of the same or similar size as the large side chains is formed at the interface of the second antibody molecule. This provides a mechanism to increase the yield of heterodimers compared to other unwanted end products (such as homodimers). The method is described, for example, in WO 96 / 27011, which is incorporated herein by reference in its entirety.
[0320] In some embodiments, a knob-into-hole (KIH) technique may be used, which involves engineering the CH3 domain to produce a “knob” or “hole” in each heavy chain to promote heterodimerization. The KIH technique is, for example, Xu, Yiren et al., “Production of bispecific antibodies in 'knobs-into-holes' using a cell-free expression system,” MAbs, Vol. 7, No. 1, Taylor & Francis, 2015, which is incorporated in its entirety by reference. In some embodiments, one heavy chain has the T366W and / or S354C (knob) substitution (EU numbering), and the other heavy chain has the Y349C, T366S, L368A and / or Y407V (hole) substitution (EU numbering). In some embodiments, one heavy chain has one or more of the substitutions Y349C and T366W (EU numbering). The other heavy chain may have one or more substitutions from E356C, T366S, L368A, and Y407V (EU numbering). Furthermore, substitutions (-ppcpScp-->-ppcpPcp-) can be introduced into the hinge region of the two-substituted IgG.
[0321] Furthermore, bispecific antibodies can be purified using anion exchange chromatography. Anion exchange chromatography is a method that separates substances based on their charge using an ion exchange resin that contains positively charged groups (such as diethylaminoethyl (DEAE)). In solution, the resin is coated with positively charged counterions (cations). The anion exchange resin binds to negatively charged molecules and displaces the counterions. Proteins can be purified using anion exchange chromatography based on the isoelectric point (pI) of the protein. The isoelectric point is defined as the pH at which a protein has no net charge. When pH > pI, the protein has a net negative charge, and when pH < pI, the protein has a net positive charge. Accordingly, in some embodiments, different amino acid substitutions can be introduced into the two heavy chains such that the pI of the homodimer comprising two Arm A is different from the pI of the homodimer comprising two Arm B. The pI of the bispecific antibody having Arm A and Arm B lies between the two pI values of the homodimers. Thus, the two homodimers and the bispecific antibody can be eluted under different pH conditions. The present disclosure shows that several amino acid residue substitutions can be introduced into the heavy chain to adjust the pI.
[0322] Accordingly, in some embodiments, the amino acid residue at Kabat numbering position 83 is lysine, arginine or histidine. In some embodiments, the amino acid residue at one or more of positions 1, 6, 43, 81 and 105 (Kabat numbering) is aspartic acid or glutamic acid. In some embodiments, the amino acid residue at one or more of positions 13 and 105 (Kabat numbering) is aspartic acid or glutamic acid. In some embodiments, the amino acid residue at one or more of positions 13 and 42 (Kabat numbering) is lysine, arginine, histidine or glycine.
[0323] Bispecific antibodies may further include, for example, crosslinked or "heterogeneous complex" antibodies. For example, one antibody in a heterogeneous complex can be coupled to an anti-biotin protein, and the other to biotin. Heterogeneous complex antibodies can also be produced using any convenient crosslinking method. Suitable crosslinking agents and techniques are well known in the art and are disclosed in U.S. Patent No. 4,676,980, which is incorporated herein by reference in its entirety.
[0324] Methods for producing bispecific antibodies from antibody fragments are also known in the art. For example, bispecific antibodies can be produced using chemical linking. Brennan et al. (Science, Vol. 229: p. 81, 1985) described a method for generating F(ab')2 fragments from a complete antibody by hydrolytic cleavage of the protein. These fragments are reduced in the presence of sodium arsenite, a dithiol complexing agent, to stabilize adjacent dithiols and prevent intermolecular disulfide formation. The resulting Fab' fragments are then converted to thionitrobenzoate (TNB) derivatives. One of the Fab' TNB derivatives is then converted to a Fab' thiol by reduction with mercaptoethylamine, and a bispecific antibody is formed by mixing it with an equimolar amount of another Fab' TNB derivative.
[0325] Recombinant vectors This disclosure further provides recombinant vectors (e.g., expression vectors) containing isolated polynucleotides disclosed herein (e.g., polynucleotides encoding polypeptides disclosed herein), host cells into which these recombinant vectors are introduced (i.e., such that these host cells contain polynucleotides and / or the polynucleotide-containing vectors), and the production of recombinant antibody polypeptides or fragments thereof by recombinant technology.
[0326] As used herein, “vector” is any construct that, once introduced into a host cell, can deliver one or more target polynucleotides to that host cell. “Expression vector” can deliver one or more target polynucleotides within the host cell into which the expression vector has been introduced and express them as encoded polypeptides. In an expression vector, the target polynucleotide is localized to be expressed in the vector so that it is translated in the host cell into which the expression vector has been introduced, by manipulably ligating it to an integration site of the target polynucleotide within the vector or in the host cell genome, or to regulatory elements (e.g., promoter, enhancer and / or poly-A tail) near or on either side thereof.
[0327] Vectors can be introduced into host cells by methods known in the art, such as electroporation, chemical transfection (e.g., DEAE-glucan), transformation, transfection, infection, and / or transduction (e.g., by recombinant viruses). Therefore, non-limiting examples of vectors include viral vectors (useful for the production of recombinant viruses), naked DNA or RNA, plasmids, cosmids, phage vectors, and DNA or RNA expression vectors associated with cationic condensants.
[0328] In some embodiments, introducing the polynucleotides disclosed herein (e.g., polynucleotides encoding the polypeptides disclosed herein) using a viral expression system (e.g., vaccinia or other poxvirus, retrovirus or adenovirus) may involve the use of non-pathogenic (defective), reproducible viruses or replication-deficient viruses. In the latter case, viral replication typically occurs only in complementary viral packaging cells. Appropriate systems include, for example, Fisher-Hoch et al., 1989, Proc. Natl. Acad. Sci. USA, Vol. 86: pp. 317-321; Flexner et al., 1989, Ann. NYAcad Sci., Vol. 569: pp. 86-103; Flexner et al., 1990, Vaccine, Vol. 8: pp. 17-21; U.S. Patent Nos. 4,603,112, 4,769,330 and 5,017,487; WO 89 / 01973; U.S. Patent No. 4,777,127; GB 2,200,651; EP 0,345,242; WO Disclosed in 91 / 02805; Berkner-Biotechniques, Vol. 6: pp. 616-627, 1988; Rosenfeld et al., 1991, Science, Vol. 252: pp. 431-434; Kolls et al., 1994, Proc. Natl. Acad. Sci. USA, Vol. 91: pp. 215-219; Kass-Esisler et al., 1993, Proc. Natl. Acad. Sci. USA, Vol. 90: pp. 11498-11502; Guzman et al., 1993, Circulation, Vol. 88: pp. 2838-2848; and Guzman et al., 1993, Cir. Res., Vol. 73: pp. 1202-1207. Techniques for incorporating DNA into such expression systems are well known to those skilled in the art. DNA may also be "naked," for example, as in Ulmer et al., 1993, Science, Vol. 259: pp. 1745-1749; and Cohen, 1993, Science, Vol. 259: pp. 1691-1692. The uptake of naked DNA can be increased by coating it onto biodegradable beads that are efficiently transported into cells.
[0329] For expression, DNA insertion fragments comprising polynucleotides encoding the antibodies or polypeptides disclosed herein can be operably ligated to suitable promoters (e.g., heterologous promoters), such as the phage λPL promoter, the E. coli lac, trp, and tac promoters, the SV40 early and late promoters, and the promoters of retroviral LTRs. Other suitable promoters are known to those skilled in the art. The expression construct may further include a transcription start site, a transcription end site, and a ribosome binding site for translation within the transcription region. The coding portion of the mature transcript expressed by the construct may include a translation start codon at the start site of the polypeptide to be translated and a termination codon (UAA, UGA, or UAG) at a suitable position at the end of the polypeptide to be translated.
[0330] As described above, the expression vector may contain at least one selectable marker. Such markers include dihydrofolate reductase or neomycin resistance genes for eukaryotic cell culture, and tetracycline or ampicillin resistance genes for culture in Escherichia coli and other bacteria. Representative examples of suitable hosts include, but are not limited to, bacterial cells such as Escherichia coli, Streptomyces, and Salmonella typhimurium cells, fungal cells such as yeast cells, insect cells such as S2 and Spodoptera fulgiperda Sf9 cells, animal cells such as CHO, COS, Bowes melanoma, and HEK 293 cells, and plant cells. Suitable media and conditions for use in the host cells described herein are known in the art.
[0331] Non-restrictive vectors for bacteria include pQE70, pQE60, and pQE-9 from Qiagen; pBS vector, Phagescript vector, Bluescript vector, pNH8A, pNH16a, pNH18A, and pNH46A from Stratagene; and ptrc99a, pKK223-3, pKK233-3, pDR540, and pRIT5 from Pharmacia. Non-restrictive eukaryotic vectors include pWLNEO, pSV2CAT, pOG44, pXT1, and pSG from Stratagene; and pSVK3, pBPV, pMSG, and pSVL from Pharmacia. Other suitable vectors will be apparent to those skilled in the art.
[0332] Suitable non-restrictive bacterial promoters include the E. coli lacI and lacZ promoters, T3 and T7 promoters, gpt promoter, λPR and PL promoter, and trp promoter. Suitable eukaryotic promoters include the CMV immediate early promoter, HSV thymidine kinase promoter, early and late SV40 promoters, retroviral LTR promoters (such as the Rous sarcoma virus (RSV) promoter), and metallothionein promoters (such as the mouse metallothionein-I promoter).
[0333] In budding yeast, many vectors can be used, including those containing α-factor, alcohol oxidase, and constitutive or inducible promoters such as PGH. For an overview, see Ausubel et al. (1989) Current Protocols in Molecular Biology, John Wiley & Sons, New York, NY, and Grant et al., Methods Enzymol., Vol. 153: pp. 516-544 (1997).
[0334] The introduction of constructs into host cells can be achieved by calcium phosphate transfection, DEAE-dextran-mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection, or other methods. These methods are described in many standard laboratory manuals, such as Davis et al., Basic Methods In Molecular Biology (1986), which are incorporated herein by reference in their entirety.
[0335] The transcription of the antibody-encoding DNA of this disclosure by higher eukaryotes can be increased by inserting enhancer sequences into the vector. Enhancers are cis-acting elements of DNA, typically about 10 bp to 300 bp in length, and their action is to increase the transcriptional activity of the promoter in a given host cell type. Examples of enhancers include SV40 enhancers located 100 to 270 base pairs later than the origin of replication, cytomegalovirus early promoter enhancers, polyoma enhancers located later than the origin of replication, and adenovirus enhancers.
[0336] Appropriate secretory signals can be incorporated into the expressed polypeptide to cause the translated protein to be secreted into the endoplasmic reticulum lumen, pericellular stroma, or extracellular environment. The signal may be an endogenous signal of the polypeptide or a heterologous signal.
[0337] Polypeptides (e.g., antibodies) may be expressed in modified forms, such as fusion proteins (e.g., GST fusion proteins) or with histidine tags, and may include not only secretory signals but also other heterologous functional regions. For example, regions of other amino acids (particularly charged amino acids) can be added to the N-terminus of a polypeptide to improve its stability and persistence in host cells, during purification, or during subsequent handling and storage. Furthermore, peptide moieties can be added to polypeptides to facilitate purification. These regions may be removed before the final preparation of the polypeptide. Adding peptide moieties to polypeptides to induce secretion or efflux, enhance stability, and facilitate purification is a well-known prior art in the art.
[0338] This disclosure relates to nucleic acid sequences having at least 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, and 99% identity with any of the nucleotide sequences described herein, and Further, we provide amino acid sequences having at least 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, and 99% identity with any of the amino acid sequences described herein.
[0339] This disclosure relates to nucleic acid sequences having at least 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, and 99% homology to any of the nucleotide sequences described herein, and Further, we provide amino acid sequences having at least 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, and 99% homology with any of the amino acid sequences described herein.
[0340] In some embodiments, the disclosure relates to a nucleotide sequence encoding any of the peptides described herein, or an amino acid sequence encoded by any of the nucleotide sequences described herein. In some embodiments, the nucleic acid sequence is less than 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 150, 200, 250, 300, 350, 400, 500, or 600 nucleotides. In some embodiments, the amino acid sequence is less than 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 250, 300, 350, or 400 amino acid residues.
[0341] In some embodiments, the amino acid sequence (i) comprises an amino acid sequence, or (ii) consists of an amino acid sequence, wherein the amino acid sequence is one of the sequences described herein.
[0342] In some embodiments, the nucleic acid sequence (i) comprises a nucleic acid sequence, or (ii) consists of a nucleic acid sequence, wherein the nucleic acid sequence is any of the sequences described herein.
[0343] To determine the percentage of identity between two amino acid sequences or two nucleic acid sequences, these sequences are aligned for optimal comparison purposes (for example, gaps may be introduced into one or both of the first and second amino acid or nucleic acid sequences for optimal alignment, and non-homologous sequences may be ignored for comparison purposes). Then, amino acid residues or nucleotides at the corresponding amino acid or nucleotide positions are compared. If a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then these molecules are identical at that position. The percentage of identity between the two sequences is a function of the number of identical positions common to the sequences, taking into account the number of gaps that need to be introduced to achieve optimal alignment of the two sequences and the length of each gap. For illustrative purposes, the comparison of sequences and the determination of the percentage of identity between two sequences may be achieved using a Blossum 62 score matrix, where the gap penalty is 12, the gap elongation penalty is 4, and the frameshift gap penalty is 5.
[0344] The percentage of sequence homology (e.g., amino acid sequence homology or nucleic acid homology) can also be determined. Methods for determining the percentage of sequence homology are known in the art. In some embodiments, conserved amino acid residues having similar physicochemical properties (homology percentage), such as leucine and isoleucine, can be used to measure sequence similarity. Families of amino acid residues having similar physicochemical properties are defined in the art. These families include, for example, amino acids with basic side chains (e.g., lysine, arginine, histidine), amino acids with acidic side chains (e.g., aspartic acid, glutamic acid), amino acids with non-charged side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), amino acids with nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), amino acids with β-branched side chains (e.g., threonine, valine, isoleucine), and amino acids with aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). In many cases, the homology percentage is higher than the identity percentage.
[0345] This disclosure provides one or more nucleic acids encoding any of the polypeptides described herein. In some embodiments, the nucleic acid (e.g., cDNA) comprises a polynucleotide encoding a heavy-chain polypeptide described herein. In some embodiments, the nucleic acid comprises a polynucleotide encoding a light-chain polypeptide described herein. In some embodiments, the nucleic acid comprises a polynucleotide encoding an scFv polypeptide described herein.
[0346] In some embodiments, the vector may have both nucleic acids encoding a VL region and a VH region that commonly bind to PD-1, as described herein. In some embodiments, a pair of vectors is provided in which each vector comprises one of the nucleic acids described herein and codes for both a VL region and a VH region that commonly bind to PD-1. In some embodiments, the vector comprises both nucleic acids described herein, where the vector codes for both a VL region and a VH region that commonly bind to CD40. In some embodiments, a pair of vectors is provided in which each vector comprises one of the nucleic acids described herein and codes for both a VL region and a VH region that commonly bind to CD40.
[0347] Vectors can also be constructed to express specific antibodies or polypeptides. In some embodiments, vectors can be constructed to co-express one or more antibody polypeptide chains. In some embodiments, vectors may contain, from the 5' end to the 3' end, the cytomegalovirus promoter (CMV), a sequence encoding a first polypeptide chain, polyadenylation (PolyA), CMV, a sequence encoding a second polypeptide chain, PolyA, monkey vacuolar virus 40 terminator (SV40), and a glutamine synthase marker (GS). In some embodiments, vectors can be constructed to express the anti-CD40 antibody scFv polypeptide chain.
[0348] Treatment method The methods described herein include methods for treating cancer-related medical conditions. Typically, the methods involve administering a therapeutically effective amount of the engineered antibody described herein, its antigen-binding fragment, or antigen-binding protein construct (e.g., a bispecific antibody) to a subject who requires or is deemed to require such treatment.
[0349] As used herein, “to treat” means to improve at least one symptom of a cancer-related condition. Cancer typically leads to death, and therefore treatment can increase life expectancy (e.g., at least one, two, three, four, five, six, seven, eight, nine, ten, eleven, or twelve months, or at least one, two, three, four, five, six, seven, eight, nine, or ten years). To treat a cancer-related condition, administration of a therapeutically effective amount of the drugs described herein results in a reduction in the number of cancer cells and / or a reduction in symptoms.
[0350] As used herein, the term “cancer” refers to an abnormal condition or situation characterized by cells having the ability to self-replicate, i.e., rapid cell proliferation. The term is intended to include all types of cancerous growth or carcinogenic processes, metastatic tissue, or malignantly transformed cells, tissues, or organs, regardless of their histopathological type or stage of invasion. As used herein, the term “tumor” refers to cancer cells, e.g., cancer cell masses. Cancers that can be treated or diagnosed using the methods described herein include malignancies of various organ systems, such as malignancies affecting the lungs, mammary glands, thyroid gland, lymphatic system, gastrointestinal tract, and urogenital tract, and adenocarcinomas, including most colon cancers, renal cell carcinoma, prostate cancer and / or testicular tumors, non-small cell lung cancer, small intestine cancer, and esophageal cancer. In some embodiments, the agents described herein are designed to treat or diagnose cancer in a subject. The term "cancer" is known in the art and refers to malignant tumors of epithelial or endocrine tissue, including respiratory cancers, gastrointestinal cancers, genitourinary cancers, testicular cancers, breast cancers, prostate cancers, endocrine cancers, and melanomas. In some embodiments, cancer is kidney cancer or melanoma. Exemplary cancers include cancers that form from tissues of the cervix, lungs, prostate, mammary glands, head and neck, colon, and ovaries. The term further includes carcinosarcomas, which include, for example, malignant tumors consisting of cancerous and sarcomatous tissues. "Adenocarcinoma" refers to cancer originating from glandular tissue, or, herein, cancer in which tumor cells form recognizable glandular structures. The term "sarcoma" is known in the art and refers to malignant tumors of mesenchymal origin.
[0351] In some embodiments, the cancer is a chemotherapy-resistant cancer. In one embodiment, the disclosure further provides a method for treating cancer in a subject, a method for reducing the rate of increase in tumor volume over time in a subject, a method for reducing the risk of metastasis formation, or a method for reducing the risk of other metastases formation in a subject. In some embodiments, the treatment can stop, mitigate, delay, or inhibit the progression of cancer. In some embodiments, the treatment can reduce the number, severity, and / or duration of one or more cancer symptoms in a subject.
[0352] In one embodiment, the Disclosure provides a method comprising administering a therapeutically effective amount of an antibody, its antigen-binding fragment, or antigen-binding protein construct (e.g., a bispecific antibody), or antibody-drug conjugate to a subject in need, for example, a subject having, or being identified or diagnosed with, cancer, such cancer being, for example, breast cancer (e.g., triple-negative breast cancer), carcinoid, cervical cancer, endometrial cancer, glioma, head and neck cancer, liver cancer, lung cancer, small cell lung cancer, lymphoma, melanoma, ovarian cancer, pancreatic cancer, prostate cancer, kidney cancer, colorectal cancer, gastric cancer, testicular cancer, thyroid cancer, bladder cancer, urinary tract cancer, or hematological malignancies. In some embodiments, the cancer is unresectable or metastatic melanoma, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), bladder cancer, or metastatic hormone-refractory prostate cancer. In some embodiments, the subject has a solid tumor. In some embodiments, the cancer is head and neck squamous cell carcinoma (SCCHN), renal cell carcinoma (RCC), triple-negative breast cancer (TNBC), or colorectal cancer. In some embodiments, the subject has Hodgkin lymphoma. In some embodiments, the subject has triple-negative breast cancer (TNBC), gastric cancer, urothelial carcinoma, Merkel cell carcinoma, or head and neck cancer.
[0353] In some embodiments, cancer is melanoma, pancreatic cancer, mesothelioma, hematological malignancies, particularly non-Hodgkin lymphoma, lymphoma, chronic lymphocytic leukemia, or progressive solid tumors.
[0354] In some embodiments, the methods described herein can be used to treat thermal tumors, which are tumors that can elicit a strong immune response. Thermal tumors typically have many molecules on their surface, which allow T cells to attack and kill tumor cells. The methods described herein can further enhance the immune response, promote the proliferation and infiltration of CD8+ T cells, and / or reduce the number of myeloid-derived immunosuppressive cells in the tumor.
[0355] In some embodiments, the methods described herein can be used to treat cold tumors. Cold tumors are tumors that are unlikely to elicit a strong immune response. Cold tumors are often surrounded by cells that have the ability to inhibit the immune response, prevent attack by T cells, and kill tumor cells. The methods described herein are effective in promoting the proliferation, infiltration, and / or activation of DC cells, thereby increasing the activity of antigen-presenting cells. In some embodiments, the methods described herein can downregulate the expression of PD-1 in T cells, thereby further reducing the interaction between PD-1 and PD-L1 and improving the immune response. As used herein, the terms “subject” and “patient” are used interchangeably throughout this specification and refer to animals (human or non-human) to which treatment is provided according to the methods of the present invention. The present invention considers both veterinary and non-veterinary applications. Human patients may be adults or adolescents (e.g., humans under 18 years of age). In addition to humans, patients include, but are not limited to, mice, rats, hamsters, guinea pigs, rabbits, ferrets, cats, dogs, and primates. Examples include non-human primates (e.g., monkeys, chimpanzees, gorillas), rodents (e.g., rats, mice, gerbils, hamsters, ferrets, rabbits), lagomorphs, pigs (e.g., pigs, miniature pigs), horses, dogs, cats, cattle, and other livestock, farm animals, and zoo animals.
[0356] In some embodiments, the compositions and methods disclosed herein can be used to treat patients at risk of cancer. Cancer patients can be identified in various ways known in the art.
[0357] As used herein, “effective dose” refers to an amount or dose sufficient to achieve a beneficial or desired outcome, including cessation, mitigation, delay, or inhibition of disease progression (e.g., cancer). The effective dose varies depending on the age and weight of the person to whom the antibody, antigen-binding fragment, antibody-drug conjugate, polynucleotide encoding the antibody, vector containing said polynucleotide, and / or composition thereof is administered, the severity of the symptoms, and the route of administration; therefore, the dose may be determined on an individual basis.
[0358] The effective dose may be administered in one or more doses. For example, the effective dose of an antibody, antigen-binding fragment, or antibody-drug conjugate is sufficient to improve, halt, stabilize, reverse, inhibit, mitigate, and / or delay the progression of an autoimmune disease or cancer in a patient, or sufficient to improve, halt, stabilize, reverse, mitigate, and / or delay the proliferation of cells (e.g., biopsy cells, any of the cancer cells described herein, or cell lines (e.g., cancer cell lines)) in vitro. As is understood in the art, the effective dose of an antibody, antigen-binding fragment, or antibody-drug conjugate may vary depending on other factors, particularly the patient's medical history, and the type (and / or dose) of the antibody used.
[0359] The effective doses and administration regimens of the antibodies, antibody-encoding polynucleotides, antibody-drug conjugates, and / or compositions disclosed herein may be determined empirically, and such determinations are within the scope of the art. Those skilled in the art will understand that the dose to be administered will vary depending, for example, on the mammal to receive the antibodies, antibody-encoding polynucleotides, antibody-drug conjugates, and / or compositions disclosed herein, the route of administration, the specific type of antibody, antibody-encoding polynucleotide, antigen-binding fragment, antibody-drug conjugate, and / or composition used, and on other drugs administered to the mammal. Guidelines for selecting an appropriate dose of antibody or antigen-binding fragment can be found in the literature on the therapeutic use of antibodies and antigen-binding fragments, e.g., Handbook of Monoclonal Antibodies, edited by Ferrone et al., Noges Publications, Park Ridge, NJ, 1985, Chapter 22, pp. 303-357; and Smith et al., Antibodies in Human Diagnosis and Therapy, edited by Haber et al., Raven Press, New York, 1977, pp. 365-389.
[0360] A typical daily dose of an effective amount of antibody, its antigen-binding fragment, or antigen-binding protein construct (e.g., a bispecific antibody) is 0.01 mg / kg to 100 mg / kg. In some embodiments, the dose may be 100 mg / kg, 50 mg / kg, 40 mg / kg, 30 mg / kg, 20 mg / kg, 10 mg / kg, 9 mg / kg, 8 mg / kg, 7 mg / kg, 6 mg / kg, 5 mg / kg, 4 mg / kg, 3 mg / kg, 2 mg / kg, 1 mg / kg, 0.5 mg / kg, or less than 0.1 mg / kg. In some embodiments, the dose may be 30 mg / kg, 20 mg / kg, 10 mg / kg, 9 mg / kg, 8 mg / kg, 7 mg / kg, 6 mg / kg, 5 mg / kg, 4 mg / kg, 3 mg / kg, 2 mg / kg, 1 mg / kg, 0.5 mg / kg, 0.1 mg / kg, 0.05 mg / kg, or 0.01 mg / kg or more. In some embodiments, the dose is about or at least 30 mg / kg, 20 mg / kg, 10 mg / kg, 9 mg / kg, 8 mg / kg, 7 mg / kg, 6 mg / kg, 5 mg / kg, 4 mg / kg, 3 mg / kg, 2 mg / kg, 1 mg / kg, 0.9 mg / kg, 0.8 mg / kg, 0.7 mg / kg, 0.6 mg / kg, 0.5 mg / kg, 0.4 mg / kg, 0.3 mg / kg, 0.2 mg / kg, or 0.1 mg / kg.
[0361] In any of the methods described herein, at least one antibody, its antigen-binding fragment, or antigen-binding protein construct (e.g., a bispecific antibody), an antibody-drug conjugate, or a pharmaceutical composition (e.g., any of the antibodies, antigen-binding fragments, antibody-drug conjugates, or pharmaceutical compositions described herein), and optionally at least one additional therapeutic agent may be administered to a subject at least once a week (e.g., once, twice, three, or four times a week, once daily, twice daily, or three times daily). In some embodiments, at least two different antibodies and / or antigen-binding fragments are administered in the same composition (e.g., a liquid composition). In some embodiments, at least one antibody, its antigen-binding fragment, an antigen-binding protein construct (e.g., a bispecific antibody), or an antibody-drug conjugate, and at least one additional therapeutic agent are administered in the same composition (e.g., a liquid composition). In some embodiments, at least one antibody or antigen-binding fragment and at least one additional therapeutic agent are administered in two different compositions (e.g., a liquid composition containing at least one antibody or antigen-binding fragment and a solid oral composition containing at least one additional therapeutic agent). In some embodiments, at least one additional therapeutic agent is administered in the form of a pill, tablet, or capsule. In some embodiments, at least one additional therapeutic agent is administered as a sustained-release oral formulation.
[0362] In some embodiments, one or more other therapeutic agents may be administered to a subject before or after administration of at least one antibody, antigen-binding antibody fragment, antibody-drug conjugate, or pharmaceutical composition (e.g., any of the antibodies, antigen-binding antibody fragments, or pharmaceutical compositions described herein). In some embodiments, one or more additional therapeutic agents and at least one antibody, antigen-binding antibody fragment, antibody-drug conjugate, or pharmaceutical composition (e.g., any of the antibodies, antigen-binding antibody fragments, or pharmaceutical compositions described herein) are administered to the subject such that the biological activity periods of the one or more additional therapeutic agents and the at least one antibody or antigen-binding fragment (e.g., any of the antibodies, antigen-binding antibody fragments, or pharmaceutical compositions described herein) overlap.
[0363] In some embodiments, at least one antibody, antigen-binding antibody fragment, antibody-drug conjugate, or pharmaceutical composition (e.g., any of the antibodies, antigen-binding antibody fragments, or pharmaceutical compositions described herein) may be administered to a subject over an extended period (e.g., a period of at least one week, two weeks, three weeks, one month, two months, three months, four months, five months, six months, seven months, eight months, nine months, ten months, eleven months, twelve months, one year, two years, three years, four years, or five years). A skilled medical professional may determine the length of the treatment period to diagnose or track therapeutic effectiveness (e.g., observe at least one symptom of cancer) using any of the methods described herein. As described herein, skilled medical professionals may further modify (e.g., increase or decrease) the identity and number of antibodies or antigen-binding antibody fragments, antibody-drug conjugates (and / or one or more additional therapeutic agents) administered to a subject, and may adjust (e.g., increase or decrease) the dose or frequency of at least one antibody or antigen-binding antibody fragment (and / or one or more additional therapeutic agents) administered to a subject based on an assessment of therapeutic efficacy (e.g., using any of the methods described herein or known in the art).
[0364] In some embodiments, one or more additional therapeutic agents may be administered to the target. These additional therapeutic agents may include one or more inhibitors selected from the group consisting of B-Raf inhibitors, EGFR inhibitors, MEK inhibitors, ERK inhibitors, K-Ras inhibitors, c-Met inhibitors, anaplastic lymphoma kinase (ALK) inhibitors, phosphatidylinositol 3-kinase (PI3K) inhibitors, Akt inhibitors, mTOR inhibitors, dual PI3K / mTOR inhibitors, Bruton's tyrosine kinase (BTK) inhibitors, and isocitrate dehydrogenase 1 (IDH1) and / or isocitrate dehydrogenase 2 (IDH2) inhibitors. In some embodiments, the additional therapeutic agent is an indoleamine 2,3-dioxygenase-1 (IDO1) inhibitor (e.g., epacadostat).
[0365] In some embodiments, the additional therapeutic agent may include one or more inhibitors selected from the group consisting of HER3 inhibitors, LSD1 inhibitors, MDM2 inhibitors, BCL2 inhibitors, CHK1 inhibitors, inhibitors of the activated hedgehog signaling pathway, and agents that selectively degrade estrogen receptors.
[0366] In some embodiments, additional therapeutic agents include trabectedin, nab-paclitaxel, trebananib, pazopanib, cediranib, palbociclib, everolimus, fluoropyrimidine, IFL, regorafenib, Reolysin, Alimta, Zykadia, Sutent, temsirolimus, axitinib, sorafenib, Votrient, IMA-901, AGS-003, and cabozantinib. The formulation may include one or more therapeutic agents selected from the group consisting of bozantinib, vinflunine, Hsp90 inhibitors, Ad-GM-CSF, temazolomide, IL-2, IFNa, vincarin, thalidomide, dacarbazine, cyclophosphamide, lenalidomide, azacitidine, bortezomid, amrubicin, carfilzomib, pralatrexate, and enzastaurin.
[0367] In some embodiments, the additional therapeutic agent may include one or more therapeutic agents selected from the group consisting of adjuvants, TLR agonists, tumor necrosis factor (TNF)α, IL-1, HMGB1, IL-10 antagonists, IL-4 antagonists, IL-13 antagonists, IL-17 antagonists, HVEM antagonists, ICOS agonists, CX3CL1 targeted therapies, CXCL9 targeted therapies, CXCL10 targeted therapies, CCL5 targeted therapies, LFA-1 agonists, ICAM1 agonists, and selectin agonists.
[0368] In some embodiments, the target is carboplatin, albumin-bound paclitaxel, cisplatin, pemetrexed, gemcitabine, FOLFOX, or FOLFIRI.
[0369] In some embodiments, the additional therapeutic agent is an anti-PD-1 antibody, an anti-PD-L1 antibody, an anti-LAG-3 antibody, an anti-TIGIT antibody, an anti-BTLA antibody, or an anti-GITR antibody.
[0370] In some embodiments, PD1 / CD40 bispecific antibodies fail to effectively activate the CD40 signaling pathway in antigen-presenting cells (APCs) in the absence of PD-1 expressing cells (e.g., T cells).
[0371] In some embodiments, PD1 / CD40 bispecific antibodies can effectively activate the CD40 signaling pathway in the presence of PD-1 expressing cells.
[0372] Pharmaceutical composition and route of administration This specification further provides pharmaceutical compositions comprising at least one (e.g., one, two, three, or four) of the antigen-binding protein constructs, antibodies (e.g., bispecific antibodies), antigen-binding fragments, or antibody-drug conjugates described herein. Any two or more (e.g., two, three, or four) of the antigen-binding protein constructs, antibodies, antigen-binding fragments, or antibody-drug conjugates described herein may be present in any combination in the pharmaceutical composition. The pharmaceutical composition may be formulated in any way known in the art.
[0373] Pharmaceutical compositions are formulated to be compatible with the intended route of administration (e.g., intravenous, intra-arterial, intramuscular, intradermal, subcutaneous, or intraperitoneal). Compositions may include sterile diluents (e.g., sterile water or saline), fixatives, polyethylene glycol, glycerin, propylene glycol, or other synthetic solvents, antimicrobial or antifungal agents (e.g., benzyl alcohol or methylparaben, chlorobutanol, phenol, ascorbic acid, thimerosal), antioxidants (e.g., ascorbic acid or sodium bisulfite), chelating agents (e.g., ethylenediaminetetraacetic acid), buffers (e.g., acetates, citrates, or phosphates), and isotonic agents (e.g., sugars (e.g., glucose), polyols (e.g., mannitol or sorbitol), or salts (e.g., sodium chloride)), or any combination thereof. Liposome suspensions may also be used as pharmaceutically acceptable vectors (see, for example, U.S. Patent No. 4,522,811). The formulations of the composition may be formulated and encapsulated in ampoules, disposable syringes, or multi-dose vials. Optionally (for example, in injectable formulations), adequate fluidity may be maintained by the use of coatings (e.g., lecithin) or surfactants. Absorption of the antibody or its antigen-binding fragment may be prolonged by including absorption-delaying agents (e.g., aluminum monostearate and gelatin). Alternatively, controlled release may be achieved by implantable and microencapsulated delivery systems, which may include biodegradable biocompatible polymers (e.g., ethylene vinyl acetate, polyanhydride, polyglycolic acid, collagen, polyorthoesters, and polylactic acid, Alza and Nova Pharmaceuticals).
[0374] Compositions comprising one or more antigen-binding protein constructs, antibodies, antigen-binding fragments, or antibody-drug conjugates described herein may be formulated for parenteral administration (e.g., intravenous, intra-arterial, intramuscular, intradermal, subcutaneous, or intraperitoneal) in dosage unit form (i.e., physically distinct units containing a predetermined amount of the active compound to facilitate administration and uniformity of administration).
[0375] The toxicity and therapeutic effect of a composition can be determined in cell cultures or experimental animals (e.g., monkeys) by standard pharmaceutical methods. The LD50 (50% ensemble lethal dose) and ED50 (50% ensemble therapeutically effective dose): the therapeutic index can be determined as the ratio of LD50:ED50. Drugs exhibiting a high therapeutic index are preferred. If a drug exhibits undesirable side effects, care should be taken to minimize potential damage (i.e., reduce the undesirable side effects). Toxicity and therapeutic effect can be determined by other standard pharmaceutical methods.
[0376] Data obtained from cell culture assays and animal studies may be used to formulate appropriate doses of any given drug for a subject (e.g., human). The therapeutically effective dose of one or more (e.g., one, two, three, or four) antigen-binding protein constructs, antibodies, or their antigen-binding fragments (e.g., any of the antibodies or antibody fragments described herein) is the amount that treats the disease (e.g., kills cancer cells) in a subject (e.g., a human subject identified as having cancer) or a subject identified as being at risk of the disease (e.g., a subject that previously had cancer but is now cured), or reduces the severity, frequency, and / or duration of one or more disease conditions in a subject (e.g., human). The efficacy and dose of any of the antigen-binding protein constructs, antibodies, or antigen-binding fragments described herein may be determined by healthcare professionals or veterinarians using methods known in the art, and by observing one or more disease conditions in a subject (e.g., human). Certain factors may influence the dosage and schedule required for effective treatment of the subject (e.g., severity of the disease or condition, previous treatments, the subject's general health status and / or age, and the presence of other diseases).
[0377] Exemplary doses include milligrams or micrograms of any of the antigen-binding protein constructs, antibodies, antigen-binding fragments, or antibody-drug conjugates described herein per kilogram of body weight of the subject (e.g., about 1 μg / kg to about 500 mg / kg, about 100 μg / kg to about 500 mg / kg, about 100 μg / kg to about 50 mg / kg, about 10 μg / kg to about 5 mg / kg, about 10 μg / kg to about 0.5 mg / kg, or about 0.1 mg / kg to about 0.5 mg / kg). While these doses cover a wide range, those skilled in the art will understand that the therapeutic effects of therapeutic agents (including antigen-binding protein constructs, antibodies, and their antigen-binding fragments) vary and that effective doses can be determined by methods known in the art. Typically, a relatively low dose is administered first, and then the dose can be gradually increased by the attending physician, healthcare professional or veterinarian (in the case of therapeutic use) or researcher (if still working in the development stage) until an appropriate response is achieved. Furthermore, it should be understood that the specific dose level for any particular target depends on various factors, including the activity of the specific compound used, the target's age, weight, general health status, sex, and diet, administration time, route of administration, elimination rate, and in vivo half-life of the antibody or antibody fragment.
[0378] The pharmaceutical composition may be contained in a container, packaging, or dispenser along with the specification of use. This disclosure also provides methods for producing antibodies or their antigen-binding fragments or antibody-drug conjugates for various uses described herein.
[0379] Examples The present invention will be further illustrated by the following embodiments, but these embodiments are not intended to limit the scope of the present invention as described in the claims.
[0380] Example 1: Production of anti-PD-1 / CD40 bispecific antibody Two anti-PD-1 / CD40 bispecific antibodies (BsAbs) were designed. As shown in Figure 1A, the Fab-ScFV-IgG BsAb has an anti-PD-1 arm containing a heavy chain and a light chain, and an anti-CD40 arm containing a single-stranded variable fragment (scFv) ligated to the CH2 and CH3 domains of IgG. As shown in Figure 1B, the ScFV-HC-IgG BsAb has an anti-CD40 scFv ligated to each of the C-terminuses of the heavy chain of the anti-PD-1 monoclonal antibody. The sequence associated with PD-1 antibody 1A7 is described in PCT / CN2018 / 077016, which is incorporated herein by reference in its entirety. The sequence associated with CD40 antibody 6A7 is described in PCT / CN2018 / 096494, which is incorporated herein by reference in its entirety.
[0381] Vectors expressing each polypeptide chain of BsAb were co-transfected into CHO cells. After 14 days of culture, the cell supernatant was collected and purified by protein A affinity chromatography and then by size exclusion chromatography (SEC) to obtain bispecific antibodies. The constant region of the bispecific antibodies was selected from human IgG1 or IgG4. In particular, IgG1 was also subjected to mutations, such as the LALA(L234A / LS235A) mutation, to reduce its Fc receptor binding affinity. These Fc mutations can improve the safety of the antibodies by minimizing antibody effector function.
[0382] Various vectors were prepared to express these antibodies, and the following experiments were performed. In the following experiments, the VH and VL of anti-PD-1 in Fab-ScFV-IgG and ScFV-HC-IgG were derived from the anti-PD1 antibody 1A7-H2K3. The VH and VL of anti-CD40 ScFV were derived from the 6A7-H4K2 anti-CD40 antibody.
[0383] In Fab-ScFV-IgG antibodies, a knob-intole (KIH) mutation was also introduced into the constant region. The PD-1 arm of Fab-ScFV-IgG4 includes the 1A7-H2K3 VH and the IgG4 constant region with the KIH mutation (SEQ ID NOs. 41 and 150). The ScFV arm includes the 6A7-H4K2 VH and VL (SEQ ID NOs. 108 and 110, or SEQ ID NOs. 126 and 127) and the corresponding IgG4 constant region with the KIH mutation (SEQ ID NOs. 151). In ScFV-HC-IgG, anti-CD40 ScFV was added to the C-terminus of the anti-PD-1 antibody using a linker sequence. As shown in Figures 2A and 2B, purified BsAbs were detected by non-reducing gel electrophoresis (6% separation gel). 2 μg of protein was added per lane. The results indicate that all BsAbs were expressed and correctly assembled.
[0384] Example 2: Antibody binding affinity The binding affinity of BsAb to human PD-1 (hPD-1) or human CD40 (hCD40) was determined using the Biacore system. Both human PD-1 protein (human PD-1 / PDCD1 protein, His-tagged) and human CD40 protein (human CD40 / TNFRSF5 protein, His-tagged) were purchased from ACRO Biosystems, with catalog numbers PD1-H5221 and CD0-H5228, respectively. The results are summarized in the table below.
[0385] [Table 1]
[0386] [Table 2]
[0387] The results indicate that both types of bispecific antibodies possess binding affinity equivalent to that of the parent monoclonal antibody. Therefore, Fc region mutations (e.g., LALA mutations) do not affect binding affinity.
[0388] Example 3: Jurkat-luc-hPD1 reporter cell activation assay Experiments were conducted to test whether BsAb Fab-ScFV-IgG4 and ScFV-HC-IgG4 can block the PD-1 / PD-L1 pathway.
[0389] Basal cells CHO-aAPC-hPD-L1 (Promega, catalog number: J1255) were inoculated into 96-well plates (cell density: 4 × 10⁴ cells / well) and incubated overnight at 37°C. Bispecific antibodies Fab-ScFV-IgG4, ScFV-HC-IgG4, and anti-PD-1 monoclonal antibody 1A7-H2K3-IgG4 were serially diluted (3-fold) to a maximum concentration of 100 μg / mL. The assay buffer was RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS). The following day, effector cells Jurkat-Luc-hPD-1 (Promega, catalog number: J1255) were centrifuged at 120 g for 10 minutes and then inoculated into 96-well plates (cell density: 5 × 10⁴ cells / well). Next, the supernatant of the culture plate inoculated with CHO-aAPC-hPD-L1 was discarded, and then 50 μL of Jurkat-Luc-hPD-1 cells were added to each well along with 25 μL of antibody. The above 96-well plate was incubated in a 37°C incubator for 6 hours. After incubation, the culture plate was removed, 75 μL of Bio-lite luciferase detection reagent (Vazem Biotech, catalog number: DD1201-02-AB) was added, and the plate was incubated at room temperature for 5-10 minutes. The culture plate was then placed in a fluorescence detector to detect the fluorescence signal. If the antibody can block the interaction between PD-1 and PD-L1, the effector cells will report a signal.
[0390] As shown in Figure 3 and Table 3, all BsAbs exhibit blocking activity against the PD-1 / PD-L1 pathway. Because Fab-ScFV-IgG4 binds to PD-1 with a single anti-PD-1 arm, its EC50 value is relatively higher compared to 1A7-H2K3-IgG4 and ScFV-HC-IgG4, which employ two anti-PD-1 arms.
[0391] [Table 3]
[0392] Example 4: T cell / APC cell crosslinking effect of bispecific antibodies In the following, experiments were conducted using reporter cells to test whether BsAb Fab-ScFV-IgG4 and ScFV-HC-IgG4 can crosslink T cells and APC cells.
[0393] Basal cells CHO-K1-hPD1 were inoculated into 96-well plates (cell density: 5 × 10⁴ cells / well) and incubated overnight at 37°C. BsAb Fab-ScFV-IgG4 and ScFV-HC-IgG4 were serially diluted (3-fold) to a maximum concentration of 5 μg / mL. Simultaneously, anti-PD-1 antibody 1A7-H2K3-IgG4 and anti-CD40 antibody 6A7-H4K2-IgG2 were combined in a 1:1 ratio and then serially diluted (3-fold) to a maximum concentration of 10 μg / mL (5 μg / mL per monoclonal antibody). The assay buffer was RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS). The following day, Jurkat-Luc-hCD40 effector cells (Promega, catalog number: JA2125) were centrifuged at 120 g for 10 minutes and then inoculated into a 96-well plate (cell density 5 × 10⁴ cells / well). Next, the supernatant of the culture plate inoculated with CHO-K1-hPD1 was discarded, and then 50 μL of Jurkat-Luc-hCD40 cells were added to each well along with 25 μL of antibody. The above 96-well plate was incubated in a 37°C incubator for 6 hours. After incubation, the culture plate was removed, 75 μL of Bio-lite luciferase detection reagent (Vazem Biotech, catalog number: DD1201-02-AB) was added, and the plate was incubated at room temperature for 5–10 minutes. The culture plate was then placed in a fluorescence detector to detect the fluorescence signal.
[0394] As shown in Figure 4A, in the presence of CHO-K1-hPD1 cells, both Fab-ScFV-IgG4 and ScFv-HC-IgG4 transactivate reporter cells. In contrast, the monoclonal antibody combination does not activate reporter cells. This is thought to be because CD40 activation requires CD40 aggregation, and this aggregation is promoted by basal cells. As shown in Figure 4B, in the absence of CHO-K1-hPD1, neither BsAb nor monoclonal antibody combination activates reporter cells. The EC50 values are shown in the table below. Therefore, the tested bispecific antibodies can crosslink T cells and APC cells.
[0395] [Table 4]
[0396] Here, Jurkat-Luc-hCD40 cells do not express PD-1 and are used to verify the activation of the CD40 pathway in APC cells (e.g., dendritic cells or macrophages). T cells (e.g., expressing PD-1 or other targets) and APC cells can stimulate CD40 aggregation on APC cells by cross-linking with BsAb, thereby amplifying immune response signals in the tumor microenvironment. The results also show that activation of the CD40 pathway by bispecific antibodies depends on their cross-linking effect with PD-1 expressing cells. Since PD-1 expressing immune cells are recruited to the tumor microenvironment and PD-1 expression is normally upregulated in the tumor microenvironment, this mechanism can also significantly restrict immune activation to the tumor microenvironment and reduce side effects such as hepatic toxicity. Furthermore, tumor dissipation lymph nodes contain antigen-presenting cells and PD-1 expressing T cells. Bispecific antibodies can effectively increase the immune response in tumor dissipation lymph nodes. At the same time, it can suppress the inhibitory activity of regulatory T cells (Tregs), thereby inhibiting the system's tolerance.
[0397] Example 5: Fc receptor-mediated reporter cell activation assay Experiments were conducted to test whether BsAb Fab-ScFV-IgG4 and ScFV-HC-IgG4 can activate reporter cells via FcR crosslinking (e.g., by the FCγRIIB receptor).
[0398] Basal cells CHO-K1-hFcγRIIB (Promega, catalog number: JA2251) were inoculated into 96-well plates (cell density: 5 × 10⁴ cells / well) and incubated overnight at 37°C. Anti-CD40 monoclonal antibody 6A7-H4K2-IgG2 and bispecific antibodies Fab-ScFV-IgG4 and ScFV-HC-IgG4 were serially diluted (3-fold) to a maximum concentration of 10 μg / mL. The assay buffer was RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS). The following day, effector cells Jurkat-Luc-hCD40 (Promega, catalog number: JA2251) were centrifuged at 120 g for 10 minutes and then inoculated into 96-well plates (cell density: 5 × 10⁴ cells / well). Next, the supernatant of the culture plate inoculated with CHO-K1-hFcγRIIB was discarded, and then 50 μL of Jurkat-Luc-hCD40 cells were added to each well along with 25 μL of antibody. The above 96-well plate was incubated in a 37°C incubator for 6 hours. After incubation, the culture plate was removed, 75 μL of Bio-lite luciferase detection reagent (Vazem Biotech, catalog number: DD1201-02-AB) was added, and it was incubated at room temperature for 5-10 minutes. The culture plate was then placed in a fluorescence detector to detect the fluorescence signal.
[0399] As shown in Figure 5 and Table 5, in the presence of CHO-K1-hFcγRIIB cells, Fab-ScFV-IgG4 activated reporter cells, and its EC50 corresponds to the anti-CD40 monoclonal antibody 6A7-H4K2-IgG2. However, ScFV-HC-IgG4 did not show FCγRIIB receptor-mediated reporter cell activation.
[0400] [Table 5]
[0401] The CD40 antibody 6A7-H4K2-IgG2 can activate reporter cells by crosslinking to the FCγRIIB receptor. However, when anti-CD40 scFv is linked to the Fc region, FCγRIIB cannot activate the CD40 pathway through FCγRIIB-mediated agglutination. Since ScFV-HC-IgG4 does not exhibit FCγRIIB receptor-mediated reporter cell activation, ScFV-HC-IgG4 can effectively reduce toxicity in tissues expressing high levels of FCγRIIB, such as toxicity in the liver.
[0402] Table 6 summarizes the in vitro activity of two bispecific antibodies, Fab-ScFV-IgG and ScFV-HC-IgG. In the presence of CHO-K1-hPD1 cells, ScFV-HC-IgG4 shows activation of the CD40 pathway in APC cells, but does not show FCγRIIB receptor-mediated T cell activation. Therefore, both ScFV-HC-IgG4 and Fab-ScFV-IgG4 can effectively treat cancer in an FcR-independent manner.
[0403] [Table 6]
[0404] Example 6: Activation of reporter cells by ScFV-HC-IgG subtype This experiment was conducted to test whether subtypes of ScFV-HC-IgG (including ScFV-HC-IgG4 and ScFV-HC-IgG1-LALA) could activate reporter cells in the presence of PD-1-expressing basal cells. The experiment was carried out in the same manner as described in Example 4, except that basal cell CHO-K1-hPD1 was replaced with Jurkat-hPD1. Basal cells were not used in Figure 6A. As shown in Figure 6B and Table 7, BsAb ScFV-HC-IgG4 and ScFV-HC-IgG1-LALA, as well as the anti-CD40 monoclonal antibody 6A7-H4K2-IgG2, all activated reporter cells.
[0405] [Table 7]
[0406] Reporter cell activation in the presence of CHO-K1-hFcγRIIB cells was also evaluated. As shown in Figure 6C, neither ScFV-HC-IgG4 nor ScFV-HC-IgG1-LALA showed FCγRIIB receptor-mediated reporter cell activation, which was consistent with the results shown in Figure 5. Therefore, ScFV-HC-IgG4 and ScFV-HC-IgG1-LALA activate the CD40 pathway in APC cells, mainly in a cell-PD-1 expressing cell-dependent manner.
[0407] Example 7: In vivo study of a bispecific antibody that inhibits tumor growth To test bispecific antibodies in vivo and predict their effects in humans, a humanized CD40 mouse model was prepared. The humanized CD40 mouse model was engineered to express a chimeric CD40 protein (SEQ ID NO: 97), in which the extracellular domain of the mouse CD40 protein was replaced with the corresponding extracellular domain of human CD40. Amino acid residues 20-192 of mouse CD40 (SEQ ID NO: 96) were replaced with amino acid residues 20-192 of human CD40 (SEQ ID NO: 95). A bihumanized CD40 / PD-1 mouse model was also created by crossing CD40 humanized mice with PD-1 humanized mice. The humanized PD1 mouse model was engineered to express a chimeric PD1 protein (SEQ ID NO: 39), in which the extracellular domain of the mouse PD1 protein was replaced with the corresponding extracellular domain of human PD1. Amino acid residues 31-141 of mouse PD1 (SEQ ID NO: 38) were replaced with amino acid residues 31-141 of human PD1 (SEQ ID NO: 37).
[0408] Humanized mouse models (e.g., B-hCD40 mice) or bihumanized CD40 / PD-1 mice (B-hPD-1 / hCD40 mice) provide novel tools for testing new therapeutic methods in a clinical setting by significantly reducing the difference in clinical outcomes between humans and normal mice expressing mouse CD40 or PD-1. For a detailed description of humanized CD40, humanized PD-1, or bihumanized CD40 / PD-1 mouse models, refer to PCT / CN2018 / 091845 and PCT / CN2017 / 090320, each of which is incorporated herein by reference in its entirety.
[0409] BsAb anti-colon cancer in vivo results The effects of bispecific antibodies ScFV-HC-IgG4 and ScFV-HC-IgG1-LALA on tumor growth in vivo were tested in a colon cancer model. MC-38 tumor cells (colon adenocarcinoma cells) were subcutaneously injected into CD40 humanized B-hCD40 mice. When the tumor volume in the mice reached 100 mm³ to 150 mm³, the mice were randomly divided into different groups based on tumor volume.
[0410] In each group, B-hCD40 mice were injected intraperitoneally (ip) with physiological saline (PS) (G1), 4 mg / kg ScFV-HC-IgG4 (G2), or 4 mg / kg ScFV-HC-IgG1-LALA (G3). The administration frequency was twice a week (a total of four doses).
[0411] The injection volume was calculated based on the mouse's body weight at 4 mg / kg. The length of the tumor's long axis and short axis were measured, and the tumor volume was calculated using the formula 0.5 × (long axis) × (short axis)². The mouse's body weight was measured at the following times: before injection, when the mice were divided into different groups (before the first antibody injection), during antibody injection (twice a week), and before euthanasia. The tumor growth inhibition rate (TGI%) was calculated using the formula TGI(%) = [1 - (Ti - T0) / (Vi - V0)] × 100%. Ti is the mean tumor volume in the treatment group on day i. T0 is the mean tumor volume in the treatment group on day 0. Vi is the mean tumor volume in the control group on day i. V0 is the mean tumor volume in the control group on day 0.
[0412] Statistical analysis was performed using the t-test. A TGI% of over 60% indicates significant suppression of tumor growth. P<0.05 is the threshold for statistical significance.
[0413] [Table 8]
[0414] Mouse body weight was monitored throughout the entire treatment period. Mean body weight increased to varying degrees in different groups (Figures 7 and 8). No significant differences in body weight were observed between the groups at the end of the treatment period. The results indicate that ScFV-HC-IgG4 and ScFV-HC-IgG1-LALA are well-tolerated by mice and do not exhibit any apparent toxicity.
[0415] The tumor volumes in the groups treated with ScFV-HC-IgG4 and ScFV-HC-IgG1-LALA are shown in Figure 9. The TGI% on day 20 (20 days after group division) was also calculated as shown in the table below.
[0416] [Table 9]
[0417] The results indicate that the bispecific antibodies ScFV-HC-IgG4 and ScFV-HC-IgG1-LALA do not suppress tumor growth in the absence of cells expressing human PD-1.
[0418] BsAb antimelanoma in vivo results The effects of bispecific antibodies ScFV-HC-IgG4 and ScFV-HC-IgG1-LALA on tumor growth in vivo were tested in a melanoma model. Human PD-L1-expressing B16F10 cells (melanoma cells) (B16F10-hPD-L1) were subcutaneously injected into bihumanized CD40 / PD-1 mice (B-hPD-1 / hCD40 mice). When the tumor volume in the mice reached 100 mm3 to 150 mm3, the mice were randomly divided into different groups based on tumor volume.
[0419] In each group, B-hPD-1 / hCD40 mice were injected intraperitoneally (ip) with physiological saline (PS) (G1), 3 mg / kg anti-PD1 monoclonal antibody 1A7-H2K3-IgG4 (G2), 3 mg / kg anti-CD40 monoclonal antibody 6A7-H4K2-IgG2 (G3), 4 mg / kg ScFV-HC-IgG1-LALA (G4), 4 mg / kg ScFV-HC-IgG4 (G5), a combination of 3 mg / kg anti-PD1 monoclonal antibody 1A7-H2K3-IgG4 and 3 mg / kg anti-CD40 monoclonal antibody 6A7-H4K2-IgG2 (G6), or 4 mg / kg bispecific antibody PD-1-MOCK-ScFV-HC-IgG4 (G7). BsAb PD-1-MOCK-ScFV-HC-IgG4 has the same structure as ScFV-HC-IgG, but scFv targets OX40 and not CD40. The administration frequency was twice a week (a total of four doses).
[0420] The injection volume was calculated based on the mouse's body weight. The length of the tumor's long axis and short axis were measured, and the tumor volume was calculated using the formula 0.5 × (long axis) × (short axis)². The mouse's body weight was measured at the following times: before injection, when the mice were divided into different groups (before the first antibody injection), during antibody injection (twice a week), and before euthanasia.
[0421] Statistical analysis was performed using the t-test. A TGI% of over 60% indicates significant suppression of tumor growth. P<0.05 is the threshold for statistical significance.
[0422] [Table 10]
[0423] Mouse body weight was monitored throughout the entire treatment period. Mean body weight increased to varying degrees in different groups (Figures 10 and 11). At the end of the treatment period, mouse body weight increased in all groups.
[0424] The tumor volume in the antibody-treated group is shown in Figure 12. TGI% at days 14 and 21 (14 or 21 days after group division) were also calculated, as shown in the table below. The P-value is based on the data from day 21. Figure 12 also includes data from day 25.
[0425] [Table 11]
[0426] The results indicate that the bispecific antibodies ScFV-HC-IgG4 and ScFV-HC-IgG1-LALA suppress tumor growth at a higher TGI% compared to monoclonal antibodies. In particular, 4 mg / kg of ScFV-HC-IgG4 (G5) and ScFV-HC-IgG1-LALA (G4) showed similar TGI% compared to the 6 mg / kg combination of anti-PD1 and anti-CD40 antibodies (G6). The results also indicate that the anti-CD40 scFv domain has a synergistic effect on tumor suppression.
[0427] Furthermore, the TGI% of PD-1-MOCK-ScFV-HC-IgG4(G7) is comparable to that of the anti-PD1 monoclonal antibody 1A7-H2K3-IgG4(G2), but significantly lower than that of ScFV-HC-IgG4(G5) and ScFV-HC-IgG1-LALA(G4) (e.g., on day 21). This indicates that the tumor suppressor effects of ScFV-HC-IgG4(G5) and ScFV-HC-IgG1-LALA(G4) are partially induced by cross-linking of PD-1-expressing cells (e.g., T cells) and CD40-expressing cells (e.g., APC cells).
[0428] BsAb anti-colon cancer in vivo results The effects of bispecific antibodies ScFV-HC-IgG4, ScFV-HC-IgG1-LALA, and Fab-ScFV-IgG4 on tumor growth in vivo were tested in a colon cancer model. MC-38 tumor cells (colon adenocarcinoma cells) expressing human PD-L1 (MC38-hPD-L1) were subcutaneously injected into bihumanized CD40 / PD-1 mice (B-hPD-1 / hCD40 mice). When the tumor volume in the mice reached approximately 400 mm3, the mice were randomly divided into different groups based on tumor volume (7 mice per group).
[0429] In each group, B-hPD-1 / hCD40 mice were injected intraperitoneally (ip) with physiological saline (NC; G1), 1 mg / kg anti-PD1 monoclonal antibody 1A7-H2K3-IgG4 (G2), 1 mg / kg anti-CD40 monoclonal antibody 6A7-H4K2-IgG2 (G3), 1.35 mg / kg ScFV-HC-IgG4 (G4), 1 mg / kg Fab-ScFV-IgG4 (G5), or a combination of 1 mg / kg anti-PD1 monoclonal antibody 1A7-H2K3-IgG4 and 1 mg / kg anti-CD40 monoclonal antibody 6A7-H4K2-IgG2 (Combo(PD-1+CD40); G6). The administration frequency was twice a week (total of 5 doses). Detailed information is shown in the table below.
[0430] [Table 12]
[0431] The injection volume was calculated based on the mouse's body weight. The length of the tumor's long axis and short axis were measured, and the tumor volume was calculated using the formula 0.5 × (long axis) × (short axis)².
[0432] The tumor volume of mice in the above groups 25 days after grouping is shown in Figure 13. The results indicate that the bispecific antibodies ScFV-HC-IgG4 and Fab-ScFV-IgG4 suppress tumor growth. In particular, ScFV-HC-IgG4 (G4; 1.35 mg / kg) and Fab-ScFV-IgG4 (G5; 1 mg / kg) have similar TGITV% compared to the 2 mg / kg anti-PD1 and anti-CD40 antibody combination (G6).
[0433] In different experiments, ScFv-HC-IgG1-LALA and the anti-PD-1 monoclonal antibody KeytrudaR (pembrolizumab) (VH SEQ ID NO: 207; VL SEQ ID NO: 208) were also included.
[0434] In each group, B-hPD-1 / hCD40 mice were given either physiological saline (NC;G1), 1 mg / kg anti-PD1 monoclonal antibody 1A7-H2K3-IgG4 (G2), 1 mg / kg anti-CD40 monoclonal antibody 6A7-H4K2-IgG2 (G3), 1.35 mg / kg ScFV-HC-IgG4 (G4), 1 mg / kg ScFV-HC-IgG1-LALA (G5), a combination of 1 mg / kg anti-PD1 monoclonal antibody 1A7-H2K3-IgG4 and 1 mg / kg anti-CD40 monoclonal antibody 6A7-H4K2-IgG2 (Combo(PD-1+CD40);G6), or 1 mg / kg anti-PD1 monoclonal antibody pembrolizumab and 1 The combination of mg / kg anti-CD40 monoclonal antibody 6A7-H4K2-IgG2 (Combo (pembrolizumab + CD40); G7) was administered by intraperitoneal injection (ip). The administration frequency was twice a week (total of 5 doses). Detailed information is shown in the table below.
[0435] [Table 13]
[0436] Mouse body weight was monitored throughout the entire treatment period. Mean body weight increased to varying degrees in different groups (Figures 14 and 15). At the end of the treatment period, mouse body weight increased in all groups.
[0437] The tumor volume in the antibody-treated group is shown in Figure 16. TGI% at days 18 and 25 (18 and 25 days after group division) were also calculated, as shown in the table below. In the control group, the p-value at day 25 was unavailable due to a large number of mouse deaths. The p-values in the table below were calculated from the data at day 18.
[0438] [Table 14]
[0439] The results showed that ScFV-HC-IgG1-LALA (G5) suppressed tumor growth, and its TGI% (e.g., on day 18) was higher than that of ScFV-HC-IgG4 (G4). Furthermore, the combination of 1A7-H2K3-IgG4 and 6A7-H4K2-IgG2 (G6) showed comparable tumor suppression effects to the combination of pembrolizumab and 6A7-H4K2-IgG2 (G7).
[0440] Example 8: Bispecific antibody toxicity in vivo test The in vivo toxicity of the bispecific antibody ScFV-HC-IgG4 was tested in a colon cancer model. MC-38 tumor cells (colon adenocarcinoma cells) expressing human PD-L1 (MC38-hPD-L1) were subcutaneously injected into bihumanized CD40 / PD-1 mice (B-hPD-1 / hCD40 mice). When the tumor volume in the mice reached approximately 100 mm3–150 mm3, the mice were randomly divided into different groups based on tumor volume (3 mice per group).
[0441] In each group, B-hPD-1 / hCD40 mice were injected intraperitoneally (ip) with either phosphate-buffered saline (PBS) (G1), 20 mg / kg sericrelumab (heavy chain SEQ ID NO: 144, light chain SEQ ID NO: 145) (G2), 20 mg / kg anti-CD40 monoclonal antibody 6A7-H4K2-IgG2 (G3), 20 mg / kg anti-PD1 monoclonal antibody 1A7-H2K3-IgG4 (G4), 26 mg / kg ScFV-HC-IgG4 (G5), or a combination of 20 mg / kg anti-PD1 monoclonal antibody 1A7-H2K3-IgG4 and 20 mg / kg anti-CD40 monoclonal antibody 6A7-H4K2-IgG2 (Combo; G6). The administration frequency was three times a week (total of three doses). Detailed information is shown in the table below.
[0442] [Table 15]
[0443] Blood biochemistry test Mouse blood was extracted on days 7 and 13 after group division, and alanine transaminase (ALT) and asparinine transaminase (AST) levels were tested. As shown in Figures 17A to 17D, mice treated with sericrelumab (G2) showed the highest levels of blood ALT and AST compared to mice in the other groups. Furthermore, mice treated with ScFV-HC-IgG4 (G5) showed similar ALT and AST levels to mice treated with monoclonal antibodies (G3 and G4) or a combination thereof (G6).
[0444] Liver histopathological examination Thirteen days after grouping, mouse livers were isolated and examined under a microscope. No significant abnormalities were found in the livers of mice in groups G1 and G5. All three mice in group G2 showed chronic inflammation, such as fibroblast proliferation, with moderate damage. In group G3, all three mice showed localized stromal inflammatory cell infiltration, with mild damage. In group G4, one mouse showed localized perivascular inflammatory cell infiltration, with mild damage. In group G7, all three mice showed localized stromal inflammatory cell infiltration. In this group, one mouse showed very minor damage, and the other two mice showed mild damage. The detailed extent of liver damage is shown in the table below. The extent of damage is determined by hepatic interstitial / perivascular inflammatory cell infiltration or chronic hepatic inflammation (mainly fibroblast proliferation). Representative tissue sections of the liver and kidneys of mice from each group are shown in Figures 17E to 17J.
[0445] [Table 16]
[0446] Example 9: Purification of PD1-C40-6A7-FV3A and activation of reporter cells Manufacturing of PD1-C40-6A7-FV3A As shown in Figure 18A, BsAb PD1-C40-6A7-FV3A contains anti-CD40 scFv fused to each heavy chain CH3 domain of the anti-PD-1 monoclonal antibody. Specifically, the anti-CD40 scFv fused to positions 358 to 362 (according to EU numbering) of the anti-PD-1 monoclonal antibody heavy chain CH3 domain. The fused heavy chain sequence of PD1-C40-6A7-FV3A is shown in SEQ ID NO: 161. The light chain sequence of PD1-C40-6A7-FV3A is the same as the light chain of its parent antibody PD1-1A7-H2K3-IgG4, which is shown in SEQ ID NO: 141. The sequences are derived from anti-PD-1 antibody 1A7 and anti-CD40 antibody 6A7.
[0447] As shown in Figure 18B, purified PD1-C40-6A7-FV3A was detected by non-reducing gel electrophoresis (6% separation gel). A single band was detected on the gel (lane 4), indicating that PD1-C40-6A7-FV3A was expressed in high purity. Furthermore, the concentration of PD1-C40-6A7-FV3A was measured to be 84 μg / mL.
[0448] Binding affinity for hCD40 The binding affinity to human CD4 (hCD40) was measured using the Biacore system. The results for PD1-C40-6A7-FV3A and its parent monoclonal antibody 6A7-H4K2-IgG2 are summarized in the table below.
[0449] [Table 17]
[0450] The results indicate that PD1-C40-6A7-FV3A has a binding affinity equivalent to that of the parent monoclonal antibody.
[0451] Fc receptor-mediated reporter cell activation assay Experiments were conducted to test whether PD1-C40-6A7-FV3A can activate reporter cells via an Fc receptor (e.g., FCγRIIB). Similar experimental steps were performed as described in Example 5.
[0452] As shown in Figure 18C, in the presence of CHO-K1-hFcγRIIB cells, both Fab-ScFV-IgG4 and the anti-CD40 monoclonal antibody 6A7-H4K2-IgG2 activated reporter cells. However, PD1-C40-6A7-FV3A did not show FCγRIIB receptor-mediated reporter cell activation.
[0453] The results indicate that when anti-CD40 scFv fuses to the heavy chain CH3 domain of an anti-PD-1 antibody, the Fc receptor (e.g., FCγRIIB) cannot activate the CD40 pathway through Fc receptor (e.g., FCγRIIB)-mediated agglutination. Since PD1-C40-6A7-FV3A does not exhibit Fc receptor-mediated reporter cell activation, PD1-C40-6A7-FV3A can effectively reduce toxicity in tissues, particularly those expressing high levels of FCγRIIB, such as liver tissue.
[0454] T cell / APC cell cross-linking effect In the following, experiments were conducted using reporter cells to test whether PD1-C40-6A7-FV3A can crosslink T cells and APC cells. The same experimental steps were followed as described in Example 4.
[0455] As shown in Figure 18D, in the presence of CHO-K1-hPD1 cells, both Fab-ScFV-IgG4 and PD1-C40-6A7-FV3A transactivated reporter cells. In contrast, the monoclonal antibody combination did not activate reporter cells.
[0456] The results also indicate that the activation of the CD40 pathway by PD1-C40-6A7-FV3A depends on its cross-linking effect with PD-1-expressing cells. Since PD-1-expressing immune cells are recruited to the tumor microenvironment, and PD-1 expression is normally upregulated in the tumor microenvironment, this mechanism can significantly restrict immune activation to the tumor microenvironment and reduce side effects such as hepatic toxicity. Furthermore, tumor dissipation lymph nodes contain antigen-presenting cells and PD-1-expressing T cells. Bispecific antibodies can effectively increase the immune response in tumor dissipation lymph nodes. At the same time, they can suppress the inhibitory activity of regulatory T cells (Tregs), thereby suppressing the tolerance of the system.
[0457] Binding affinity for FcRn The binding affinity to the neonatal Fc receptor (FcRn) was measured using the Biacore® system. The results for PD1-C40-6A7-FV3A and the anti-PD-1 monoclonal antibody 1A7 are summarized in the table below.
[0458] [Table 18]
[0459] The results show that the binding affinity of PD1-C40-6A7-FV3A to FcRn is equivalent to that of the anti-PD-1 antibody (1A7-H2K3-IgG4), and that the fusion of anti-CD40 scFv in the anti-PD-1 antibody heavy chain CH3 domain region from position 358 to 362 (according to EU numbering) does not affect FcRn binding.
[0460] Example 10: Efficacy comparison between ScFV-HC-IgG1-LALA and a commercially available anti-PD-1 monoclonal antibody. Currently, there are approximately 10 types of anti-PD-1 monoclonal antibodies that have received approval from the U.S. Food and Drug Administration (FDA) and the China Medical Products Administration (NMPA). The approved anti-PD-1 monoclonal antibodies include Keytruda® (pembrolizumab) developed by Merck & Co., Opdivo® (nivolumab, VH SEQ ID NO: 209; VL SEQ ID NO: 210) developed by Bristol Myers Squibb (BMS), Libtayo® (semiprimab, VH SEQ ID NO: 185; VL SEQ ID NO: 186) jointly developed by Sanofi SA and Regeneron Pharmaceuticals, Inc., and Innovent Biologics. This includes Tyvyt® (scintilimab, VH SEQ ID NO: 183; VL SEQ ID NO: 184) developed by (Company Inc.), tislerizumab (BGB-A317, VH SEQ ID NO: 187; VL SEQ ID NO: 188) developed by BeiGene, and tripalimab (VH SEQ ID NO: 181; VL SEQ ID NO: 182) developed by Kimizumi Biological Co., Ltd. Furthermore, there are several types of anti-PD-1 monoclonal antibodies in the clinical and preclinical stages. In this experiment, the in vivo efficacy of the bispecific antibody ScFV-HC-IgG1-LALA was compared with the efficacy of these approved anti-PD-1 monoclonal antibodies.
[0461] The experiment was conducted as follows: The in vivo tumor growth inhibitory effects of five anti-PD-1 antibodies—pembrolizumab, cemiplimab, cintilimab, tislerizumab, tripalimab, and the bispecific antibody ScFV-HC-IgG1-LALA—were tested in a mouse melanoma model. Specifically, B16F10 cells expressing human PD-L1 (melanoma cells) (B16F10-hPD-L1) were subcutaneously injected into bihumanized CD40 / PD-1 mice (B-hPD-1 / hCD40 mice). When the tumor volume in the mice reached approximately 100 mm3 to 150 mm3, the mice were randomly divided into different groups based on tumor volume (7 mice per group). In the control group, B-hPD-1 / hCD40 mice were injected with PBS (G1). In the treatment groups (G2-G7), B-hPD-1 / hCD40 mice were injected intraperitoneally (ip) with either 3 mg / kg of pembrolizumab (G2), 3 mg / kg of cemiplimab (G3), 3 mg / kg of scintirimab (G4), 3 mg / kg of tislerizumab (G5), 3 mg / kg of tripalimab (G6), or 4 mg / kg of the bispecific antibody ScFV-HC-IgG1-LALA (G7). The administration frequency was twice a week (total of 4 doses). Tumor volume was measured twice a week, and the body weight of the mice was recorded. Mice were euthanized when their tumor volume reached 3000 mm3.
[0462] [Table 19]
[0463] The experimental results showed that the mice in the treatment group exhibited good tolerance to all anti-PD-1 monoclonal antibodies and ScFV-HC-IgG1-LALA at the above dosages and frequencies. As shown in Figure 27, there was no significant difference in the average body weight of the mice throughout the experiment. However, with respect to tumor volume (Figure 28), the bispecific antibody ScFV-HC-IgG1-LALA (G7) showed the best efficacy (TGITV%).
[0464] [Table 20]
[0465] Example 11: In vivo efficacy and toxicity of ScFV-HC-IgG1-LALA The in vivo toxicity and efficacy of the bispecific antibody ScFV-HC-IgG1-LALA were tested in various tumor models. For example, B16F10-hPD-L1 cells were subcutaneously injected into bihumanized CD40 / PD-1 mice (B-hPD-1 / hCD40 mice). When the tumor volume in the mice reached 100 mm3 to 150 mm3, the mice were randomly divided into different groups based on tumor volume (7 mice per group).
[0466] In the control group G1, B-hPD-1 / hCD40 mice were injected with physiological saline (PS). In the treatment groups G2-G7, B-hPD-1 / hCD40 mice were injected with the bispecific antibody ScFV-HC-IgG1-LALA at doses ranging from 0.1 mg / kg to 30 mg / kg (i.e., 0.1 mg / kg, 0.3 mg / kg, 1 mg / kg, 3 mg / kg, 10 mg / kg, or 30 mg / kg) by intraperitoneal injection (ip). The administration frequency was twice a week (total of 4 doses). Tumor volume was measured twice a week, and the body weight of the mice was recorded. Mice were euthanized when their tumor volume reached 3000 mm3. The experiment was completed 70 days after group assignment.
[0467] Similar to the results described above, the experimental results showed that the treatment group mice had very good tolerance to different doses of ScFV-HC-IgG1-LALA at the above dose levels and administration frequencies, and there were no significant differences in the mean mouse body weight throughout the experiment. However, the TGITV% for tumor volume (Figure 29A) and mouse survival rate (Figure 29B) showed an increasing trend, meaning that mouse survival rate significantly increased with increasing dose levels. Specifically, on day 21 after group division, the number of surviving mice was as follows: Group G1 (PBS) 3 mice, Group G2 (0.1 mg / kg) 2 mice, Group G3 (0.3 mg / kg) 5 mice, all showing an observable therapeutic effect (TGITV%=29.7%); Group G4 (1 mg / kg) 6 mice, all showing a significant therapeutic effect (TGITV%=62.6%); Group G5 (3 mg / kg) 7 mice, including 2 tumor-free mice, all showing a significant therapeutic effect (TGITV%=78.3%); Group G6 (10 mg / kg) 7 mice, including 5 tumor-free mice, all showing a significant therapeutic effect (TGITV%=99.4%); and Group G7 (30 mg / kg) 7 mice, including 4 tumor-free mice, all showing a significant therapeutic effect (TGITV%=87.3%). Mice remaining by day 21 (non-surviving mice) were euthanized if their tumor volume exceeded 3000 mm3. All mice in the control group reached the euthanasia criteria 21 days after group assignment. The tumor volume and TGITV% on days 18 and 21, as well as the survival status at the end of the experimental period (day 70), are summarized below.
[0468] [Table 21]
[0469] At the end of the experimental period, all mice in groups G1-G4 were euthanized due to excessively large tumor volume, while the number of surviving mice in groups G5-G7 was 2, 4, and 4, respectively. This indicates that the efficacy of the bispecific antibody ScFV-HC-IgG1-LALA in mice correlates with the dose. Furthermore, the therapeutic effects of ScFV-HC-IgG1-LALA were similar in groups G6 (10 mg / kg) and G7 (30 mg / kg), indicating that 10 mg / kg is the saturation dose level for ScFV-HC-IgG1-LALA in vivo.
[0470] Example 12: Tumor-infiltrating lymphocyte (TIL) analysis TILs were analyzed as follows: MC38-hPD-L1 cells were subcutaneously injected into bihumanized CD40 / PD-1 mice (B-hPD-1 / hCD40 mice). On days 11, 14, and 18 post-injection, PBS (G1), 3 mg / kg anti-PD-1 monoclonal antibody 1A7-H2K3-IgG4 (G2), 3 mg / kg anti-CD40 monoclonal antibody 6A7-H4K2-IgG2 (G3), and a combination of 4 mg / kg bispecific antibody ScFV-HC-IgG1-LALA (G4) or 3 mg / kg anti-PD-1 monoclonal antibody 1A7-H2K3-IgG4 and 3 mg / kg anti-CD40 monoclonal antibody 6A7-H4K2-IgG2 (G5) were administered by intraperitoneal injection (ip). On day 21 post-injection, TILs were analyzed from tumor tissue in the control group G1 and the treatment groups G2-G5. The test results are shown in Figures 30A to 30C.
[0471] In a similar experiment, B16F10-hPD-L1 cells were subcutaneously injected into bihumanized CD40 / PD-1 mice (B-hPD-1 / hCD40 mice). On days 9 and 13 post-injection, PBS (G1), 3 mg / kg anti-PD-1 monoclonal antibody 1A7-H2K3-IgG4 (G2), 3 mg / kg anti-CD40 monoclonal antibody 6A7-H4K2-IgG2 (G3), and 4 mg / kg bispecific antibody ScFV-HC-IgG1-LALA (G4), or a combination of 3 mg / kg anti-PD-1 monoclonal antibody 1A7-H2K3-IgG4 and 3 mg / kg anti-CD40 monoclonal antibody 6A7-H4K2-IgG2 (G5) were administered by intraperitoneal injection (ip). On day 15 post-injection, TILs were analyzed from tumor tissue in the control group G1 and the treatment groups G2-G5. The test results are shown in Figures 30D to 30F.
[0472] As shown in Figures 30A-III and 30D-III, in the MC38 tumor model and the B16F10 tumor model, the bispecific antibody ScFV-HC-IgG1-LALA group (G4) effectively improved the ratio of CD8+ T cells to Treg cells (CTLS / Tregs) in T cells compared to the control group (G1).
[0473] Furthermore, analysis of PD-1 expression (Figures 30B and 30E) shows that in the MC38 tumor model and the B16F10 tumor model, the proportion of PD-1-positive cells among CD8+ T cells, Treg cells, CD4+ (non-Treg) T cells, or NK cells in the bispecific antibody group (G4) was significantly lower compared to the monoclonal antibody group (G2 or G3) and the control group (G1). In particular, in the B16F10 tumor model, the proportion of PD-1-positive cells among CD8+ T cells was significantly reduced (P<0.0001, see Figures 30E-30I), indicating that PD-1 expression on the surface of these cells is downregulated after treatment with ScFV-HC-IgG1-LALA.
[0474] Further analysis of bone marrow-derived cells was performed. In the MC38 tumor model, the percentages of dendritic cells (DCs) and myeloid-derived immunosuppressive cells (MDSCs) within leukocytes (CD45+) showed a decreasing trend (Figures 30C-I and 30C-II). In contrast, in the B16F10 tumor model, the percentages of these two cell types (CD45+) within leukocytes showed an increasing trend (Figures 30F-I and 30F-II). By combining the detection results of DC cell activation (CD80 / CD86+DC and MHCII+DC) in the MC38 tumor model (Figures 30C-III and 30C-IV) and the B16F10 tumor model (Figures 30F-III and 30F-IV), it was found that in the MC38 tumor model, the bispecific antibody group (G4) exhibited better T-cell proliferation / infiltration promotion and reduction of the proportion of myeloid-derived suppressor cells (MDSCs) compared to the monoclonal antibody group (G2 or G3) and the antibody combination group (G5). In the B16F10 tumor model, the bispecific antibody group (G4) promoted mainly DC cell proliferation / infiltration and activation, as well as the downregulation of the PD-1 ratio in CD8+ T cells, compared to the monoclonal antibody group (G2 or G3) and the antibody combination group (G5). The MC38 tumor model exhibits characteristics of a thermal tumor. The results indicate that in a thermal tumor model, bispecific antibodies can effectively promote the proliferation and invasion of CD8+ T cells and reduce the number of myeloid-derived immunosuppressive cells. In the B16F10-PDL1 tumor model with cold tumor characteristics, bispecific antibodies can effectively promote the proliferation, invasion, and activation of DC cells and downregulate the expression of PD1 in CD8+ T cells. The flow cytometry analysis strategy is shown in Figures 31A and 31B.
[0475] Example 13: Substitution of different PD-1 antibodies in the ScFV-HC-IgG structure Two commercially available anti-PD-1 monoclonal antibodies, tripalimab and pembrolizumab, were selected, and their variable regions were used to replace the anti-PD-1 variable region of a bispecific antibody, ScFV-HC-IgG1-LALA, according to their sequences. The resulting antibodies were named tripalimab-6A7-HC-IgG1-LALA (heavy chain sequence shown in SEQ ID NO: 162, light chain sequence shown in SEQ ID NO: 163) and pembrolizumab-6A7-HC-IgG1-LALA (heavy chain sequence shown in SEQ ID NO: 164, light chain sequence shown in SEQ ID NO: 165), respectively.
[0476] Similar to previous in vivo drug efficacy experiments, the effects of the bispecific antibodies tripalimab-6A7-HC-IgG1-LALA and pembrolizumab-6A7-HC-IgG1-LALA on in vivo tumor growth were tested in a colon cancer mouse model. Human PD-L1-expressing MC-38 tumor cells (colon adenocarcinoma cells) (MC38-hPD-L1) were subcutaneously injected into bihumanized CD40 / PD-1 mice (B-hPD-1 / hCD40 mice). When the tumor volume in the mice reached approximately 400 mm3, the mice were randomly divided into different groups based on tumor volume (6 mice per group).
[0477] In each group, B-hPD-1 / hCD40 mice were given phosphate-buffered saline (PBS, G1), 1 mg / kg anti-CD40 monoclonal antibody 6A7-H4K2-IgG2 (G2), 1 mg / kg anti-PD1 monoclonal antibody tripalimab (G3), 1 mg / kg anti-PD1 monoclonal antibody pembrolizumab (G4), 1.35 mg / kg (based on similar molar amounts) tripalimab-6A7-HC-IgG1-LALA (G5), 1.35 mg / kg pembrolizumab-6A7-HC-IgG1-LALA (G6), a combination of 1 mg / kg anti-PD1 monoclonal antibody tripalimab and 1 mg / kg anti-CD40 monoclonal antibody 6A7-H4K2-IgG2 (G7), or 1 mg / kg anti-PD1 monoclonal antibody pembrolizumab and 1 The combination of mg / kg anti-CD40 monoclonal antibody 6A7-H4K2-IgG2 (G8) was administered by intraperitoneal injection (ip). The administration frequency was twice a week (total of 5 doses). Detailed information is shown in the table below.
[0478] [Table 22]
[0479] Mouse body weight was monitored throughout the entire treatment period. Mean body weight increased to varying degrees in the different groups (Figures 32 and 33). At the end of the treatment period, mouse body weight increased in all different groups.
[0480] The tumor volume in the antibody-treated group is shown in Figure 34. The TGITV% on days 17 and 21 (17 and 21 days after group division) were calculated as shown in the table below. A large number of mice in the control group were euthanized due to excessive tumor volume, so the P-value on day 21 could not be obtained. The P-values in the table below were calculated based on the data from day 17.
[0481] [Table 23]
[0482] The results showed that both tripalimab-6A7-HC-IgG1-LALA (G5) and pembrolizumab-6A7-HC-IgG1-LALA (G6) suppressed tumor growth, with a TGITV% higher than that of monoclonal antibodies (G2, G3, and G4) and antibody combinations (G7 and G8) (e.g., on day 21). Notably, all mice in the G5 group survived, and the tumor in one mouse completely disappeared. The results suggest that different anti-PD-1 antigen binding fragments can be used with anti-CD40 scFv on the ScFV-HC-IgG structure to obtain better efficacy.
[0483] Example 14: Substitution of different CD40 scFv in the ScFV-HC-IgG structure CD40 is an important immune costimulatory pathway receptor, present on the surface of antigen-presenting cells (APCs) in the immune system, and plays a crucial role in the activation of innate and adaptive immune system mechanisms. Currently developed anti-CD40 antibodies include, for example, APX005M (VH SEQ ID NO: 191; VL SEQ ID NO: 192) developed by Apexigen, RG7876 (sericrelumab) developed by Roche, VIB4920 developed by Viela Bio, and ADC-1013 developed by Alligator Biosciences. In this experiment, two anti-CD40 monoclonal antibodies, namely sericrelumab and APX005M, were selected and used in combination with pembrolizumab to produce bispecific antibodies. The obtained antibodies had the structure of ScFV-HC-IgG, as shown in Figure 1B, and these antibodies were named pembrolizumab-Seli-FVHC-IgG4 (heavy chain sequence shown in SEQ ID NO: 175, light chain sequence shown in SEQ ID NO: 176) and pembrolizumab-APX005M-FVHC-IgG4 (heavy chain sequence shown in SEQ ID NO: 177, light chain sequence shown in SEQ ID NO: 178). Furthermore, the PD-1 antigen binding site in 1A7-sericrelumab-FVHC-IgG4 was exchanged with the CD40 antigen binding site, producing sericrelumab-1A7-FVHC-IgG4 (heavy chain sequence shown in SEQ ID NO: 201, light chain sequence shown in SEQ ID NO: 202).
[0484] The effects of the bispecific antibodies pembrolizumab-Seli-FVHC-IgG4 and pembrolizumab-APX005M-FVHC-IgG4 on in vivo tumor growth were tested in a mouse model of colon cancer. Specifically, MC-38 tumor cells (colon adenocarcinoma cells) expressing human PD-L1 (MC38-hPD-L1) were subcutaneously injected into bihumanized CD40 / PD-1 mice (B-hPD-1 / hCD40 mice). When the tumor volume in the mice reached approximately 400 mm3, the mice were randomly divided into different groups based on tumor volume (6 mice per group).
[0485] Similar to previous in vivo drug efficacy experiments, the effects of the bispecific antibodies pembrolizumab-Seli-FVHC-IgG4, pembrolizumab-APX005M-FVHC-IgG4, and sericrelumab-1A7-FVHC-IgG4 on in vivo tumor growth were tested in a colon cancer mouse model. Human PD-L1-expressing MC-38 tumor cells (colon adenocarcinoma cells) (MC38-hPD-L1) were subcutaneously injected into bihumanized CD40 / PD-1 mice (B-hPD-1 / hCD40 mice). When the tumor volume in the mice reached approximately 400 mm3, the mice were randomly divided into different groups based on tumor volume (6 mice per group).
[0486] In each group, B-hPD-1 / hCD40 mice were given either physiological saline (PS, G1), 1 mg / kg anti-PD1 monoclonal antibody pembrolizumab (G2), 1 mg / kg anti-CD40 monoclonal antibody APX005M (IgG1-S267E) (G3), sericrelumab-IgG2 (G4), 1.35 mg / kg pembrolizumab-Seli-FVHC-IgG4 (G5), 1.35 mg / kg pembrolizumab-APX005M-FVHC-IgG4 (G6), 1.35 mg / kg sericrelumab-1A7-FVHC-IgG4 (G7), or a combination of 1 mg / kg anti-PD1 monoclonal antibody pembrolizumab and 1 mg / kg anti-CD40 monoclonal antibody APX005M (G8), or 1 A combination of mg / kg anti-PD1 monoclonal antibody pembrolizumab and 1 mg / kg anti-CD40 monoclonal antibody sericrelumab (G8) was administered by intraperitoneal injection (ip). The administration frequency was twice a week (total of 6 doses). Detailed information is shown in the table below.
[0487] [Table 24]
[0488] Fourteen days after group assignment, there was no significant difference in the mean body weight of the mice in each group (Figures 44A and 44B). Body weight increased in all mice across all groups. Tumor volume in each group is shown in Figure 44C. The results indicate that pembrolizumab-APX005M-FVHC-IgG4 (G6) has better efficacy than monoclonal antibodies (G2) and (G3) or combination therapy (G8).
[0489] Example 15: In vivo toxicity test of bispecific antibodies with different structures Numerous structural forms of PD-1 / CD40 bispecific antibodies were constructed. Specifically, four different structural bispecific antibodies were produced using the scFv of sericrelumab and the sequence of the anti-PD-1 monoclonal antibody 1A7, and their toxicity was tested. The obtained antibodies were 1A7-sericrelumab-FVKH-IgG4 (structure shown in Figure 1A, heavy chain sequence shown in SEQ ID NO: 166 or SEQ ID NO: 173, light chain sequence shown in SEQ ID NO: 167), and 1A7-sericrelumab-FV3A-IgG4 (structure shown in Figure 18A, heavy chain sequence shown in SEQ ID NO: 168), which involves substituting the anti-CD40 antibody 6A7 sequence with the corresponding sequence of sericrelumab. The following were named: 1A7-sericrelumab-DART-IgG4 (structure shown in Figure 37, heavy chain sequence shown in Sequence ID No. 170, light chain sequence shown in Sequence ID No. 171), and 1A7-sericrelumab-FVHC-IgG4 (structure shown in Figure 1B, heavy chain sequence shown in Sequence ID No. 172, light chain sequence shown in Sequence ID No. 174).
[0490] Sericrelumab is known in this field to be relatively toxic. The toxicity of numerous structural forms of PD-1 / CD40 bispecific antibodies was tested in mice. Dihumanized CD40 / PD-1 mice (approximately 7 weeks old) were randomly divided into 8 groups (3 mice per group) based on their body weight. Participants were randomly selected from the following antibodies: anti-CD40 monoclonal antibody sericrelumab (G2), anti-PD-1 monoclonal antibody 1A7-H2K3-IgG4 (G3), 1A7-sericrelumab-FVHC-IgG4 (G4), 1A7-sericrelumab-FV3A-IgG4 (G5), 1A7-sericrelumab-DART-IgG4 (G6), 1A7-sericrelumab-FVKH-IgG4 (G7), and bispecific antibody ScFV-HC-IgG1-LALA (G8). The antibody was administered on the day of group assignment and every three days thereafter. The control group (G1) received PBS injections.
[0491] [Table 25]
[0492] As shown in Figures 35-36, the experimental results indicate that only the G2 group mice showed a significant reduction in body weight compared to the control group mice, but there was no significant difference in body weight among the other treatment groups. Seven days after group assignment, peripheral blood was collected and the concentrations of asparanin transaminase (AST) and alanine transaminase (ALT) were detected. As shown in Figures 38A and 38B, the ALT and AST detection results indicate that the concentrations of ALT and AST transaminase were highest in mice in group G2 (administered with the anti-CD40 monoclonal antibody sericrelumab). The transaminase concentrations in the bispecific antibody groups (G4-G8) were lower than those in group G2. Specifically, only mice in groups G4 and G6 showed a tendency for increased transaminase concentrations. The transaminase concentrations in mice from the other groups were similar to those in group G1.
[0493] Ten days after group division, mouse livers were isolated and examined under a microscope. The results are shown in the table below, which indicates that the toxicity of the bispecific antibody ScFV-HC-IgG1-LALA (G8) was lower than that of the monoclonal antibodies (G2-G3) and other bispecific antibodies (G4-G7). In fact, the bispecific antibody ScFV-HC-IgG1-LALA showed no toxic effects at all. The results indicate that PD-1 / CD40 bispecific antibodies in various forms can significantly reduce the toxicity of anti-CD40 antibodies.
[0494] [Table 26]
[0495] Example 16: In vivo results of BsAb anticolon cancer Similar to previous in vivo drug efficacy experiments, the effect of the above antibody on in vivo tumor growth was tested in a colon cancer mouse model. MC-38 tumor cells (colon adenocarcinoma cells) expressing human PD-L1 (MC38-hPD-L1) were subcutaneously injected into bihumanized CD40 / PD-1 mice (B-hPD-1 / hCD40 mice). When the tumor volume in the mice reached approximately 400 mm3, the mice were randomly divided into different groups based on tumor volume (8 mice per group).
[0496] In each group, B-hPD-1 / hCD40 mice were administered intraperitoneally (ip) with phosphate-buffered saline (PBS, G1), 1 mg / kg anti-CD40 monoclonal antibody sericrelumab (sericrelumab-IgG2, G2), 1 mg / kg anti-PD-1 monoclonal antibody 1A7-H2K3-IgG4 (G3), a combination of 1 mg / kg sericrelumab and 1 mg / kg 1A7-H2K3-IgG4 (G4), 1.35 mg / kg 1A7-sericrelumab-FV3A-IgG4 (G5), or 1.35 mg / kg 1A7-sericrelumab-FVHC-IgG4 (G6). The administration frequency was twice a week (total of 6 doses). Detailed information is shown in the table below.
[0497] [Table 27]
[0498] Mouse body weight was monitored throughout the entire treatment period. Mean body weight increased to varying degrees in different groups (Figures 39 and 40). At the end of the treatment period, mouse body weight increased in all groups.
[0499] The tumor volume in the antibody-treated group is shown in Figure 41. The TGITV% on day 17 (17 days after group division) was also calculated as shown in the table below. The P values in the table below were calculated based on the data from day 17.
[0500] [Table 28]
[0501] The results show that both 1A7-sericrelumab-FV3A-IgG4 (G5) and 1A7-sericrelumab-FVHC-IgG4 (G6) suppressed tumor growth, and their TGITV% (e.g., on day 17) was higher than that of monoclonal antibodies (G2 and G3) and antibody combinations (G4). The results indicate that PD-1 / CD40 bispecific antibodies with different structural forms can significantly suppress tumor growth with superior therapeutic efficacy.
[0502] Example 17: T cell / APC cell crosslinking effect of bispecific antibodies Experiments were conducted to test whether CD40 activation induced by PD1 / CD40 BsAb depends on the presence of PD-1 expressing cells. Two types of PD-1 / CD40 bispecific antibodies were produced as follows.
[0503] The scFv sequence of pembrolizumab-APX005M-FVHC-IgG4 was ligated to the C-terminus of the pembrolizumab heavy chain, an anti-PD-1 monoclonal antibody, to obtain the bispecific antibody pembrolizumab-APX005M-FVHC-IgG4. SdAb-6A7-FVHC-IgG1-LALA:SdAb is an anti-PD-1 nanobody (or camelid single-domain antibody) (the single variable domain (VHH) sequence is shown in SEQ ID NO: 204 of the publicly available information). The scFv sequence of the anti-CD40 monoclonal antibody 6A7-H4K2-IgG2 was ligated to the C-terminus of SdAb to obtain the bispecific antibody SdAb-6A7-FVHC-IgG1-LALA.
[0504] Effector cells Jurkat-Luc-hCD40 and basal cells Jurkat-hPD1 were inoculated into 96-well plates (cell density 5 × 10⁴ cells / well) and incubated at 37°C. BsAb pembrolizumab-6A7-HC-IgG1-LALA, pembrolizumab-Seli-FVHC-IgG4, SdAb-6A7-FVHC-IgG1-LALA, 1A7-sericrelumab-FV3A-IgG4, 1A7-sericrelumab-FVHC-IgG4, 1A7-sericrelumab-FVKH-IgG4, 1A7-sericrelumab-DART-IgG4, pembrolizumab-APX005M-FVHC-IgG4, and anti-CD40 antibody APX005M (IgG1-S267E), sericrelumab-IgG2, and 6A7-H4K2-IgG2 were serially diluted (3-fold) to a maximum concentration of 3 μg / mL. 25 μL of antibody was added to each well and incubated in a 37°C incubator for 6 hours. After incubation, the culture plate was removed, 75 μL of Bio-lite luciferase detection reagent (Vazem Biotech, catalog number: DD1201-02-AB) was added, and the plate was incubated at room temperature for 5-10 minutes. The culture plate was then placed in a light emission detector to detect the fluorescence signal. A control experiment was performed using the same steps, but no basal cells containing Jurkat-luc-hPD1 were present.
[0505] As shown in Figures 42A and 42B, in the presence of basal cells Jurkat-luc-hPD1, only BsAb (i.e., pembrolizumab-6A7-HC-IgG1-LALA, pembrolizumab-Seli-FVHC-IgG4, SdAb-6A7-FVHC-IgG1-LALA, 1A7-sericrelumab-FV3A-IgG4, 1A7-sericrelumab-FVHC-IgG4, 1A7-sericrelumab-FVKH-IgG4, 1A7-sericrelumab-DART-IgG4, and pembrolizumab-APX005M-FVHC-IgG4) transactivated reporter cells. In contrast, monoclonal anti-CD40 antibodies, with the exception of sericrelumab-IgG2, did not activate reporter cells. As shown in Figures 42C to 42D, when basal cells Jurkat-luc-hPD1 were absent, BsAb and monoclonal antibodies (excluding sericrelumab-IgG2) did not activate reporter cells.
[0506] The results indicate that activation of the CD40 pathway by the bispecific antibodies described herein is dependent on CD40 aggregation, which may be achieved by crosslinking with PD-1 on PD-1 expressing cells. Against sericrelumab-IgG2, the anti-CD40 antibody can activate CD40 without crosslinking activity (e.g., without crosslinking with FCγRIIB).
[0507] Example 18: Substitution of variable domains in various anti-PD-1 and anti-CD40 antibodies Further experiments were conducted to investigate whether VH and VL, or other VHH, in various anti-PD-1 antibodies could be used to substitute the anti-PD-1 variable region in ScFV-HC-IgG1 bispecific antibodies. Additionally, VH and VL of various anti-CD40 monoclonal antibodies were also tested. These antibodies and their sequences are listed below.
[0508] [Table 29-1]
[0509] [Table 29-2]
[0510] Similar to previous in vivo drug efficacy experiments, the effects of these bispecific antibodies on tumor growth in vivo were tested in a mouse model. Cancer cells expressing human PD-L1 (e.g., MC38-hPD-L1) were subcutaneously injected into bihumanized CD40 / PD-1 mice (B-hPD-1 / hCD40 mice). When the tumor volume in the mice reached approximately 300 mm3 to 500 mm3, the mice were randomly divided into different groups based on tumor volume (6 mice per group).
[0511] In each group, B-hPD-1 / hCD40 mice were injected intraperitoneally (ip) with phosphate-buffered saline (PBS, G1), 1 mg / kg anti-CD40 monoclonal antibody (G2), 1 mg / kg anti-PD1 monoclonal antibody (G3), 1.35 mg / kg ScFV-HC-IgG1-LALA (G4), and a combination of 1 mg / kg anti-PD1 monoclonal antibody and 1 mg / kg anti-CD40 monoclonal antibody (G5). The administration frequency was twice a week, and the number of administrations was appropriate (e.g., a total of 5 administrations). Body weight and tumor volume of each mouse were monitored throughout the entire treatment period. These anti-PD1 / CD40 bispecific antibodies in the ScFV-HC-IgG1-LALA form (e.g., Figure 1B) are expected to have excellent efficacy and low toxicity in the treatment of cancer.
[0512] Furthermore, experiments were conducted to test the efficacy of these FV3A morphologies of antibodies (e.g., Figure 18A). In this structure, the anti-CD40 antigen binding site was inserted into the 3A site of the anti-PD-1 antibody.
[0513] [Table 30-1]
[0514] [Table 30-2]
[0515] The effects of these bispecific antibodies on tumor growth in vivo were tested in a mouse model. Cancer cells expressing human PD-L1 (e.g., MC38-hPD-L1) were subcutaneously injected into bihumanized CD40 / PD-1 mice (B-hPD-1 / hCD40 mice). When the tumor volume in the mice reached approximately 300 mm3 to 500 mm3, the mice were randomly divided into different groups based on tumor volume (6 mice per group).
[0516] In each group, B-hPD-1 / hCD40 mice were injected intraperitoneally (ip) with phosphate-buffered saline (PBS, G1), 1 mg / kg anti-CD40 monoclonal antibody (G2), 1 mg / kg anti-PD1 monoclonal antibody (G3), 1.35 mg / kg PD1-C40-FV3A (G4), and a combination of 1 mg / kg anti-PD1 monoclonal antibody and 1 mg / kg anti-CD40 monoclonal antibody (G5). The administration frequency was twice a week, and the number of administrations was appropriate (e.g., a total of 5 administrations). Body weight and tumor volume were monitored throughout the entire treatment period. These anti-PD1 / CD40 bispecific antibodies with the PD1-C40-FV3A form (e.g., Figure 18A) are expected to have excellent efficacy and low toxicity in the treatment of cancer.
[0517] Furthermore, experiments were conducted to test the efficacy of these Fab-ScFV-IgG4 forms of antibodies (e.g., Figure 1A). In this structure, the anti-PD-1 arm includes a heavy chain and a light chain, and the anti-CD40 arm includes a single-stranded variable fragment (scFv) linked to the CH2 and CH3 domains of IgG4. Alternatively, the anti-PD-1 arm has only one heavy chain, and the VHH is linked to optional CH1, CH2, and CH3.
[0518] [Table 31-1]
[0519] [Table 31-2]
[0520] Furthermore, experiments were conducted to test the efficacy of these Fc-containing DART forms of antibodies (Figure 37) against VH, VL, and VHH listed in Table 31. These anti-PD1 / CD40 bispecific antibodies are expected to exhibit excellent efficacy and low toxicity in the treatment of cancer.
[0521] Example 19: In vivo results of bispecific antibody anti-colon cancer Atezolizumab is a humanized anti-PD-L1 monoclonal antibody (VH SEQ ID NO: 211; VL SEQ ID NO: 212) developed by Genentech. Avelumab is a human anti-PD-L1 monoclonal antibody (VH SEQ ID NO: 213; VL SEQ ID NO: 214) developed by Merck / Pfizer. In this experiment, the VH and VL sequences of the anti-PD-1 arm of the bispecific antibodies described herein (for example, as shown in Figure 1B) were replaced with the VH and VL sequences of the anti-PD-L1 antibody. Furthermore, the efficacy of the resulting PD-L1 / CD40 bispecific antibodies was compared with the efficacy of the corresponding PD-1 / CD40 bispecific antibodies disclosed herein.
[0522] Similar to previous in vivo drug efficacy experiments, the effects of the antibodies ScFV-HC-IgG1-LALA, atezolizumab-6A7-FVHC-IgG1-LALA (heavy chain sequence shown in SEQ ID NO: 215, light chain sequence shown in SEQ ID NO: 216), and avelumab-6A7-FVHC-IgG1-LALA (heavy chain sequence shown in SEQ ID NO: 217, light chain sequence shown in SEQ ID NO: 218) on in vivo tumor growth were tested in a colon cancer mouse model. Human PD-L1-expressing MC-38 tumor cells (colon adenocarcinoma cells) (MC38-hPD-L1) were subcutaneously injected into humanized PD1 / PD-L1 / CD40 mice (B-hPD-1 / hPD-L1 / hCD40 mice). When the tumor volume in mice reached approximately 100 mm³ to 150 mm³, the mice were randomly divided into different groups based on tumor volume (6 mice per group). Detailed information on the humanized PD-L1 mice can be found, for example, in PCT application numbers PCT / CN2017 / 099574 and US10945418B2, which are incorporated herein by reference in their entirety.
[0523] In each group, B-hPD-1 / hPD-L1 / hCD40 mice (mice possessing humanized PD-1, humanized PD-L1, and humanized CD40 genes) were given phosphate-buffered saline (PBS, G1), 1 mg / kg anti-PD-1 / CD40 antibody ScFV-HC-IgG1-LALA (G2), 1 mg / kg anti-PD-L1 / CD40 bispecific antibody atezolizumab-6A7-FVHC-IgG1-LALA (G3), 1 mg / kg anti-PD-L1 / CD40 bispecific antibody avelumab-6A7-FVHC-IgG1-LALA (G4), 3 mg / kg ScFV-HC-IgG1-LALA (G5), 3 mg / kg atezolizumab-6A7-FVHC-IgG1-LALA (G6), or 3 Avelumab-6A7-FVHC-IgG1-LALA(G7) mg / kg was administered by intraperitoneal injection (ip). The administration frequency was twice a week (total of 4 doses). Detailed information is shown in the table below.
[0524] [Table 32]
[0525] Mouse body weight was monitored throughout the entire treatment period. Mean body weight increased to varying degrees in different groups (Figures 45 and 46). At the end of the treatment period, mouse body weight increased in all groups. The tumor volume in the antibody-treated group is shown in Figure 47. The TGITV% on day 21 (21 days after group division) was also calculated as shown in the table below. The P values in the table below were calculated based on the data from day 21.
[0526] [Table 33]
[0527] The results show that, at the same dose level, the ScFV-HC-IgG1-LALA antibody exhibits better in vivo efficacy than atezolizumab-6A7-FVHC-IgG1-LALA or avelumab-6A7-FVHC-IgG1-LALA. Higher dose levels indicate greater therapeutic efficacy.
[0528] More specifically, the results show that at different dose levels, ScFV-HC-IgG1 (G2, G5) suppressed tumor growth at a higher TGITV% (69.6%, 92.5%) than atezolizumab-6A7-FVHC-IgG1-LALA (G3, G6) or avelumab-6A7-FVHC-IgG1-LALA (G4, G7), indicating that higher doses resulted in greater therapeutic efficacy. Therefore, the data demonstrate that different morphologies of ScFV-HC-IgG1 have different therapeutic effects in B-hPD-1 / hPD-L1 / hCD40 mice.
[0529] Other examples While the present invention has been described in relation to specific embodiments of the invention, it should be understood that the foregoing description is intended to illustrate, not to limit, the scope of the invention as defined by the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.
Claims
1. An antigen-binding protein construct comprising: a first antigen-binding site that specifically binds to PD-1, wherein the first antigen-binding site blocks the binding of PD-1 to PD-L1; and a second antigen-binding site that specifically binds to CD40, wherein the first antigen-binding site comprises a heavy chain variable region (VH1) and a light chain variable region (VL1), and the second antigen-binding site comprises a heavy chain variable region (VH2) and a light chain variable region (VL2). The antigen-binding protein construct includes an Fc region, The second antigen-binding site is linked to the C-terminus of the Fc region, and The Fc region is a human IgG1 Fc region containing a LALA mutation or an N297A mutation, or a human IgG4 Fc region. The aforementioned antigen-binding protein construct induces activation of the CD40 pathway in the tumor microenvironment, but does not induce activation of the CD40 pathway in the absence of one or more cells expressing PD-1.
2. An antigen-binding protein construct according to claim 1, having one or more features selected from the group consisting of the following: (1) The first antigen-binding site binds to a cell expressing PD-1, and the cell expressing PD-1 may be a T cell, B cell, NK cell, or myeloid cell (for example, macrophage, myeloid immunosuppressive cell (MDSC)), (2) The second antigen-binding site binds to a cell expressing CD40, and the cell expressing CD40 is optionally an antigen-presenting cell. (3) The antigen-binding protein construct can activate the CD40 pathway, where the activation of the CD40 pathway depends on the binding of the antigen-binding protein construct to cells expressing PD-1, and the cells expressing PD-1 are optionally T cells, B cells, NK cells, or myeloid cells (e.g., macrophages, myeloid immunosuppressive cells (MDSCs)). (4) The antigen-binding protein construct induces activation of the CD40 pathway in the presence of one or more cells expressing PD-1, wherein the cells expressing PD-1 are optionally T cells, B cells, NK cells, or myeloid cells (e.g., macrophages, myeloid immunosuppressive cells (MDSCs)). (5) The cells expressing PD-1 are T cells, B cells, NK cells, or myeloid cells (for example, macrophages, myeloid immunosuppressive cells (MDSCs)), (6) The antigen-binding protein construct includes an Fc region, wherein the antigen-binding protein construct cannot activate the CD40 pathway by an Fc receptor-mediated mechanism. (7) The antigen-binding protein construct is a bispecific antibody, (8) The first antigen-binding site that specifically binds to PD-1 includes ScFv, (9) The antigen-binding protein construct according to claim 1, wherein the second antigen-binding site that specifically binds to CD40 includes ScFv.
3. The heavy chain variable region (VH1) of the first antigen-binding site includes complementarity-determining regions (CDRs) 1, 2 and 3, wherein the VH1 CDR1 region includes an amino acid sequence identical to the selected VH1 CDR1 amino acid sequence, the VH1 CDR2 region includes an amino acid sequence identical to the selected VH1 CDR2 amino acid sequence, the VH1 CDR3 region includes an amino acid sequence identical to the selected VH1 CDR3 amino acid sequence, and The light chain variable region (VL1) of the first antigen-binding site includes CDR1, 2, and 3, where the VL1 CDR1 region includes an amino acid sequence identical to the selected VL1 CDR1 amino acid sequence, the VL1 CDR2 region includes an amino acid sequence identical to the selected VL1 CDR2 amino acid sequence, and the VL1 CDR3 region includes an amino acid sequence identical to the selected VL1 CDR3 amino acid sequence. The selected VH1 CDR1, 2, and 3 amino acid sequences and the selected VL1 CDR1, 2, and 3 amino acid sequences are one of the following: (1) In accordance with the Kabat numbering rules, the selected VH1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs: 1, 2, and 3, respectively, and the selected VL1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs: 4, 5, and 6, respectively. (2) In accordance with the Chothia numbering rules, the selected VH1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs: 19, 20, and 21, respectively, and the selected VL1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs: 22, 23, and 24, respectively. (3) In accordance with the Kabat numbering rules, the selected VH1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs: 7, 8, and 9, respectively, and the selected VL1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs: 10, 11, and 12, respectively. (4) In accordance with the Chothia numbering rules, the selected VH1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs. 25, 26, and 27, respectively, and the selected VL1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs. 28, 29, and 30, respectively. (5) In accordance with the Kabat numbering rules, the selected VH1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs: 13, 14, and 15, respectively, and the selected VL1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs: 16, 17, and 18, respectively, and (6) The antigen-binding protein construct according to claim 1 or 2, wherein the selected VH1 CDR1,2,3 amino acid sequences are shown in SEQ ID NOs. 31, 32, and 33, respectively, and the selected VL1 CDR1,2,3 amino acid sequences are shown in SEQ ID NOs. 34, 35, and 36, respectively.
4. The heavy chain variable region (VH2) of the second antigen-binding site comprises CDR1, 2 and 3, wherein the VH2 CDR1 region comprises an amino acid sequence identical to the selected VH2 CDR1 amino acid sequence, the VH2 CDR2 region comprises an amino acid sequence identical to the selected VH2 CDR2 amino acid sequence, the VH2 CDR3 region comprises an amino acid sequence identical to the selected VH2 CDR3 amino acid sequence, and The light chain variable region (VL2) of the second antigen-binding site includes CDR1, 2, and 3, where the VL2 CDR1 region includes an amino acid sequence identical to the selected VL2 CDR1 amino acid sequence, the VL2 CDR2 region includes an amino acid sequence identical to the selected VL2 CDR2 amino acid sequence, and the VL2 CDR3 region includes an amino acid sequence identical to the selected VL2 CDR3 amino acid sequence. The selected VH2 CDR1, 2, and 3 amino acid sequences and the selected VL2 CDR1, 2, and 3 amino acid sequences are one of the following: (1) In accordance with the Kabat numbering rules, the selected VH2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs. 65, 66, and 67, respectively, and the selected VL2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs. 68, 69, and 70, respectively. (2) In accordance with the Chothia numbering rules, the selected VH2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs. 83, 84, and 85, respectively, and the selected VL2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs. 86, 87, and 88, respectively. (3) In accordance with the Kabat numbering rules, the selected VH2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs. 59, 60, and 61, respectively, and the selected VL2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs. 62, 63, and 64, respectively. (4) In accordance with the Chothia numbering rules, the selected VH2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs. 77, 78, and 79, respectively, and the selected VL2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs. 80, 81, and 82, respectively. (5) In accordance with the Kabat numbering rules, the selected VH2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs. 71, 72, and 73, respectively, and the selected VL2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs. 74, 75, and 76, respectively, and (6) The antigen-binding protein construct according to any one of claims 1 to 3, wherein the selected VH2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs. 89, 90, and 91, respectively, and the selected VL2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs. 92, 93, and 94, respectively.
5. A first heavy chain variable region (VH1) and a first light chain variable region (VL1) that bind to each other, specifically bind to PD-1, and form a first antigen-binding site that blocks the binding of PD-1 and PD-L1, An antigen-binding protein construct comprising a second heavy chain variable region (VH2) and a second light chain variable region (VL2) that bind to each other, specifically bind to CD40, and form a second antigen-binding site that is a CD40 agonist, Here, the antigen-binding protein construct is A first polypeptide comprising the first heavy chain variable region, the second heavy chain variable region, and the second light chain variable region, The second polypeptide comprises the first light chain variable region, Here, the first polypeptide further comprises a heavy chain steady region 1 (CH1), a heavy chain steady region 2 (CH2), and a heavy chain steady region 3 (CH3).
6. A first heavy chain variable region (VH1) and a first light chain variable region (VL1) that bind to each other, specifically bind to PD-1, and form a first antigen-binding site that blocks the binding of PD-1 and PD-L1, An antigen-binding protein construct comprising a second heavy chain variable region (VH2) and a second light chain variable region (VL2) that bind to each other, specifically bind to CD40, and form a second antigen-binding site that is a CD40 agonist, Here, the antigen-binding protein construct is A first polypeptide comprising the first heavy chain variable region, the first heavy chain steady region 2 (CH2), and the first heavy chain steady region 3 (CH3), The second polypeptide comprises the second heavy chain variable region, the second heavy chain steady region 2 (CH2), and the second heavy chain steady region 3 (CH3), Here, the second polypeptide further comprises the second light chain variable region, and the antigen-binding protein construct comprises a third polypeptide comprising the first light chain variable region.
7. The first heavy chain variable region (VH1) includes complementarity determining regions (CDRs) 1, 2, and 3, where the VH1 CDR1 region includes an amino acid sequence identical to the selected VH1 CDR1 amino acid sequence, the VH1 CDR2 region includes an amino acid sequence identical to the selected VH1 CDR2 amino acid sequence, the VH1 CDR3 region includes an amino acid sequence identical to the selected VH1 CDR3 amino acid sequence, and The first light chain variable region (VL1) includes CDR1, 2, and 3, where the VL1 CDR1 region includes an amino acid sequence identical to the selected VL1 CDR1 amino acid sequence, the VL1 CDR2 region includes an amino acid sequence identical to the selected VL1 CDR2 amino acid sequence, and the VL1 CDR3 region includes an amino acid sequence identical to the selected VL1 CDR3 amino acid sequence. The selected VH1 CDR1, 2, and 3 amino acid sequences and the selected VL1 CDR1, 2, and 3 amino acid sequences are one of the following: (1) In accordance with the Kabat numbering rules, the selected VH1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs: 1, 2, and 3, respectively, and the selected VL1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs: 4, 5, and 6, respectively. (2) In accordance with the Chothia numbering rules, the selected VH1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs: 19, 20, and 21, respectively, and the selected VL1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs: 22, 23, and 24, respectively. (3) In accordance with the Kabat numbering rules, the selected VH1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs: 7, 8, and 9, respectively, and the selected VL1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs: 10, 11, and 12, respectively. (4) In accordance with the Chothia numbering rules, the selected VH1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs. 25, 26, and 27, respectively, and the selected VL1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs. 28, 29, and 30, respectively. (5) In accordance with the Kabat numbering rules, the selected VH1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs: 13, 14, and 15, respectively, and the selected VL1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs: 16, 17, and 18, respectively, and (6) The antigen-binding protein construct according to claim 5 or 6, wherein the selected VH1 CDR1,2,3 amino acid sequences are shown in SEQ ID NOs. 31, 32, and 33, respectively, and the selected VL1 CDR1,2,3 amino acid sequences are shown in SEQ ID NOs. 34, 35, and 36, respectively.
8. The second heavy chain variable region (VH2) includes CDR1, 2, and 3, where the VH2 CDR1 region includes an amino acid sequence identical to the selected VH2 CDR1 amino acid sequence, the VH2 CDR2 region includes an amino acid sequence identical to the selected VH2 CDR2 amino acid sequence, the VH2 CDR3 region includes an amino acid sequence identical to the selected VH2 CDR3 amino acid sequence, and The second light chain variable region (VL2) includes CDR1, 2, and 3, where the VL2 CDR1 region includes an amino acid sequence identical to the selected VL2 CDR1 amino acid sequence, the VL2 CDR2 region includes an amino acid sequence identical to the selected VL2 CDR2 amino acid sequence, and the VL2 CDR3 region includes an amino acid sequence identical to the selected VL2 CDR3 amino acid sequence. The selected VH2 CDR1, 2, and 3 amino acid sequences and the selected VL2 CDR1, 2, and 3 amino acid sequences are one of the following: (1) In accordance with the Kabat numbering rules, the selected VH2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs. 65, 66, and 67, respectively, and the selected VL2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs. 68, 69, and 70, respectively. (2) In accordance with the Chothia numbering rules, the selected VH2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs. 83, 84, and 85, respectively, and the selected VL2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs. 86, 87, and 88, respectively. (3) In accordance with the Kabat numbering rules, the selected VH2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs. 59, 60, and 61, respectively, and the selected VL2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs. 62, 63, and 64, respectively. (4) In accordance with the Chothia numbering rules, the selected VH2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs. 77, 78, and 79, respectively, and the selected VL2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs. 80, 81, and 82, respectively. (5) In accordance with the Kabat numbering rules, the selected VH2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs. 71, 72, and 73, respectively, and the selected VL2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs. 74, 75, and 76, respectively, and (6) The antigen-binding protein construct according to any one of claims 5 to 7, wherein the selected VH2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs. 89, 90, and 91, respectively, and the selected VL2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NOs. 92, 93, and 94, respectively.
9. The first heavy chain variable region (VH1) includes complementarity determination regions (CDRs) 1, 2 and 3, the first light chain variable region (VL1) includes CDRs 1, 2 and 3, the second heavy chain variable region (VH2) includes complementarity determination regions (CDRs) 1, 2 and 3, and the second light chain variable region (VL2) includes CDRs 1, 2 and 3. Here, the amino acid sequences of CDR1, 2, and 3 of VH1, the amino acid sequences of CDR1, 2, and 3 of VL1, the amino acid sequences of CDR1, 2, and 3 of VH2, and the amino acid sequences of CDR1, 2, and 3 of VL2 are one of the following: (1) In accordance with the Kabat numbering rules, the amino acid sequences of VH1 CDR1, 2, and 3 are shown in SEQ ID NOs: 1, 2, and 3, respectively, and the amino acid sequences of VL1 CDR1, 2, and 3 are shown in SEQ ID NOs: 4, 5, and 6, respectively, the amino acid sequences of VH2 CDR1, 2, and 3 are shown in SEQ ID NOs: 65, 66, and 67, respectively, and the amino acid sequences of VL2 CDR1, 2, and 3 are shown in SEQ ID NOs: 68, 69, and 70, respectively, or (2) In accordance with the Chothia numbering rules, the amino acid sequences of VH1 CDR1, 2, and 3 are shown in SEQ ID NOs: 19, 20, and 21, respectively, and the amino acid sequences of VL1 CDR1, 2, and 3 are shown in SEQ ID NOs: 22, 23, and 24, respectively, the amino acid sequences of VH2 CDR1, 2, and 3 are shown in SEQ ID NOs: 83, 84, and 85, respectively, and the amino acid sequences of VL2 CDR1, 2, and 3 are shown in SEQ ID NOs: 86, 87, and 88, respectively. An antigen-binding protein construct according to any one of claims 5 to 8.
10. The first heavy chain variable region includes a sequence having at least 90% or 95% identity with sequence numbers 40, 41, 42, or 53, and the first light chain variable region includes a sequence having at least 90% or 95% identity with sequence numbers 43, 44, 45, or 54; or the first heavy chain variable region includes a sequence having at least 90% or 95% identity with sequence numbers 46, 47, 48, 49, or 55, and the first light chain variable region includes a sequence having at least 90% or 95% identity with sequence numbers 50, 51, 52, or 56. The first heavy chain variable region includes a sequence having at least 90% or 95% identity with sequence number 57, and the first light chain variable region includes a sequence having at least 90% or 95% identity with sequence number 58, or the second heavy chain variable region includes a sequence having at least 90% or 95% identity with sequence number 98, 99, 100 or 120, and the second light chain variable region includes a sequence having at least 90% or 95% identity with sequence number 101, 102, 103, 104 or 121, or the second heavy chain variable region is The second light chain variable region includes a sequence having at least 90% or 95% identity with sequence numbers 105, 106, 107, 108, 122, 126, or 128, and the second light chain variable region includes a sequence having at least 90% or 95% identity with sequence numbers 109, 110, 111, 123, 127, or 129, or the second heavy chain variable region includes a sequence having at least 90% or 95% identity with sequence numbers 112, 113, 114, 115, or 124, and the second light chain variable region includes a sequence having at least 90% or 95% identity with sequence numbers 116, 117, 118, 119, or 12 The first heavy chain variable region includes a sequence having at least 90% or 95% identity with sequence number 41, the first light chain variable region includes a sequence having at least 90% or 95% identity with sequence number 45, the second heavy chain variable region includes a sequence having at least 90% or 95% identity with sequence number 108 or 126, and the second light chain variable region includes a sequence having at least 90% or 95% identity with sequence number 110 or 127. The first heavy chain variable region (VH1) includes complementarity determination regions (CDRs) 1, 2, and 3, the first light chain variable region (VL1) includes CDRs 1, 2, and 3, the second heavy chain variable region (VH2) includes complementarity determination regions (CDRs) 1, 2, and 3, and the second light chain variable region (VL2) includes CDRs 1, 2, and 3. (a) The amino acid sequences of CDR1, 2, and 3 of VH1 and the amino acid sequences of CDR1, 2, and 3 of VL1 are any of the following: (a-1) In accordance with the Kabat numbering rules, the amino acid sequences of CDR1, 2, and 3 of VH1 are the sequences shown in sequence numbers 1, 2, and 3 of the sequence listing, respectively, and the amino acid sequences of CDR1, 2, and 3 of VL1 are the sequences shown in sequence numbers 4, 5, and 6 of the sequence listing, respectively. (a-2) In accordance with the Chothia numbering rules, the amino acid sequences of CDR1, 2, and 3 of VH1 are the sequences shown in sequence numbers 19, 20, and 21 of the sequence listing, respectively, and the amino acid sequences of CDR1, 2, and 3 of VL1 are the sequences shown in sequence numbers 22, 23, and 24 of the sequence listing, respectively. (a-3) In accordance with the Kabat numbering rules, the amino acid sequences of CDR1, 2, and 3 of VH1 are the sequences shown in sequence numbers 7, 8, and 9 of the sequence listing, respectively, and the amino acid sequences of CDR1, 2, and 3 of VL1 are the sequences shown in sequence numbers 10, 11, and 12 of the sequence listing, respectively. (a-4) In accordance with the Chothia numbering rules, the amino acid sequences of CDR1, 2, and 3 of VH1 are the sequences shown in sequence numbers 25, 26, and 27 of the sequence listing, respectively, and the amino acid sequences of CDR1, 2, and 3 of VL1 are the sequences shown in sequence numbers 28, 29, and 30 of the sequence listing, respectively. (a-5) In accordance with the Kabat numbering rules, the amino acid sequences of CDR1, 2, and 3 of VH1 are the sequences shown in sequence numbers 13, 14, and 15 of the sequence listing, respectively, and the amino acid sequences of CDR1, 2, and 3 of VL1 are the sequences shown in sequence numbers 16, 17, and 18 of the sequence listing, respectively, and (a-6) In accordance with the Chothia numbering rules, the amino acid sequences of CDR1, 2, and 3 of VH1 are the sequences shown in sequence numbers 31, 32, and 33 of the sequence listing, respectively, and the amino acid sequences of CDR1, 2, and 3 of VL1 are the sequences shown in sequence numbers 34, 35, and 36 of the sequence listing, respectively. (b) The amino acid sequences of CDR1, 2, and 3 of VH2 and the amino acid sequences of CDR1, 2, and 3 of VL2 are any of the following: (b-1) In accordance with the Kabat numbering rules, the amino acid sequences of CDR1, 2, and 3 of VH2 are the sequences shown in sequence numbers 65, 66, and 67 of the sequence listing, respectively, and the amino acid sequences of CDR1, 2, and 3 of VL2 are the sequences shown in sequence numbers 68, 69, and 70 of the sequence listing, respectively. (b-2) In accordance with the Chothia numbering rules, the amino acid sequences of CDR1, 2, and 3 of VH2 are the sequences shown in sequence numbers 83, 84, and 85 of the sequence listing, respectively, and the amino acid sequences of CDR1, 2, and 3 of VL2 are the sequences shown in sequence numbers 86, 87, and 88 of the sequence listing, respectively. (b-3) In accordance with the Kabat numbering rules, the amino acid sequences of CDR1, 2, and 3 of VH2 are the sequences shown in sequence numbers 59, 60, and 61 of the sequence listing, respectively, and the amino acid sequences of CDR1, 2, and 3 of VL2 are the sequences shown in sequence numbers 62, 63, and 64 of the sequence listing, respectively. (b-4) In accordance with the Chothia numbering rules, the amino acid sequences of CDR1, 2, and 3 of VH2 are the sequences shown in sequence numbers 77, 78, and 79 of the sequence listing, respectively, and the amino acid sequences of CDR1, 2, and 3 of VL2 are the sequences shown in sequence numbers 80, 81, and 82 of the sequence listing, respectively. (b-5) In accordance with the Kabat numbering rules, the amino acid sequences of CDR1, 2, and 3 of VH2 are the sequences shown in sequence numbers 71, 72, and 73 of the sequence listing, respectively, and the amino acid sequences of CDR1, 2, and 3 of VL2 are the sequences shown in sequence numbers 74, 75, and 76 of the sequence listing, respectively, and (b-6) In accordance with the Chothia numbering rules, the amino acid sequences of CDR1, 2, and 3 of VH2 are the sequences shown in sequence numbers 89, 90, and 91 of the sequence listing, respectively, and the amino acid sequences of CDR1, 2, and 3 of VL2 are the sequences shown in sequence numbers 92, 93, and 94 of the sequence listing, respectively. An antigen-binding protein construct according to any one of claims 5 to 9.
11. The second polypeptide further comprises the second light chain variable region, the antigen-binding protein construct comprises a third polypeptide comprising the first light chain variable region, the first polypeptide comprising a sequence having at least 90% or 95% identity with SEQ ID NO: 130, the third polypeptide comprising a sequence having at least 90% or 95% identity with SEQ ID NO: 131, and / or the second polypeptide comprising a sequence having at least 90% or 95% identity with SEQ ID NO: 132 or 133. The first heavy chain variable region (VH1) includes complementarity determination regions (CDRs) 1, 2, and 3, the first light chain variable region (VL1) includes CDRs 1, 2, and 3, the second heavy chain variable region (VH2) includes complementarity determination regions (CDRs) 1, 2, and 3, and the second light chain variable region (VL2) includes CDRs 1, 2, and 3. (a) The amino acid sequences of CDR1, 2, and 3 of VH1 and the amino acid sequences of CDR1, 2, and 3 of VL1 are any of the following: (a-1) In accordance with the Kabat numbering rules, the amino acid sequences of CDR1, 2, and 3 of VH1 are the sequences shown in sequence numbers 1, 2, and 3 of the sequence listing, respectively, and the amino acid sequences of CDR1, 2, and 3 of VL1 are the sequences shown in sequence numbers 4, 5, and 6 of the sequence listing, respectively. (a-2) In accordance with the Chothia numbering rules, the amino acid sequences of CDR1, 2, and 3 of VH1 are the sequences shown in sequence numbers 19, 20, and 21 of the sequence listing, respectively, and the amino acid sequences of CDR1, 2, and 3 of VL1 are the sequences shown in sequence numbers 22, 23, and 24 of the sequence listing, respectively. (a-3) In accordance with the Kabat numbering rules, the amino acid sequences of CDR1, 2, and 3 of VH1 are the sequences shown in sequence numbers 7, 8, and 9 of the sequence listing, respectively, and the amino acid sequences of CDR1, 2, and 3 of VL1 are the sequences shown in sequence numbers 10, 11, and 12 of the sequence listing, respectively. (a-4) In accordance with the Chothia numbering rules, the amino acid sequences of CDR1, 2, and 3 of VH1 are the sequences shown in sequence numbers 25, 26, and 27 of the sequence listing, respectively, and the amino acid sequences of CDR1, 2, and 3 of VL1 are the sequences shown in sequence numbers 28, 29, and 30 of the sequence listing, respectively. (a-5) In accordance with the Kabat numbering rules, the amino acid sequences of CDR1, 2, and 3 of VH1 are the sequences shown in sequence numbers 13, 14, and 15 of the sequence listing, respectively, and the amino acid sequences of CDR1, 2, and 3 of VL1 are the sequences shown in sequence numbers 16, 17, and 18 of the sequence listing, respectively, and (a-6) In accordance with the Chothia numbering rules, the amino acid sequences of CDR1, 2, and 3 of VH1 are the sequences shown in sequence numbers 31, 32, and 33 of the sequence listing, respectively, and the amino acid sequences of CDR1, 2, and 3 of VL1 are the sequences shown in sequence numbers 34, 35, and 36 of the sequence listing, respectively. (b) The amino acid sequences of CDR1, 2, and 3 of VH2 and the amino acid sequences of CDR1, 2, and 3 of VL2 are any of the following: (b-1) In accordance with the Kabat numbering rules, the amino acid sequences of CDR1, 2, and 3 of VH2 are the sequences shown in sequence numbers 65, 66, and 67 of the sequence listing, respectively, and the amino acid sequences of CDR1, 2, and 3 of VL2 are the sequences shown in sequence numbers 68, 69, and 70 of the sequence listing, respectively. (b-2) In accordance with the Chothia numbering rules, the amino acid sequences of CDR1, 2, and 3 of VH2 are the sequences shown in sequence numbers 83, 84, and 85 of the sequence listing, respectively, and the amino acid sequences of CDR1, 2, and 3 of VL2 are the sequences shown in sequence numbers 86, 87, and 88 of the sequence listing, respectively. (b-3) In accordance with the Kabat numbering rules, the amino acid sequences of CDR1, 2, and 3 of VH2 are the sequences shown in sequence numbers 59, 60, and 61 of the sequence listing, respectively, and the amino acid sequences of CDR1, 2, and 3 of VL2 are the sequences shown in sequence numbers 62, 63, and 64 of the sequence listing, respectively. (b-4) In accordance with the Chothia numbering rules, the amino acid sequences of CDR1, 2, and 3 of VH2 are the sequences shown in sequence numbers 77, 78, and 79 of the sequence listing, respectively, and the amino acid sequences of CDR1, 2, and 3 of VL2 are the sequences shown in sequence numbers 80, 81, and 82 of the sequence listing, respectively. (b-5) In accordance with the Kabat numbering rules, the amino acid sequences of CDR1, 2, and 3 of VH2 are the sequences shown in sequence numbers 71, 72, and 73 of the sequence listing, respectively, and the amino acid sequences of CDR1, 2, and 3 of VL2 are the sequences shown in sequence numbers 74, 75, and 76 of the sequence listing, respectively, and (b-6) In accordance with the Chothia numbering rules, the amino acid sequences of CDR1, 2, and 3 of VH2 are the sequences shown in sequence numbers 89, 90, and 91 of the sequence listing, respectively, and the amino acid sequences of CDR1, 2, and 3 of VL2 are the sequences shown in sequence numbers 92, 93, and 94 of the sequence listing, respectively. Preferably, the antigen-binding protein construct according to claim 6, wherein the first polypeptide comprises a sequence having at least 90% or 95% identity with SEQ ID NO: 130, the second polypeptide comprises a sequence having at least 90% or 95% identity with SEQ ID NO: 132 or 133, and the third polypeptide comprises a sequence having at least 90% or 95% identity with SEQ ID NO:
131.
12. The first polypeptide comprises a sequence having at least 90% or 95% identity with SEQ ID NO: 134 or 135, the second polypeptide comprises a sequence having at least 90% or 95% identity with SEQ ID NO: 136, or the first polypeptide comprises a sequence having at least 90% or 95% identity with SEQ ID NO: 137 or 138, the second polypeptide comprises a sequence having at least 90% or 95% identity with SEQ ID NO: 139, The first heavy chain variable region (VH1) includes complementarity determination regions (CDRs) 1, 2, and 3, the first light chain variable region (VL1) includes CDRs 1, 2, and 3, the second heavy chain variable region (VH2) includes complementarity determination regions (CDRs) 1, 2, and 3, and the second light chain variable region (VL2) includes CDRs 1, 2, and 3. (a) The amino acid sequences of CDR1, 2, and 3 of VH1 and the amino acid sequences of CDR1, 2, and 3 of VL1 are any of the following: (a-1) In accordance with the Kabat numbering rules, the amino acid sequences of CDR1, 2, and 3 of VH1 are the sequences shown in sequence numbers 1, 2, and 3 of the sequence listing, respectively, and the amino acid sequences of CDR1, 2, and 3 of VL1 are the sequences shown in sequence numbers 4, 5, and 6 of the sequence listing, respectively. (a-2) In accordance with the Chothia numbering rules, the amino acid sequences of CDR1, 2, and 3 of VH1 are the sequences shown in sequence numbers 19, 20, and 21 of the sequence listing, respectively, and the amino acid sequences of CDR1, 2, and 3 of VL1 are the sequences shown in sequence numbers 22, 23, and 24 of the sequence listing, respectively. (a-3) In accordance with the Kabat numbering rules, the amino acid sequences of CDR1, 2, and 3 of VH1 are the sequences shown in sequence numbers 7, 8, and 9 of the sequence listing, respectively, and the amino acid sequences of CDR1, 2, and 3 of VL1 are the sequences shown in sequence numbers 10, 11, and 12 of the sequence listing, respectively. (a-4) In accordance with the Chothia numbering rules, the amino acid sequences of CDR1, 2, and 3 of VH1 are the sequences shown in sequence numbers 25, 26, and 27 of the sequence listing, respectively, and the amino acid sequences of CDR1, 2, and 3 of VL1 are the sequences shown in sequence numbers 28, 29, and 30 of the sequence listing, respectively. (a-5) In accordance with the Kabat numbering rules, the amino acid sequences of CDR1, 2, and 3 of VH1 are the sequences shown in sequence numbers 13, 14, and 15 of the sequence listing, respectively, and the amino acid sequences of CDR1, 2, and 3 of VL1 are the sequences shown in sequence numbers 16, 17, and 18 of the sequence listing, respectively, and (a-6) In accordance with the Chothia numbering rules, the amino acid sequences of CDR1, 2, and 3 of VH1 are the sequences shown in sequence numbers 31, 32, and 33 of the sequence listing, respectively, and the amino acid sequences of CDR1, 2, and 3 of VL1 are the sequences shown in sequence numbers 34, 35, and 36 of the sequence listing, respectively. (b) The amino acid sequences of CDR1, 2, and 3 of VH2 and the amino acid sequences of CDR1, 2, and 3 of VL2 are any of the following: (b-1) In accordance with the Kabat numbering rules, the amino acid sequences of CDR1, 2, and 3 of VH2 are the sequences shown in sequence numbers 65, 66, and 67 of the sequence listing, respectively, and the amino acid sequences of CDR1, 2, and 3 of VL2 are the sequences shown in sequence numbers 68, 69, and 70 of the sequence listing, respectively. (b-2) In accordance with the Chothia numbering rules, the amino acid sequences of CDR1, 2, and 3 of VH2 are the sequences shown in sequence numbers 83, 84, and 85 of the sequence listing, respectively, and the amino acid sequences of CDR1, 2, and 3 of VL2 are the sequences shown in sequence numbers 86, 87, and 88 of the sequence listing, respectively. (b-3) In accordance with the Kabat numbering rules, the amino acid sequences of CDR1, 2, and 3 of VH2 are the sequences shown in sequence numbers 59, 60, and 61 of the sequence listing, respectively, and the amino acid sequences of CDR1, 2, and 3 of VL2 are the sequences shown in sequence numbers 62, 63, and 64 of the sequence listing, respectively. (b-4) In accordance with the Chothia numbering rules, the amino acid sequences of CDR1, 2, and 3 of VH2 are the sequences shown in sequence numbers 77, 78, and 79 of the sequence listing, respectively, and the amino acid sequences of CDR1, 2, and 3 of VL2 are the sequences shown in sequence numbers 80, 81, and 82 of the sequence listing, respectively. (b-5) In accordance with the Kabat numbering rules, the amino acid sequences of CDR1, 2, and 3 of VH2 are the sequences shown in sequence numbers 71, 72, and 73 of the sequence listing, respectively, and the amino acid sequences of CDR1, 2, and 3 of VL2 are the sequences shown in sequence numbers 74, 75, and 76 of the sequence listing, respectively, and (b-6) In accordance with the Chothia numbering rules, the amino acid sequences of CDR1, 2, and 3 of VH2 are the sequences shown in sequence numbers 89, 90, and 91 of the sequence listing, respectively, and the amino acid sequences of CDR1, 2, and 3 of VL2 are the sequences shown in sequence numbers 92, 93, and 94 of the sequence listing, respectively. The antigen-binding protein construct according to claim 5.
13. The antigen-binding protein construct is either a bispecific antibody, or a Fab-scFv-Fc antibody, or a scFv-IgG or Fab-scFv-Fc antibody. The antigen-binding protein construct optionally comprises one or more heavy chain constant domains derived from IgG1 or IgG4. The antigen-binding protein construct according to any one of claims 1 and 5 to 10, wherein the antigen-binding protein construct optionally comprises one or more heavy chain constant domains, and the one or more heavy chain constant domains comprises a LALA mutation and / or a knob-into-hole (KIH) mutation.
14. An antibody-drug conjugate comprising an antigen-binding protein construct according to any one of claims 1 to 13 that is covalently bound to a therapeutic agent: The aforementioned therapeutic agent may optionally be a cytotoxic agent or a cell inhibitor.
15. A pharmaceutical composition comprising an antigen-binding protein construct according to any one of claims 1 to 13, or an antibody-drug conjugate according to claim 14 for treating a subject suffering from cancer, reducing the rate of tumor growth, or killing tumor cells in a subject requiring such treatment.
16. Having one or more characteristics selected from the following group: (1) The subject is suffering from a solid tumor, (2) The cancers mentioned above are non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (SCCHN), head and neck cancer, renal cell carcinoma (RCC), melanoma, bladder cancer, gastric cancer, urothelial carcinoma, Merkel cell carcinoma, triple-negative breast cancer (TNBC), or colorectal cancer. (3) The cancer is melanoma, pancreatic cancer, mesothelioma, or malignant hematological malignancy. (4) The pharmaceutical composition is administered in combination with an anti-CTLA4 antibody, an anti-Her2 antibody, or an antibody targeting tumor-associated antigen (TAA), (5) The pharmaceutical composition according to claim 15, wherein the pharmaceutical composition is administered in combination with chemotherapy.
17. A pharmaceutical composition comprising an antigen-binding protein construct according to any one of claims 1 to 13, or an antibody-drug conjugate according to claim 14, and a pharmaceutically acceptable vector.
Citation Information
Patent Citations
Combination anti-CD40 antibodies and methods of use
JP2019534292A
Anti-PD-1 antibodies and uses thereof
WO2019161536A1
Anti-CD40 antibodies and uses thereof
WO2020014974A1
